AU9205898A - A method of treating cancer - Google Patents
A method of treating cancer Download PDFInfo
- Publication number
- AU9205898A AU9205898A AU92058/98A AU9205898A AU9205898A AU 9205898 A AU9205898 A AU 9205898A AU 92058/98 A AU92058/98 A AU 92058/98A AU 9205898 A AU9205898 A AU 9205898A AU 9205898 A AU9205898 A AU 9205898A
- Authority
- AU
- Australia
- Prior art keywords
- protein
- geranylgeranyl
- seq
- compound
- triphosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 130
- 206010028980 Neoplasm Diseases 0.000 title description 32
- 201000011510 cancer Diseases 0.000 title description 19
- 150000001875 compounds Chemical class 0.000 claims description 207
- 102000004357 Transferases Human genes 0.000 claims description 144
- 108090000992 Transferases Proteins 0.000 claims description 144
- 150000001450 anions Chemical class 0.000 claims description 101
- 230000002401 inhibitory effect Effects 0.000 claims description 96
- 108090000623 proteins and genes Proteins 0.000 claims description 94
- 102000004169 proteins and genes Human genes 0.000 claims description 88
- -1 dithiophosphate Chemical compound 0.000 claims description 81
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 71
- 239000000758 substrate Substances 0.000 claims description 68
- 238000000338 in vitro Methods 0.000 claims description 67
- 238000003556 assay Methods 0.000 claims description 61
- 238000012546 transfer Methods 0.000 claims description 56
- 239000003112 inhibitor Substances 0.000 claims description 55
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 48
- 238000005259 measurement Methods 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 28
- 230000012010 growth Effects 0.000 claims description 23
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims description 22
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 22
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 22
- 229960001456 adenosine triphosphate Drugs 0.000 claims description 22
- 239000003558 transferase inhibitor Substances 0.000 claims description 22
- 238000012360 testing method Methods 0.000 claims description 21
- 241000124008 Mammalia Species 0.000 claims description 20
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 20
- 238000001727 in vivo Methods 0.000 claims description 18
- 229940125436 dual inhibitor Drugs 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 17
- 210000002950 fibroblast Anatomy 0.000 claims description 17
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 17
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 15
- 235000011180 diphosphates Nutrition 0.000 claims description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 14
- 229940123468 Transferase inhibitor Drugs 0.000 claims description 14
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 11
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 claims description 11
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 claims description 11
- 239000001226 triphosphate Substances 0.000 claims description 11
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 9
- WKKCYLSCLQVWFD-UHFFFAOYSA-N 1,2-dihydropyrimidin-4-amine Chemical compound N=C1NCNC=C1 WKKCYLSCLQVWFD-UHFFFAOYSA-N 0.000 claims description 8
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 claims description 8
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 claims description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 8
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims description 8
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 8
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 claims description 8
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 claims description 8
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- 230000005907 cancer growth Effects 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 238000010348 incorporation Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims description 4
- BEALYENGMRDLRK-LKEWCRSYSA-N [hydroxy-[[(2s,4r,5r)-4-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)C[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 BEALYENGMRDLRK-LKEWCRSYSA-N 0.000 claims description 3
- MLBHNPAXTLCWTO-SDZVROEXSA-N (2s)-2-[[2-[[(2s,3s)-2-[[2-[3-[(4-cyanophenyl)methyl]imidazol-4-yl]acetyl]amino]-3-methylpentyl]-(naphthalen-1-ylmethyl)amino]acetyl]amino]-4-methylsulfanylbutanoic acid Chemical compound N([C@H](CN(CC(=O)N[C@@H](CCSC)C(O)=O)CC=1C2=CC=CC=C2C=CC=1)[C@@H](C)CC)C(=O)CC1=CN=CN1CC1=CC=C(C#N)C=C1 MLBHNPAXTLCWTO-SDZVROEXSA-N 0.000 claims description 2
- BJFPYGGTDAYECS-UHFFFAOYSA-N (3-chlorophenyl)methanamine Chemical compound NCC1=CC=CC(Cl)=C1 BJFPYGGTDAYECS-UHFFFAOYSA-N 0.000 claims description 2
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- QKHJABHUVQGAER-UHFFFAOYSA-N 4-[[2-[[3-oxo-4-[3-(trifluoromethoxy)phenyl]piperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound FC(F)(F)OC1=CC=CC(N2C(CN(CC=3N(C=CN=3)CC=3C=CC(=CC=3)C#N)CC2)=O)=C1 QKHJABHUVQGAER-UHFFFAOYSA-N 0.000 claims description 2
- WROAKLRNBCHVHW-UHFFFAOYSA-N 4-[[5-[(4-benzoylanilino)methyl]imidazol-1-yl]methyl]benzonitrile 2-methoxy-4-[[2-[[3-oxo-4-[3-(trifluoromethoxy)phenyl]piperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound C(#N)C1=CC=C(CN2C=NC=C2CNC2=CC=C(C(=O)C3=CC=CC=C3)C=C2)C=C1.FC(OC=1C=C(C=CC1)N1C(CN(CC1)CC=1N(C=CN1)CC1=CC(=C(C=C1)C#N)OC)=O)(F)F WROAKLRNBCHVHW-UHFFFAOYSA-N 0.000 claims description 2
- DIBDFQXGSRBIDI-UHFFFAOYSA-N 4-[[5-[2-(3-oxo-4-phenylpiperazin-1-yl)ethyl]imidazol-1-yl]methyl]benzonitrile Chemical compound C1CN(C=2C=CC=CC=2)C(=O)CN1CCC1=CN=CN1CC1=CC=C(C#N)C=C1 DIBDFQXGSRBIDI-UHFFFAOYSA-N 0.000 claims description 2
- PEDQWIDLAAUREZ-UHFFFAOYSA-N 4-[[5-[[4-(3-bromophenyl)-3-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound BrC1=CC=CC(N2C(CN(CC=3N(C=NC=3)CC=3C=CC(=CC=3)C#N)CC2)=O)=C1 PEDQWIDLAAUREZ-UHFFFAOYSA-N 0.000 claims description 2
- DBHQZLQBOHLAJT-UHFFFAOYSA-N 4-[[5-[[4-(3-chlorophenyl)-4-hydroxypiperidin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound C1CC(O)(C=2C=C(Cl)C=CC=2)CCN1CC1=CN=CN1CC1=CC=C(C#N)C=C1 DBHQZLQBOHLAJT-UHFFFAOYSA-N 0.000 claims description 2
- YFQPIROEEXURMA-UHFFFAOYSA-N ClC=1C=C(C=CC1)N1C(CN(CC1)CC=1N(C=CN1)CC1=CC(=C(C=C1)C#N)OC)=O.IC=1C=C(C=CC1)N1C(CN(CC1)CC=1N(C=CN1)CC1=CC=C(C=C1)C#N)=O Chemical compound ClC=1C=C(C=CC1)N1C(CN(CC1)CC=1N(C=CN1)CC1=CC(=C(C=C1)C#N)OC)=O.IC=1C=C(C=CC1)N1C(CN(CC1)CC=1N(C=CN1)CC1=CC=C(C=C1)C#N)=O YFQPIROEEXURMA-UHFFFAOYSA-N 0.000 claims description 2
- PFMUCCYYAAFKTH-YFKPBYRVSA-N Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CN PFMUCCYYAAFKTH-YFKPBYRVSA-N 0.000 claims description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- HQFUINJGHRJKJL-DPGDXNODSA-N methyl (2s)-2-[[2-[[(2s,3s)-2-[[2-[3-[(4-cyanophenyl)methyl]imidazol-4-yl]acetyl]amino]-3-methylpentyl]-(naphthalen-1-ylmethyl)amino]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound N([C@H](CN(CC(=O)N[C@@H](CCSC)C(=O)OC)CC=1C2=CC=CC=C2C=CC=1)[C@@H](C)CC)C(=O)CC1=CN=CN1CC1=CC=C(C#N)C=C1 HQFUINJGHRJKJL-DPGDXNODSA-N 0.000 claims description 2
- OLLNEOSHRLKQRI-OFNKIYASSA-N n-[(2s)-1-[(2r)-2-amino-3-sulfanylpropyl]-4-(naphthalene-1-carbonyl)piperazin-2-yl]benzamide Chemical compound N([C@@H]1CN(CCN1C[C@H](CS)N)C(=O)C=1C2=CC=CC=C2C=CC=1)C(=O)C1=CC=CC=C1 OLLNEOSHRLKQRI-OFNKIYASSA-N 0.000 claims description 2
- NARSWBLQNUFOIM-UHFFFAOYSA-N naphthalen-1-yl(piperazin-1-yl)methanone Chemical compound C=1C=CC2=CC=CC=C2C=1C(=O)N1CCNCC1 NARSWBLQNUFOIM-UHFFFAOYSA-N 0.000 claims description 2
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 claims 5
- 101710120037 Toxin CcdB Proteins 0.000 claims 2
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 claims 1
- MMWFWBGOJWANCT-UHFFFAOYSA-N 1-methylsulfonylbutan-1-amine Chemical compound CCCC(N)S(C)(=O)=O MMWFWBGOJWANCT-UHFFFAOYSA-N 0.000 claims 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims 1
- KNJIXCAYSLDPMD-UHFFFAOYSA-N 4-[[5-[[1-(3-chlorophenyl)-2-oxopyridin-4-yl]methyl]imidazol-1-yl]methyl]-2-methoxybenzonitrile Chemical compound C1=C(C#N)C(OC)=CC(CN2C(=CN=C2)CC2=CC(=O)N(C=3C=C(Cl)C=CC=3)C=C2)=C1 KNJIXCAYSLDPMD-UHFFFAOYSA-N 0.000 claims 1
- QIKDIZLPGLFBLJ-UHFFFAOYSA-N 4-[[5-[[4-(2,3-dimethylphenyl)-2,3-dioxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound CC1=CC=CC(N2C(C(=O)N(CC=3N(C=NC=3)CC=3C=CC(=CC=3)C#N)CC2)=O)=C1C QIKDIZLPGLFBLJ-UHFFFAOYSA-N 0.000 claims 1
- OBMVDAMYNMONNX-UHFFFAOYSA-N 4-[[5-[[4-hydroxy-4-(3-methylphenyl)piperidin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound CC1=CC=CC(C2(O)CCN(CC=3N(C=NC=3)CC=3C=CC(=CC=3)C#N)CC2)=C1 OBMVDAMYNMONNX-UHFFFAOYSA-N 0.000 claims 1
- 108091006027 G proteins Proteins 0.000 claims 1
- 102000030782 GTP binding Human genes 0.000 claims 1
- 108091000058 GTP-Binding Proteins 0.000 claims 1
- 101000574352 Mus musculus Protein phosphatase 1 regulatory subunit 17 Proteins 0.000 claims 1
- OIJBGUALWNWZNL-PKTZIBPZSA-N [(3s)-4-[(2r)-2-amino-3-sulfanylpropyl]-3-(phenylmethoxymethyl)piperazin-1-yl]-naphthalen-1-ylmethanone Chemical compound C([C@@H]1CN(CCN1C[C@H](CS)N)C(=O)C=1C2=CC=CC=C2C=CC=1)OCC1=CC=CC=C1 OIJBGUALWNWZNL-PKTZIBPZSA-N 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 229940125846 compound 25 Drugs 0.000 claims 1
- 125000002946 cyanobenzyl group Chemical group 0.000 claims 1
- KLTDYIRYXYPZAQ-GMAHTHKFSA-N methyl (2s)-2-[[2-[(2-chlorophenyl)methyl-[[(2s)-1-[3-(1h-imidazol-5-yl)propanoyl]pyrrolidin-2-yl]methyl]amino]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@H]1CN(CC(=O)N[C@@H](CCSC)C(=O)OC)CC=2C(=CC=CC=2)Cl)CCN1C(=O)CCC1=CNC=N1 KLTDYIRYXYPZAQ-GMAHTHKFSA-N 0.000 claims 1
- RJEDCSBFWPXDQX-GOTSBHOMSA-N methyl (2s)-2-[[2-[[(2s)-1-[3-(1h-imidazol-5-yl)propanoyl]pyrrolidin-2-yl]methyl-[(2-methoxyphenyl)methyl]amino]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@H]1CN(CC(=O)N[C@@H](CCSC)C(=O)OC)CC=2C(=CC=CC=2)OC)CCN1C(=O)CCC1=CNC=N1 RJEDCSBFWPXDQX-GOTSBHOMSA-N 0.000 claims 1
- BTTAYOKAUFIVBM-SDZVROEXSA-N methyl (2s)-2-[[2-[[(2s,3s)-3-methyl-2-[[2-[3-[(4-nitrophenyl)methyl]imidazol-4-yl]acetyl]amino]pentyl]-(naphthalen-1-ylmethyl)amino]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound N([C@H](CN(CC(=O)N[C@@H](CCSC)C(=O)OC)CC=1C2=CC=CC=C2C=CC=1)[C@@H](C)CC)C(=O)CC1=CN=CN1CC1=CC=C([N+]([O-])=O)C=C1 BTTAYOKAUFIVBM-SDZVROEXSA-N 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 117
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 113
- 125000003118 aryl group Chemical group 0.000 description 94
- 239000000243 solution Substances 0.000 description 82
- 125000000623 heterocyclic group Chemical group 0.000 description 79
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 78
- 229910052739 hydrogen Inorganic materials 0.000 description 75
- 239000001257 hydrogen Substances 0.000 description 70
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 47
- 239000000047 product Substances 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 46
- 238000002360 preparation method Methods 0.000 description 44
- 150000002431 hydrogen Chemical class 0.000 description 42
- 239000000543 intermediate Substances 0.000 description 42
- 239000000203 mixture Substances 0.000 description 42
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- 108010014186 ras Proteins Proteins 0.000 description 32
- 125000003107 substituted aryl group Chemical group 0.000 description 32
- 125000000753 cycloalkyl group Chemical group 0.000 description 31
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 30
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 30
- 102000016914 ras Proteins Human genes 0.000 description 28
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 27
- 239000002904 solvent Substances 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- 125000001424 substituent group Chemical group 0.000 description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 20
- 150000001299 aldehydes Chemical class 0.000 description 20
- 102200160920 rs35304565 Human genes 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 19
- 239000012267 brine Substances 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- 229910052736 halogen Inorganic materials 0.000 description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 16
- 150000002367 halogens Chemical class 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 14
- 125000003342 alkenyl group Chemical group 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 13
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 13
- 229910052801 chlorine Inorganic materials 0.000 description 13
- 229910052731 fluorine Inorganic materials 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 11
- 238000005804 alkylation reaction Methods 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 11
- 125000002883 imidazolyl group Chemical group 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 125000004076 pyridyl group Chemical group 0.000 description 10
- 238000005932 reductive alkylation reaction Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
- 231100000252 nontoxic Toxicity 0.000 description 9
- 230000003000 nontoxic effect Effects 0.000 description 9
- 230000013823 prenylation Effects 0.000 description 9
- 229910000104 sodium hydride Inorganic materials 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 102000006495 integrins Human genes 0.000 description 8
- 108010044426 integrins Proteins 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 8
- 108700042226 ras Genes Proteins 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 102100039788 GTPase NRas Human genes 0.000 description 7
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 229910052681 coesite Inorganic materials 0.000 description 7
- 229910052906 cristobalite Inorganic materials 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
- 125000001041 indolyl group Chemical group 0.000 description 7
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 125000005494 pyridonyl group Chemical group 0.000 description 7
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 235000012239 silicon dioxide Nutrition 0.000 description 7
- 229910052682 stishovite Inorganic materials 0.000 description 7
- 125000000335 thiazolyl group Chemical group 0.000 description 7
- 125000001544 thienyl group Chemical group 0.000 description 7
- 229910052905 tridymite Inorganic materials 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- VWFJDQUYCIWHTN-FBXUGWQNSA-N Farnesyl diphosphate Natural products CC(C)=CCC\C(C)=C/CC\C(C)=C/COP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-FBXUGWQNSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 150000007522 mineralic acids Chemical class 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 6
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 5
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000010265 fast atom bombardment Methods 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- OINNEUNVOZHBOX-KGODAQDXSA-N geranylgeranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C\CC\C(C)=C\CO[P@@](O)(=O)OP(O)(O)=O OINNEUNVOZHBOX-KGODAQDXSA-N 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 4
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102000005454 Dimethylallyltranstransferase Human genes 0.000 description 4
- 108010006731 Dimethylallyltranstransferase Proteins 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 101150040459 RAS gene Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229940034982 antineoplastic agent Drugs 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 238000010931 ester hydrolysis Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 150000003505 terpenes Chemical class 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- VHYIMLUJJQTCQU-UHFFFAOYSA-N 4-[[2-[[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile;dihydrochloride Chemical compound Cl.Cl.ClC1=CC=CC(N2C(CN(CC=3N(C=CN=3)CC=3C=CC(=CC=3)C#N)CC2)=O)=C1 VHYIMLUJJQTCQU-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 239000007818 Grignard reagent Substances 0.000 description 3
- 101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 102100029645 UBX domain-containing protein 11 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000004693 imidazolium salts Chemical class 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 108091005629 prenylated proteins Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- GDGVOGGJKRMIOF-OLZOCXBDSA-N 1-o-tert-butyl 2-o-methyl (2s,4r)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C(C)(C)C)CN1C(=O)OC(C)(C)C GDGVOGGJKRMIOF-OLZOCXBDSA-N 0.000 description 2
- MZMNEDXVUJLQAF-SFYZADRCSA-N 1-o-tert-butyl 2-o-methyl (2s,4r)-4-hydroxypyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)[C@@H]1C[C@@H](O)CN1C(=O)OC(C)(C)C MZMNEDXVUJLQAF-SFYZADRCSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 2
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 2
- BWWMMRLOKSMBEK-UHFFFAOYSA-N 4-[[2-[[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]-2-methoxybenzonitrile;dihydrochloride Chemical compound Cl.Cl.C1=C(C#N)C(OC)=CC(CN2C(=NC=C2)CN2CC(=O)N(CC2)C=2C=C(Cl)C=CC=2)=C1 BWWMMRLOKSMBEK-UHFFFAOYSA-N 0.000 description 2
- IXAZAZYWGZLJQI-UHFFFAOYSA-N 4-[[5-(1-hydroxyethyl)imidazol-1-yl]methyl]benzonitrile Chemical compound CC(O)C1=CN=CN1CC1=CC=C(C#N)C=C1 IXAZAZYWGZLJQI-UHFFFAOYSA-N 0.000 description 2
- OLXZPDWKRNYJJZ-UHFFFAOYSA-N 5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 108091006109 GTPases Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 229940123038 Integrin antagonist Drugs 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000009905 Neurofibromatoses Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 125000005336 allyloxy group Chemical group 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 2
- 125000005002 aryl methyl group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 108091005640 farnesylated proteins Proteins 0.000 description 2
- 238000002143 fast-atom bombardment mass spectrum Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 239000012742 immunoprecipitation (IP) buffer Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- ZORHSASAYVIBLY-UHNVWZDZSA-N methyl (2s,4r)-4-hydroxypyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1C[C@@H](O)CN1 ZORHSASAYVIBLY-UHNVWZDZSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- 150000002825 nitriles Chemical group 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000001151 peptidyl group Chemical group 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
- 239000003600 podophyllotoxin derivative Substances 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- COWIOXVRYHZUMU-QWHCGFSZSA-N tert-butyl (2s,4r)-2-(azidomethyl)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H](O[Si](C)(C)C(C)(C)C)C[C@H]1CN=[N+]=[N-] COWIOXVRYHZUMU-QWHCGFSZSA-N 0.000 description 2
- IIITUHPEBILIQR-QWHCGFSZSA-N tert-butyl (2s,4r)-4-[tert-butyl(dimethyl)silyl]oxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H](O[Si](C)(C)C(C)(C)C)C[C@H]1CO IIITUHPEBILIQR-QWHCGFSZSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- DVQYFYUODSFBFS-UHFFFAOYSA-N (1-tritylimidazol-4-yl)methanol Chemical compound C1=NC(CO)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 DVQYFYUODSFBFS-UHFFFAOYSA-N 0.000 description 1
- YNVRNJRVLZDDPH-UHFFFAOYSA-N (1-tritylimidazol-4-yl)methyl acetate Chemical compound C1=NC(COC(=O)C)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 YNVRNJRVLZDDPH-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WWGONUOHFVVGEW-DZMJNENTSA-N (2s)-2-[[2-[[(2s,3s)-3-methyl-2-[[2-[3-[(4-nitrophenyl)methyl]imidazol-4-yl]acetyl]amino]pentyl]-(naphthalen-1-ylmethyl)amino]acetyl]amino]-4-methylsulfanylbutanoic acid Chemical compound N([C@H](CN(CC(=O)N[C@@H](CCSC)C(O)=O)CC=1C2=CC=CC=C2C=CC=1)[C@@H](C)CC)C(=O)CC1=CN=CN1CC1=CC=C([N+]([O-])=O)C=C1 WWGONUOHFVVGEW-DZMJNENTSA-N 0.000 description 1
- MCEHFIXEKNKSRW-LBPRGKRZSA-N (2s)-2-[[3,5-dichloro-4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=C(Cl)C=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1Cl MCEHFIXEKNKSRW-LBPRGKRZSA-N 0.000 description 1
- YSPAKPPINKSOKX-BYPYZUCNSA-N (2s)-3-acetamido-2-aminopropanoic acid Chemical group CC(=O)NC[C@H](N)C(O)=O YSPAKPPINKSOKX-BYPYZUCNSA-N 0.000 description 1
- RINPOXNCRXGFAV-FNXAHOOKSA-N (2s,4s,5r,6r)-5-amino-2-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-amino-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-6-[(e)-2-amino-3-hydroxyicos-4-enoxy]-4,5-dihydroxy-2-(h Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(N)C(O)/C=C/CCCCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](N)[C@@H](O)C2)C(O)C(O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RINPOXNCRXGFAV-FNXAHOOKSA-N 0.000 description 1
- QFIJRVVOFRXAPM-FQEVSTJZSA-N (3s)-n-[2-[3-[(4-cyanophenyl)methyl]imidazol-4-yl]ethyl]-1-(3,5-dichlorophenyl)sulfonylpiperidine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC(S(=O)(=O)N2C[C@H](CCC2)C(=O)NCCC=2N(C=NC=2)CC=2C=CC(=CC=2)C#N)=C1 QFIJRVVOFRXAPM-FQEVSTJZSA-N 0.000 description 1
- RBKHNGHPZZZJCI-UHFFFAOYSA-N (4-aminophenyl)-phenylmethanone Chemical compound C1=CC(N)=CC=C1C(=O)C1=CC=CC=C1 RBKHNGHPZZZJCI-UHFFFAOYSA-N 0.000 description 1
- BMTZOXHSVXPSTN-UHFFFAOYSA-N (4-butylpiperazin-1-yl)-naphthalen-1-ylmethanone Chemical compound C1CN(CCCC)CCN1C(=O)C1=CC=CC2=CC=CC=C12 BMTZOXHSVXPSTN-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- QACMXJJLQXUOPQ-UHFFFAOYSA-N 1,2-dichloroethane;3-(ethyliminomethylideneamino)-n,n-dimethylpropan-1-amine Chemical compound ClCCCl.CCN=C=NCCCN(C)C QACMXJJLQXUOPQ-UHFFFAOYSA-N 0.000 description 1
- SQLHSSGGJDQOTB-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazin-2-one Chemical compound ClC1=CC=CC(N2C(CNCC2)=O)=C1 SQLHSSGGJDQOTB-UHFFFAOYSA-N 0.000 description 1
- KETINLJXSJBQPL-UHFFFAOYSA-N 1-[2-(1h-imidazol-2-yl)ethyl]piperidine Chemical compound C1CCCCN1CCC1=NC=CN1 KETINLJXSJBQPL-UHFFFAOYSA-N 0.000 description 1
- HUVFKEDHIUORES-UHFFFAOYSA-N 1-[3-[(4-cyanophenyl)methyl]imidazol-4-yl]propane-1-sulfonic acid Chemical compound CCC(S(O)(=O)=O)C1=CN=CN1CC1=CC=C(C#N)C=C1 HUVFKEDHIUORES-UHFFFAOYSA-N 0.000 description 1
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- JZUMPNUYDJBTNO-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 JZUMPNUYDJBTNO-UHFFFAOYSA-N 0.000 description 1
- ZLKNPIVTWNMMMH-UHFFFAOYSA-N 1-imidazol-1-ylsulfonylimidazole Chemical compound C1=CN=CN1S(=O)(=O)N1C=CN=C1 ZLKNPIVTWNMMMH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 1
- OFGDSGVGRWPQJQ-UHFFFAOYSA-N 1h-imidazol-1-ium;acetate Chemical class CC(O)=O.C1=CNC=N1 OFGDSGVGRWPQJQ-UHFFFAOYSA-N 0.000 description 1
- VWUCIBOKNZGWLX-UHFFFAOYSA-N 1h-imidazol-1-ium;bromide Chemical compound [Br-].C1=C[NH+]=CN1 VWUCIBOKNZGWLX-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- SXFWKZNLYYRHMK-UHFFFAOYSA-N 1h-indolo[7,6-f]quinoline Chemical class C1=CC=C2C3=C(NC=C4)C4=CC=C3C=CC2=N1 SXFWKZNLYYRHMK-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 description 1
- VSKLHTDOXYIACD-UHFFFAOYSA-N 2,2-diethoxyethane-1,1-diamine Chemical compound CCOC(C(N)N)OCC VSKLHTDOXYIACD-UHFFFAOYSA-N 0.000 description 1
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 1
- WLYVAVCZXRPTIH-UHFFFAOYSA-N 2-(1-tritylimidazol-4-yl)acetaldehyde Chemical compound C1=NC(CC=O)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WLYVAVCZXRPTIH-UHFFFAOYSA-N 0.000 description 1
- UGHWFYKQWZHCHK-UHFFFAOYSA-N 2-(chloromethyl)-1h-imidazole Chemical class ClCC1=NC=CN1 UGHWFYKQWZHCHK-UHFFFAOYSA-N 0.000 description 1
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- PCNXNSPEWIRGJO-UHFFFAOYSA-N 2-butylpiperidine Chemical compound CCCCC1CCCCN1 PCNXNSPEWIRGJO-UHFFFAOYSA-N 0.000 description 1
- KIBKALCWZILPKW-UHFFFAOYSA-N 2-methoxy-4-[[2-[[3-oxo-4-[3-(trifluoromethoxy)phenyl]piperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile 1-[3-(trifluoromethoxy)phenyl]piperazin-2-one trihydrochloride Chemical compound Cl.FC(OC=1C=C(C=CC1)N1C(CNCC1)=O)(F)F.Cl.Cl.FC(OC=1C=C(C=CC1)N1C(CN(CC1)CC=1N(C=CN1)CC1=CC(=C(C=C1)C#N)OC)=O)(F)F KIBKALCWZILPKW-UHFFFAOYSA-N 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- IKZGUGJTKRXASK-UHFFFAOYSA-N 3-(3-chloro-n-(2-chloroacetyl)anilino)-n-[(2-methylpropan-2-yl)oxy]propanamide Chemical compound CC(C)(C)ONC(=O)CCN(C(=O)CCl)C1=CC=CC(Cl)=C1 IKZGUGJTKRXASK-UHFFFAOYSA-N 0.000 description 1
- SADHVOSOZBAAGL-UHFFFAOYSA-N 3-(trifluoromethoxy)aniline Chemical compound NC1=CC=CC(OC(F)(F)F)=C1 SADHVOSOZBAAGL-UHFFFAOYSA-N 0.000 description 1
- VXUMRYMTYKDWMO-UHFFFAOYSA-N 3-bromo-4-methylbenzonitrile Chemical compound CC1=CC=C(C#N)C=C1Br VXUMRYMTYKDWMO-UHFFFAOYSA-N 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 1
- MOJLLVYUOHXGPT-UHFFFAOYSA-N 3-hydroxy-3h-cinnolin-4-one Chemical compound C1=CC=C2C(=O)C(O)N=NC2=C1 MOJLLVYUOHXGPT-UHFFFAOYSA-N 0.000 description 1
- UBOOKRVGOBKDMM-UHFFFAOYSA-N 3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=C2NC=NC2=C1 UBOOKRVGOBKDMM-UHFFFAOYSA-N 0.000 description 1
- CGMMQOGAAVPKGE-UHFFFAOYSA-N 4-[(5-formylimidazol-1-yl)methyl]-2-methoxybenzonitrile Chemical compound C1=C(C#N)C(OC)=CC(CN2C(=CN=C2)C=O)=C1 CGMMQOGAAVPKGE-UHFFFAOYSA-N 0.000 description 1
- AMUOEEKBBOOOCV-UHFFFAOYSA-N 4-[(5-formylimidazol-1-yl)methyl]benzonitrile Chemical compound O=CC1=CN=CN1CC1=CC=C(C#N)C=C1 AMUOEEKBBOOOCV-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QKVMXOAHKSFONR-UHFFFAOYSA-N 4-[[2-[[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound ClC1=CC=CC(N2C(CN(CC=3N(C=CN=3)CC=3C=CC(=CC=3)C#N)CC2)=O)=C1 QKVMXOAHKSFONR-UHFFFAOYSA-N 0.000 description 1
- LNPBSSAEDQGPMU-UHFFFAOYSA-N 4-[[2-[[4-(3-methylphenyl)-3-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound CC1=CC=CC(N2C(CN(CC=3N(C=CN=3)CC=3C=CC(=CC=3)C#N)CC2)=O)=C1 LNPBSSAEDQGPMU-UHFFFAOYSA-N 0.000 description 1
- FXAKHFBTNKKTOL-UHFFFAOYSA-N 4-[[5-(hydroxymethyl)imidazol-1-yl]methyl]-2-methoxybenzonitrile Chemical compound C1=C(C#N)C(OC)=CC(CN2C(=CN=C2)CO)=C1 FXAKHFBTNKKTOL-UHFFFAOYSA-N 0.000 description 1
- ACFSBQWDVYWNRT-UHFFFAOYSA-N 4-[[5-(hydroxymethyl)imidazol-1-yl]methyl]benzonitrile Chemical compound OCC1=CN=CN1CC1=CC=C(C#N)C=C1 ACFSBQWDVYWNRT-UHFFFAOYSA-N 0.000 description 1
- OLRULWVLCYZZGW-UHFFFAOYSA-N 4-[[5-[(4-benzoylanilino)methyl]imidazol-1-yl]methyl]benzonitrile;hydrochloride Chemical compound Cl.C=1C=C(NCC=2N(C=NC=2)CC=2C=CC(=CC=2)C#N)C=CC=1C(=O)C1=CC=CC=C1 OLRULWVLCYZZGW-UHFFFAOYSA-N 0.000 description 1
- GQGVBSHMRYHBTF-UOWFLXDJSA-N 4-amino-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 GQGVBSHMRYHBTF-UOWFLXDJSA-N 0.000 description 1
- NFPYJDZQOKCYIE-UHFFFAOYSA-N 4-amino-3-hydroxybenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1O NFPYJDZQOKCYIE-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- YRQZAUSIVGMFNN-UHFFFAOYSA-N 4-aminopiperidine-4-carbonitrile Chemical compound N#CC1(N)CCNCC1 YRQZAUSIVGMFNN-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical class [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- SQPXCCXENKRCBW-QMAYBDLHSA-N C(C)(=O)NCCCC[C@@H]1N(CCN(C1)C(=O)C1=CC=CC2=CC=CC=C12)C[C@H](CS)N.COC([C@@H](NC(CN(CC1=C(C=CC=C1)OC)C[C@H]1N(CCC1)C(CCC=1N=CNC1)=O)=O)CCSC)=O Chemical compound C(C)(=O)NCCCC[C@@H]1N(CCN(C1)C(=O)C1=CC=CC2=CC=CC=C12)C[C@H](CS)N.COC([C@@H](NC(CN(CC1=C(C=CC=C1)OC)C[C@H]1N(CCC1)C(CCC=1N=CNC1)=O)=O)CCSC)=O SQPXCCXENKRCBW-QMAYBDLHSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- BEOXJQSSFKSNHC-DEOSSOPVSA-N C1CN(C(=O)[C@@H](N1CC2=CN(C=N2)CC3=CC=C(C=C3)C#N)CCOCC(F)(F)F)C4=CC=CC(=C4)C(F)(F)F Chemical compound C1CN(C(=O)[C@@H](N1CC2=CN(C=N2)CC3=CC=C(C=C3)C#N)CCOCC(F)(F)F)C4=CC=CC(=C4)C(F)(F)F BEOXJQSSFKSNHC-DEOSSOPVSA-N 0.000 description 1
- 101100181929 Caenorhabditis elegans lin-3 gene Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- GXMFRJSRHLEDDL-UHFFFAOYSA-N FC(OC=1C=C(C=CC1)C1=NC=C(C=C1)CN1C=NC=C1CC1=CC=C(C=C1)C#N)(F)F.C(#N)C1=CC=C(CN2C=NC=C2CN2C(C(N(CC2)C2=C(C(=CC=C2)C)C)=O)=O)C=C1 Chemical compound FC(OC=1C=C(C=CC1)C1=NC=C(C=C1)CN1C=NC=C1CC1=CC=C(C=C1)C#N)(F)F.C(#N)C1=CC=C(CN2C=NC=C2CN2C(C(N(CC2)C2=C(C(=CC=C2)C)C)=O)=O)C=C1 GXMFRJSRHLEDDL-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- KBHMEHLJSZMEMI-UHFFFAOYSA-N Formycin A Natural products N1N=C2C(N)=NC=NC2=C1C1OC(CO)C(O)C1O KBHMEHLJSZMEMI-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- JPXZQMKKFWMMGK-KQYNXXCUSA-N IDP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 JPXZQMKKFWMMGK-KQYNXXCUSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- QJPWUUJVYOJNMH-VKHMYHEASA-N L-homoserine lactone Chemical class N[C@H]1CCOC1=O QJPWUUJVYOJNMH-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- JXLYSJRDGCGARV-PJXZDTQASA-N Leurosidine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-PJXZDTQASA-N 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 102100026379 Neurofibromin Human genes 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101150054980 Rhob gene Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 229910020929 Sn-Sn Inorganic materials 0.000 description 1
- 229910008827 Sn—Sn Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000006612 Transducin Human genes 0.000 description 1
- 108010087042 Transducin Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- RWTUFNRGNZOHDD-UHFFFAOYSA-N [3-[(4-cyano-3-methoxyphenyl)methyl]imidazol-4-yl]methyl acetate;hydrobromide Chemical compound Br.C1=C(C#N)C(OC)=CC(CN2C(=CN=C2)COC(C)=O)=C1 RWTUFNRGNZOHDD-UHFFFAOYSA-N 0.000 description 1
- SVEKMMWJGWKHNT-UHFFFAOYSA-N [3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl acetate;hydrobromide Chemical compound Br.CC(=O)OCC1=CN=CN1CC1=CC=C(C#N)C=C1 SVEKMMWJGWKHNT-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- NZHXEWZGTQSYJM-UHFFFAOYSA-N [bromo(diphenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Br)C1=CC=CC=C1 NZHXEWZGTQSYJM-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-KSNABSRWSA-N ac1l29ym Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-KSNABSRWSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 101150024193 alp1 gene Proteins 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical class Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- GDAQDTCKYVKPPC-PMERELPUSA-N benzyl n-[(3-chlorophenyl)methyl]-n-[(2s)-2-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methylamino]-4-methylsulfonylbutyl]carbamate Chemical compound C([C@H](CCS(=O)(=O)C)NCC=1N(C=NC=1)CC=1C=CC(=CC=1)C#N)N(C(=O)OCC=1C=CC=CC=1)CC1=CC=CC(Cl)=C1 GDAQDTCKYVKPPC-PMERELPUSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- AZSFNUJOCKMOGB-UHFFFAOYSA-K cyclotriphosphate(3-) Chemical compound [O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 AZSFNUJOCKMOGB-UHFFFAOYSA-K 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- LTFMZDNNPPEQNG-UHFFFAOYSA-N deoxyguanylic acid Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(COP(O)(O)=O)O1 LTFMZDNNPPEQNG-UHFFFAOYSA-N 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004597 dihydrobenzothiopyranyl group Chemical group S1C(CCC2=C1C=CC=C2)* 0.000 description 1
- WOKPSXJEBSRSAT-UHFFFAOYSA-N dihydrobenzothiopyranyl sulfone group Chemical group S1C(CCC2=C1C=CC=C2)S(=O)(=O)C2SC1=C(CC2)C=CC=C1 WOKPSXJEBSRSAT-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- NLHWCTNYFFIPJT-UHFFFAOYSA-N disodium bis(trimethylsilyl)azanide Chemical compound [Na+].[Na+].C[Si](C)(C)[N-][Si](C)(C)C.C[Si](C)(C)[N-][Si](C)(C)C NLHWCTNYFFIPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- 229940093495 ethanethiol Drugs 0.000 description 1
- OMAYPGGVIXHKRO-UHFFFAOYSA-N ethanethiol Chemical compound [CH2]CS OMAYPGGVIXHKRO-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- KBHMEHLJSZMEMI-KSYZLYKTSA-N formycin A Chemical compound N=1NC=2C(N)=NC=NC=2C=1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KBHMEHLJSZMEMI-KSYZLYKTSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000006130 geranylgeranylation Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- WFNASTYGEKUMIY-UHFFFAOYSA-N hydron;1h-imidazol-5-ylmethanol;chloride Chemical compound Cl.OCC1=CN=CN1 WFNASTYGEKUMIY-UHFFFAOYSA-N 0.000 description 1
- MWHLCFYPFGFBQO-UHFFFAOYSA-N hydron;2-(1h-imidazol-5-yl)acetic acid;chloride Chemical compound Cl.OC(=O)CC1=CN=CN1 MWHLCFYPFGFBQO-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- PRJKNHOMHKJCEJ-UHFFFAOYSA-N imidazol-4-ylacetic acid Chemical compound OC(=O)CC1=CN=CN1 PRJKNHOMHKJCEJ-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical class OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- GUWHRJQTTVADPB-UHFFFAOYSA-N lithium azide Chemical compound [Li+].[N-]=[N+]=[N-] GUWHRJQTTVADPB-UHFFFAOYSA-N 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- OGOVUFLIQYXZKW-UHFFFAOYSA-N methyl 2-(1h-imidazol-5-yl)acetate;hydrochloride Chemical compound Cl.COC(=O)CC1=CNC=N1 OGOVUFLIQYXZKW-UHFFFAOYSA-N 0.000 description 1
- LXCQVWRESZDFGW-UHFFFAOYSA-N methyl 3-hydroxy-4-iodobenzoate Chemical compound COC(=O)C1=CC=C(I)C(O)=C1 LXCQVWRESZDFGW-UHFFFAOYSA-N 0.000 description 1
- OCZXDVNSNDITBS-UHFFFAOYSA-N methyl 4-amino-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(N)C(O)=C1 OCZXDVNSNDITBS-UHFFFAOYSA-N 0.000 description 1
- VDEARWYDVSYTNZ-UHFFFAOYSA-N methyl 4-cyano-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(C#N)C(O)=C1 VDEARWYDVSYTNZ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- OOOBVIKCNDPOAB-UHFFFAOYSA-N n'-(3-chlorophenyl)ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNC1=CC=CC(Cl)=C1 OOOBVIKCNDPOAB-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000008692 neointimal formation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 108010091742 peptide F Proteins 0.000 description 1
- RJSZPKZQGIKVAU-UXBJKDEOSA-N peptide f Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C(C)C)C(C)C)C1=CC=CC=C1 RJSZPKZQGIKVAU-UXBJKDEOSA-N 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- RJUAEBLXGFKZMS-UHFFFAOYSA-N piperidin-1-ylmethanol Chemical compound OCN1CCCCC1 RJUAEBLXGFKZMS-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PSAYJRPASWETSH-UHFFFAOYSA-N pyridine-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CC=N1 PSAYJRPASWETSH-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000004620 quinolinyl-N-oxide group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000004276 retinal vascularization Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- LFAGQMCIGQNPJG-UHFFFAOYSA-N silver cyanide Chemical compound [Ag+].N#[C-] LFAGQMCIGQNPJG-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- DKCJFKXHBRAYKQ-QWHCGFSZSA-N tert-butyl (2s,4r)-2-(aminomethyl)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H](O[Si](C)(C)C(C)(C)C)C[C@H]1CN DKCJFKXHBRAYKQ-QWHCGFSZSA-N 0.000 description 1
- NPAHVNPWHLQLNI-UONOGXRCSA-N tert-butyl (2s,4r)-4-[tert-butyl(dimethyl)silyl]oxy-2-(methylsulfonyloxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H](O[Si](C)(C)C(C)(C)C)C[C@H]1COS(C)(=O)=O NPAHVNPWHLQLNI-UONOGXRCSA-N 0.000 description 1
- VQUGQCMRKRLMOF-UHFFFAOYSA-N tert-butyl 4-(3-chlorophenyl)-3-oxopiperazine-1-carboxylate Chemical compound O=C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC(Cl)=C1 VQUGQCMRKRLMOF-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZUSPXVZVYRCDTB-UHFFFAOYSA-N tert-butyl n-[2-(3-chloroanilino)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCNC1=CC=CC(Cl)=C1 ZUSPXVZVYRCDTB-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- GMRIOAVKKGNMMV-UHFFFAOYSA-N tetrabutylazanium;azide Chemical compound [N-]=[N+]=[N-].CCCC[N+](CCCC)(CCCC)CCCC GMRIOAVKKGNMMV-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004589 thienofuryl group Chemical group O1C(=CC2=C1C=CS2)* 0.000 description 1
- 125000004587 thienothienyl group Chemical group S1C(=CC2=C1C=CS2)* 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000003597 transferase activity assay Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- JPBPEJWATPZGAD-UHFFFAOYSA-N tris(3-chlorophenyl)bismuthane Chemical compound ClC1=CC=CC([Bi](C=2C=C(Cl)C=CC=2)C=2C=C(Cl)C=CC=2)=C1 JPBPEJWATPZGAD-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
WO 99/10523 PCT/US98/17697 TITLE OF THE INVENTION A METHOD OF TREATING CANCER BACKGROUND OF THE INVENTION 5 The present invention relates to a method of treating cancer which utilizes prenyl-protein transferase inhibitors which are efficacious in vivo as inhibitors of geranylgeranyl-protein transferase type I (GGTase-I). The invention also relates to a method for identifying such prenyl-protein transferase inhibitors. 10 Prenylation of proteins by prenyl-protein transferases represents a class of post-translational modification (Glomset, J. A., Gelb, M. H., and Farnsworth, C. C. (1990), Trends Biochem. Sci. 15, 139-142; Maltese, W. A. (1990), FASEB J. 4, 3319-3328). This modification typically is required for the membrane localization and 15 function of these proteins. Prenylated proteins share characteristic C-terminal sequences including CAAX (C, Cys; A, an aliphatic amino acid; X, another amino acid), XXCC, or XCXC. Three post-translational processing steps have been described for proteins having a C-terminal CAAX sequence: addition of either a 15 carbon 20 (farnesyl) or 20 carbon (geranylgeranyl) isoprenoid to the Cys residue, proteolytic cleavage of the last 3 amino acids, and methylation of the new C-terminal carboxylate (Cox, A. D. and Der, C. J. (1992a), Critical Rev. Oncogenesis 3:365-400; Newman, C. M. H. and Magee, A. I. (1993), Biochim. Biophys. Acta 1155:79-96). Some proteins 25 may also have a fourth modification: palmitoylation of one or two Cys residues N-terminal to the farnesylated Cys. While some mammalian cell proteins terminating in XCXC are carboxymethylated, it is not clear whether carboxy methylation follows prenylation of proteins terminat ing with a XXCC motif (Clarke, S. (1992), Annu. Rev. Biochem. 61, 30 355-386). For all of the prenylated proteins, addition of the isoprenoid is the first step and is required for the subsequent steps (Cox, A. D. and Der, C. J. (1992a), Critical Rev. Oncogenesis 3:365-400; Cox, A. D. and Der, C. J. (1992b) Current Opinion Cell Biol. 4:1008-1016). - 1 - WO 99/10523 PCT/US98/17697 Three enzymes have been described that catalyze protein prenylation: farnesyl-protein transferase (FPTase), geranylgeranyl protein transferase type I (GGPTase-I), and geranylgeranyl-protein transferase type-II (GGPTase-II, also called Rab GGPTase). These 5 enzymes are found in both yeast and mammalian cells (Clarke, 1992; Schafer, W. R. and Rine, J. (1992) Annu. Rev. Genet. 30:209-237). Each of these enzymes selectively uses farnesyl diphosphate or geranyl geranyl diphosphate as the isoprenoid donor and selectively recognizes the protein substrate. FPTase farnesylates CAAX-containing proteins 10 that end with Ser, Met, Cys, Gln or Ala. For FPTase, CAAX tetra peptides comprise the minimum region required for interaction of the protein substrate with the enzyme. The enzymological characterization of these three enzymes has demonstrated that it is possible to selectively inhibit one with little inhibitory effect on the others (Moores, S. L., 15 Schaber, M. D., Mosser, S. D., Rands, E., O'Hara, M. B., Garsky, V. M., Marshall, M. S., Pompliano, D. L., and Gibbs, J. B., J. Biol. Chem., 266:17438 (1991), U.S. Pat. No. 5,470,832). The prenylation reactions have been shown genetically to be essential for the function of a variety of proteins (Clarke, 1992; Cox 20 and Der, 1992a; Gibbs, J. B. (1991). Cell 65: 1-4; Newman and Magee, 1993; Schafer and Rine, 1992). This requirement often is demonstrated by mutating the CAAX Cys acceptors so that the proteins can no longer be prenylated. The resulting proteins are devoid of their central biological activity. These studies provide a genetic "proof of principle" 25 indicating that inhibitors of prenylation can alter the physiological responses regulated by prenylated proteins. The Ras protein is part of a signaling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation. Biological and biochemical studies of Ras action indicate 30 that Ras functions like a G-regulatory protein. In the inactive state, Ras is bound to GDP. Upon growth factor receptor activation, Ras is induced to exchange GDP for GTP and undergoes a conformational change. The GTP-bound form of Ras propagates the growth stimulatory signal until the signal is terminated by the intrinsic GTPase activity of -2- WO 99/10523 PCT/US98/17697 Ras, which returns the protein to its inactive GDP bound form (D.R. Lowy and D.M. Willumsen, Ann. Rev. Biochem. 62:851-891 (1993)). Activation of Ras leads to activation of multiple intracellular signal transduction pathways, including the MAP Kinase pathway and the 5 Rho/Rac pathway (Joneson et al., Science 271:810-812). Mutated ras genes are found in many human cancers, including colorectal carcinoma, exocrine pancreatic carcinoma, and myeloid leukemias. The protein products of these genes are defective in their GTPase activity and constitutively transmit a growth stimulatory 10 signal. The Ras protein is one of several proteins that are known to undergo post-translational modification. Farnesyl-protein transferase utilizes farnesyl pyrophosphate to covalently modify the Cys thiol group of the Ras CAAX box with a farnesyl group (Reiss et al., Cell, 62:81-88 15 (1990); Schaber et al., J. Biol. Chem., 265:14701-14704 (1990); Schafer et al., Science, 249:1133-1139 (1990); Manne et al., Proc. Natl. Acad. Sci USA, 87:7541-7545 (1990)). Ras must be localized to the plasma membrane for both normal and oncogenic functions. At least 3 post-translational 20 modifications are involved with Ras membrane localization, and all 3 modifications occur at the C-terminus of Ras. The Ras C-terminus contains a sequence motif termed a "CAAX" or "Cys-Aaa-Aaa-Xaa" box (Cys is cysteine, Aaa is an aliphatic amino acid, the Xaa is any amino acid) (Willumsen et al., Nature 310:583-586 (1984)). Depend 25 ing on the specific sequence, this motif serves as a signal sequence for the enzymes farnesyl-protein transferase or geranylgeranyl-protein transferase, which catalyze the alkylation of the cysteine residue of the CAAX motif with a C15 or C20 isoprenoid, respectively. (S. Clarke., Ann. Rev. Biochem. 61:355-386 (1992); W.R. Schafer and J. Rine, 30 Ann. Rev. Genetics 30:209-237 (1992)). Other farnesylated proteins include the Ras-related GTP-binding proteins such as RhoB, fungal mating factors, the nuclear lamins, and the gamma subunit of transducin. James, et al., J. Biol. Chem. 269, 14182 (1994) have identified a peroxisome associated -3- WO 99/10523 PCT/US98/17697 protein Pxf which is also farnesylated. James, et al., have also suggested that there are farnesylated proteins of unknown structure and function in addition to those listed above. Inhibitors of farnesyl-protein transferase (FPTase) have 5 been described in two general classes. The first class includes analogs of farnesyl diphosphate (FPP), while the second is related to protein substrates (e.g., Ras) for the enzyme. The peptide derived inhibitors that have been described are generally cysteine containing molecules that are related to the CAAX motif that is the signal for protein prenylation. 10 (Schaber et al., ibid; Reiss et. al., ibid; Reiss et al., PNAS, 88:732-736 (1991)). Such inhibitors may inhibit protein prenylation while serving as alternate substrates for the farnesyl-protein transferase enzyme, or may be purely competitive inhibitors (U.S. Patent 5,141,851, University of Texas; N.E. Kohl et al., Science, 260:1934-1937 (1993); Graham, 15 et al., J. Med. Chem., 37, 725 (1994)). Mammalian cells express four types of Ras proteins (H-, N-, K4A-, and K4B-Ras) among which K4B-Ras is the most frequently mutated form of Ras in human cancers. The genes that encode these proteins are abbreviated H-ras, N-ras , K4A-ras and K4B 20 ras respectively. H-ras is an abbreviation for Harvey-ras. K4A-ras and K4B-ras are abbreviations for the Kirsten splice variants of ras that contain the 4A and 4B exons, respectively. Inhibition of farnesyl protein transferase has been shown to block the growth of H-ras transformed cells in soft agar and to modify other aspects of their 25 transformed phenotype. It has also been demonstrated that certain inhibitors of farnesyl-protein transferase selectively block the process ing of the H-Ras oncoprotein intracellularly (N.E. Kohl et al., Science, 260:1934-1937 (1993) and G.L. James et al., Science, 260:1937-1942 (1993). Recently, it has been shown that an inhibitor of farnesyl-protein 30 transferase blocks the growth of H-ras-dependent tumors in nude mice (N.E. Kohl et al., Proc. Natl. Acad. Sci U.S.A., 91:9141-9145 (1994) and induces regression of mammary and salivary carcinomas in H-ras transgenic mice (N.E. Kohl et al., Nature Medicine, 1:792-797 (1995). -4- WO 99/10523 PCT/US98/17697 Indirect inhibition of farnesyl-protein transferase in vivo has been demonstrated with lovastatin (Merck & Co., Rahway, NJ) and compactin (Hancock et al., ibid; Casey et al., ibid; Schafer et al., Science 245:379 (1989)). These drugs inhibit HMG-CoA reductase, 5 the rate limiting enzyme for the production of polyisoprenoids includ ing farnesyl pyrophosphate. Inhibition of farnesyl pyrophosphate biosynthesis by inhibiting HMG-CoA reductase blocks Ras membrane localization in cultured cells. It has been disclosed that the lysine-rich region and 10 terminal CVIM sequence of the C-terminus of K4B-Ras confer resist ance to inhibition of the cellular processing of that protein by certain selective FPTase inhibitors. (James, et al., J. Biol. Chem. 270, 6221 (1995)) Those FPTase inhibitors were effective in inhibiting the processing of H-Ras proteins. James et al., suggested that prenylation 15 of the K4B-Ras protein by GGTase contributed to the resistance to the selective FPTase inhibitors. (Zhang et al, J. Biol. Chem. 272 :10232-239 (1997); Rowell et al, J. Biol. Chem. 272 :14093-14097 (1997); Whyte et al, J. Biol. Chem. 272 :14459-14464 (1997)). Several groups of scientists have recently disclosed 20 compounds that are non-selective FPTase/GGTase inhibitors. (Nagasu et al. Cancer Research, 55:5310-5314 (1995); PCT application WO 95/25086). Recently, synergy between certain anions and farnesyl diphosphate competitive inhibitors of FPTase has been disclosed 25 (J. D. Scholten et al. J. Biol. Chem. 272:18077-18081 (1997)). It is the object of the present invention to provide a method of inhibiting prenyl-protein transferases and treating cancer which utilizes a compound which is a prenyl-protein transferase inhibitor, and which is efficacious in vivo as an inhibitor of the 30 growth of cancer cells characterized by a mutated K4B-Ras protein. A composition which comprises such an inhibitor compound is used in the present invention to treat cancer. It is also the object of the instant invention to provide a -5- WO 99/10523 PCT/US98/17697 method for identifying a prenyl-protein transferase inhibitor which is efficacious in vivo as an inhibitor of geranylgeranyl-protein transferase type I (GGTase-I), also known as CAAX GGTase. 5 SUMMARY OF THE INVENTION The instant invention provides for a method of inhibiting prenyl-protein transferases and treating cancer which comprises administering to a mammal a prenyl-protein transferase inhibitor which is efficacious in vivo as an inhibitor of geranylgeranyl 10 protein transferase type I (GGTase-I). The invention also provides for a method of inhibiting farnesyl-protein transferase and geranylgeranyl protein transferase type I by administering a compound that is a dual inhibitor of both of those prenyl-protein transferases. The invention also provides for a method of identifying such a compound, the method 15 comprising a modified inhibitory assay that incorporates a modulator anion that alters the in vitro potency of prenyl-protein transferase inhibitors in a way that predicts their potency in vivo, thus providing convenient identification of compounds that possess such in vivo activity. 20 BRIEF DESCRIPTION OF THE FIGURES FIGURES 1A and 1B: Effect of P-glycerol phosphate on IC50 of Compound 1 in GGTase-I reaction 25 Effect of P-glycerol phosphate on IC50 of Compound 1 in GGTase-I reaction using recombinant enzyme and K4B-Ras protein substrate is illustrated. Figure 1A : Titrations of Compound 1 were performed at various fixed concentrations of P-glycerol phosphate. Figure 1B : Compound 1 IC50's were re-plotted as a function of the 30 concentration of glycerophosphate. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method of inhibiting prenyl-protein transferases which comprises administering to a mammal 35 in need thereof a pharmaceutically effective amount of a prenyl-protein -6- WO 99/10523 PCT/US98/17697 transferase inhibitor which is efficacious in vivo as an inhibitor of geranylgeranyl-protein transferase type I (GGTase-I). Such an inhibitor is characterized by: a) an IC 50 (a measurement of in vitro inhibitory activity) of less 5 than about 5 gM against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAX G motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion. The inhibitor used in the instant method may be further 10 characterized by one or both: b) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 1 gM against transfer of a farnesyl residue to a protein or peptide substrate comprising a CAAX F motif by farnesyl-protein transferase; and 15 c) an IC 5 0 (a measurement of in vitro inhibitory activity) of less than about 100 nM against the anchorage independent growth of H-ras transformed mammalian fibroblasts. The inhibitor compounds useful in the instant method are also useful in the treatment of cancer and other proliferative disorders 20 in mammals in need thereof. In an embodiment of the invention the inhibitor compounds have inhibitory concentrations (IC50) of less than about 1 gM against GGTase-I in the presence of a modulating anion. Preferably such compounds have inhibitory concentrations (IC50) of less than about 500 nM against GGTase-I in the presence of 25 a modulating anion. Most preferably, such compounds have an IC50 of less than 250 nM against GGTase-I in the presence of a modulating anion. A preferred cancer is one which is characterized by mutated K4B-Ras. In another embodiment, the compound useful in the 30 methods of the instant inventions is characterized by an IC 50 (a measurement of in vitro inhibitory activity) of less than about 500 nM, but greater than about 5 nM against transfer of a gerany eranyl residue to a protein or peptide substrate comprising a CAAX motif -7- WO 99/10523 PCT/US98/17697 by geranylgeranyl-protein transferase type I in the presence of a modulating anion. Preferably, the prenyl-protein transferases that are being inhibited by the instant method are both farnesyl-protein transferase 5 and geranylgeranyl-protein transferase type I. The invention also relates to a method of identifying a prenyl-protein transferase inhibitor which is efficacious in vivo as an inhibitor of geranylgeranyl-protein transferase type I (GGTase-I). The instant method comprises the step of determining the inhibitory activity 10 of a test compound against GGTase-I in a novel modified in vitro enzymatic assay. The modified GGTase-I inhibition assay of the instant invention comprises an anion at a concentration that modulates the in vitro GGTase-I inhibitory potency of the prenyl-protein transferase 15 inhibitor. In an embodiment of the instant methods, the prenyl-protein transferase inhibitor which is efficacious in vivo as an inhibitor of GGTase-I is characterized by an increased potency in vitro against GGTase-I in the instant modified assay when compared to its potency in the absence of the modulating anion. The ratio of the inhibitory 20 activities in the presence vs the absence of the modulating anion may also provide useful mechanistic information on the interaction of the inhibitory compound with GGTase-I. In this embodiment of the instant invention, with regard to the compound utilized in the instant methods of inhibiting farnesyl 25 protein transferase and GGTase-I and treating cancer, the IC 50 (a measurement of in vitro inhibitory activity) of the compound against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAX G motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion is greater than 5 fold lower than 30 the IC50 against said transfer of a geranylgeranyl residue in the absence of a modulating anion. It is more preferred in this embodiment that the compound in the presence of a modulating anion has greater than 7 fold lower IC50. It is more preferred that the compound in the presence of -8- WO 99/10523 PCT/US98/17697 a modulating anion has greater than 10 fold lower IC50. It is still more preferred in this embodiment that the compound in the presence of a modulating anion has greater than 25 fold lower IC50. It is most preferred in this embodiment that the compound in the presence of 5 a modulating anion has greater than 150 fold lower IC50. In another embodiment of the instant invention, with regard to the compound utilized in the instant methods of inhibiting famesyl protein transferase and GGTase-I and treating cancer, the IC 5 0 (a measurement of in vitro inhibitory activity) of the compound against 10 transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAX G motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion is 5 fold or less lower than the IC50 against said transfer of a geranylgeranyl residue in the absence of a modulating anion. 15 In particular, the assay for identifying compounds that inhibit geranylgeranyl-protein transferase type I activity (also referred to as the modified in vitro GGTase-I assay), comprises the steps of: a) reacting a protein or peptide substrate comprising a CAAXG motif with geranylgeranyl pyrophosphate and geranylgeranyl-protein 20 transferase type I in the presence of a test compound and further in the presence of a modulating anion; b) detecting whether the geranylgeranyl residue is incorporated into the protein or peptide substrate, in which the ability of the test compound to inhibit geranylgeranyl-protein transferase type I 25 activity is indicated by a decrease in the incorporation of the geranylgeranyl residue into the protein or peptide substrate as compared to the amount of the geranylgeranyl residue incorporated into the protein or peptide substrate in the absence of the test substance. 30 The modulating anion may be selected from any type of molecule containing an anion moiety. Preferably the modulating anion is selected from a phosphate or sulfate containing anion. Particular examples of modulating anions useful in the instant GGTase-I inhibition assay include adenosine 5'-triphosphate (ATP), 2'-deoxyadenosine -9- WO 99/10523 PCT/US98/17697 5'-triphosphate (dATP), 2'-deoxycytosine 5'-triphosphate (dCTP), P-glycerol phosphate, pyrophosphate, guanosine 5'-triphosphate (GTP), 2'-deoxyguanosine 5'-triphosphate (dGTP), uridine 5' triphosphate, dithiophosphate, 3'-deoxythymidine 5'-triphosphate, 5 tripolyphosphate, D-myo-inositol 1,4,5-triphosphate, chloride, guanosine 5'-monophosphate, 2'-deoxyguanosine 5'-monophosphate, orthophosphate, formycin A, inosine diphosphate, trimetaphosphate, sulfate and the like. Preferably, the modulating anion is selected from adenosine 5'-triphosphate, 2'-deoxyadenosine 5'-triphosphate, 10 2'-deoxycytosine 5'-triphosphate, P-glycerol phosphate, pyrophosphate, guanosine 5'-triphosphate, 2-deoxyguanosine 5'-triphosphate, uridine 5'-triphosphate, dithiophosphate, 3'-deoxythymidine 5'-triphosphate, tripolyphosphate, D-myo-inositol 1,4,5-triphosphate and sulfate. Most preferably, the modulating anion is selected from adenosine 15 5'-triphosphate, -glycerol phosphate, pyrophosphate, dithiophosphate and sulfate. The extent to which the in vitro GGTase-I inhibitory potency of the prenyl-protein transferase inhibitor is increased in the presence of the modulating anion is dependent on the amount of 20 anion that is added to the buffered assay system and the nature of the modulating anion. Preferably from about 0.1 mM to about 100 mM of the modulating anion is added to the buffered assay system. Most preferably, from about 1 mM to about 10 mM of the modulating anion is added. 25 The protein or peptide substrate utilized in the instant assay may incorporate any CAAX motif that is geranylgeranylated by GGTase-I. The term "CAAXG"9 will refer to such motifs that may be geranylgeranylated by GGTase-I. In particular such "CAAX
G
,, motifs include (the corresponding human protein is in parentheses): 30 CVIM (K4B-Ras) (SEQ.ID.: 1), CVLL (mutated H-Ras) (SEQ.ID.: 2), CVVM (N-Ras) (SEQ.ID.: 3), CIIM (K4A-Ras) (SEQ.ID.: 4), CLLL (Rap-IA) (SEQ.ID.: 5), CQLL (Rap-IB) (SEQ.ID.: 6), CSIM (SEQ.ID.: 7), CAIM (SEQ.ID.: 8), CKVL (SEQ.ID.: 9), CLIM (PFX) (SEQ.ID.: 10) and CVIL (Rap-2B) (SEQ.ID.: 14). Preferably, the - 10- WO 99/10523 PCT/US98/17697 CAAX motif is CVIM (SEQ.ID.: 1). It is understood that some of the "CAAXG,, containing protein or peptide substrates may also be farnesylated by farnesyl-protein transferase. As used herein, the term "CAAX
F
" is used to designate 5 a protein or peptide substrate that incorporates four amino acid C-terminus motif that is farnesylated by farnesyl-protein transferase. In particular such "CAAX
F
" motifs include (the corresponding human protein is in parentheses): CVLS (H-ras) (SEQ.ID.: 11), CVIM (K4B Ras) (SEQ.ID.: 1), CVVM (N-Ras) (SEQ.ID.: 3) and CNIQ (Rap-2A) 10 (SEQ.ID.: 15). It is understood that certain of the "CAAX
F
,, containing protein or peptide substrates may also be geranylgeranylated by GGTase-I. When a particular Ras protein is referred to herein by a term such as "K4B-Ras", "N-Ras", "H-Ras" and the like, such 15 a term represents both the protein arising from expression of the corresponding wild type ras gene and various proteins arising from expression of ras genes containing various point mutations. When a particular ras gene is referred to herein by a term such as "K4B-ras", "N-ras", "H-ras" and the like, such a term represents both the wild 20 type ras gene and ras genes containing various point mutations. It is further preferred that the compound identified by the instant method is also a potent in vivo farnesyl-protein transferase inhibitor. It has been surprisingly found that such a potent dual inhibitor is particularly useful as an in vivo inhibitor of the growth of 25 cancer cells, particularly those cancers characterized by a mutated K4B Ras protein, at concentrations of inhibitor that do not cause mechanism based toxicity. Mechanism-based toxicity of farnesyl-protein transferase inhibitors can be anticipated in rapidly proliferating tissues, for example, the bone marrow. Such an inhibitor can be identified by the 30 steps of: a) assessing a test compound for its in vitro inhibitory activity against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAXG motif by geranylgeranyl-protein transferase in the presence of a modulating anion; - 11 - WO 99/10523 PCT/US98/17697 b) assessing a test compound for its in vitro inhibitory activity against transfer of a farnesyl residue to a protein or peptide substrate comprising a CAAX F motif by farnesyl-protein transferase; and c) assessing the test compound for its ability to inhibit the anchorage 5 independent growth of H-ras-transformed mammalian fibroblasts. Preferably, the potent dual inhibitor identified by the instant method has an IC50 of less than about 100 nM against the anchorage independent growth of H-ras-transformed mammalian fibroblasts in a cell culture assay (referred to herein as the SALSA 10 assay). Other methods of assessing the ability of a test compound to inhibit the anchorage independent growth of ras-transformed mammalian fibroblasts have been previously described (eg. N. E. Kohl et al. Science, 260:1934-1937 (1993)). Most preferably, the potent dual inhibitor identified by the instant method has an IC50 of less than about 15 20 nM in the SALSA assay. Preferably the potent dual inhibitor has an inhibitory concentration (IC50) of less than about 1 jtM against GGTase-I in the modified in vitro GGTase-I assay. More preferably such compounds have inhibitory concentrations (IC50) of less than about 500 nM against 20 GGTase-I in the presence of a modulating anion. Preferably the potent dual inhibitor has an inhibitory concentration (IC50) of less than about 500 nM against FPTase in the in vitro FPTase assay. More preferably, the instant inhibitor has an inhibitory concentration (IC50) of less than about 100 nM against FPTase in the in vitro FPTase assay. Still more 25 preferably, the instant inhibitor has an inhibitory concentration (IC50) of less than about 10 nM against FPTase in the in vitro FPTase assay. Preferably, the potent dual inhibitor identified by the instant method has an IC50 of less than about 1 RM against the anchorage independent growth of H-ras-transformed mammalian 30 fibroblasts in a cell culture assay (referred to herein as the SALSA assay), an inhibitory concentration (IC50) of less than about 1 RM against GGTase-I in the modified in vitro GGTase-I assay and an inhibitory concentration (IC50) of less than about 500 nM against FPTase in the in vitro FPTase assay. - 12 - WO 99/10523 PCT/US98/17697 In a further embodiment of the instant invention, with regard to the compound utilized in the instant methods of inhibiting both farnesyl-protein transferase and GGTase-I and treating cancer, the ratio of the apparent enzymologic K i value of the compound against transfer 5 of a geranylgeranyl residue to a protein or peptide substrate comprising G a CAAX motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion (hereafter Kia G) (determined as described in Example 11) to the apparent enzymologic K i value of the compound against transfer of a farnesyl residue to a protein or peptide F 10 substrate comprising a CAAX motif by farnesyl-protein transferase (hereafter Kia ) (determined as described in Example 10) is greater than 0.002 and less than 5,000. As used herein, the term "apparent enzymologic Ki" represents either the only enzymologic Ki exhibited by a compound in the assay and calculations or, if multiple enzymologic 15 Ki's are exhibited by a compound in the assay and calculations, then the G F lowest enzymologic Ki. Preferably, the ratio of Kia to Kia is greater G F than 0.1 and less than 500. Most preferably, ratio of Kia to Kia Fis greater than 1 and less than 100. The term GGTase-I or farnesyl-protein transferase 20 inhibiting compound refers to compounds which antagonize, inhibit or counteract the activities of: the gene coding GGTase-I or farnesyl protein transferase or the proteins encoded by these genes. The preferred therapeutic effect provided by the instant composition is the treatment of cancer and specifically the inhibition 25 of cancerous tumor growth and/or the regression of cancerous tumors. Cancers which are treatable in accordance with the invention described herein include cancers of the brain, breast, colon, genitourinary tract, prostate, skin, lymphatic system, pancreas, rectum, stomach, larynx, liver and lung. More particularly, such cancers include histiocytic 30 lymphoma, lung adenocarcinoma, pancreatic carcinoma, colo-rectal carcinoma, small cell lung cancers, bladder cancers, head and neck cancers, acute and chronic leukemias, melanomas, and neurological tumors. - 13 - WO 99/10523 PCT/US98/17697 The composition of this invention is also useful for inhibiting other proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes (i.e., the ras gene itself is not activated by 5 mutation to an oncogenic form) with said inhibition being accomplished by the administration of an effective amount of the instant composition to a mammal in need of such treatment. For example, the composition is useful in the treatment of neurofibromatosis, which is a benign proliferative disorder. 10 The composition of the instant invention is also useful in the prevention of restenosis after percutaneous transluminal coronary angioplasty by inhibiting neointimal formation (C. Indolfi et al. Nature medicine, 1:541-545(1995). The instant composition may also be useful in the treatment 15 and prevention of polycystic kidney disease (D.L. Schaffner et al. American Journal of Pathology, 142:1051-1060 (1993) and B. Cowley, Jr. et al. FASEB Journal, 2:A3160 (1988)). The instant compounds may also inhibit tumor angio genesis, thereby affecting the growth of tumors (J. Rak et al. Cancer 20 Research, 55:4575-4580 (1995)). Such anti-angiogenesis properties of the instant compounds may also be useful in the treatment of certain forms of vision deficit related to retinal vascularization. The instant compounds may also be useful in the treatment of certain viral infections, in particular in the treatment of hepatitis 25 delta and related viruses (J.S. Glenn et al. Science, 256:1331-1333 (1992). The instant compounds may also be useful as inhibitors of proliferation of vascular smooth muscle cells and therefore useful in the prevention and therapy of arteriosclerosis and diabetic vascular 30 pathologies. The compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers, excipients - 14- WO 99/10523 PCT/US98/17697 or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice. The compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration. 5 The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according 10 to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain 15 the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, 20 microcrystalline cellulose, sodium crosscarmellose, corn starch, or alginic acid; binding agents, for example starch, gelatin, polyvinyl pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to mask the unpleasant taste of the drug 25 or delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a water soluble taste masking material such as hydroxypropylmethyl cellulose or hydroxypropylcellulose, or a time delay material such as ethyl cellulose, cellulose acetate buryrate may be employed. 30 Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed - 15 - WO 99/10523 PCT/US98/17697 with water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil. Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous 5 suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an 10 alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or 15 condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or 20 more sweetening agents, such as sucrose, saccharin or aspartame. Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, 25 hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as butylated hydroxyanisol or alpha-tocopherol. Dispersible powders and granules suitable for preparation 30 of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, - 16 - WO 99/10523 PCT/US98/17697 flavoring and coloring agents, may also be present. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. The pharmaceutical compositions of the invention may also 5 be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol 10 anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring agents, preservatives and antioxidants. Syrups and elixirs may be formulated with sweetening 15 agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant. The pharmaceutical compositions may be in the form of a sterile injectable aqueous solutions. Among the acceptable vehicles and 20 solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. The sterile injectable preparation may also be a sterile injectable oil-in-water microemulsion where the active ingredient is dissolved in the oily phase. For example, the active ingredient may be 25 first dissolved in a mixture of soybean oil and lecithin. The oil solution then introduced into a water and glycerol mixture and processed to form a microemulation. The injectable solutions or microemulsions may be introduced into a patient's blood-stream by local bolus injection. 30 Alternatively, it may be advantageous to administer the solution or microemulsion in such a way as to maintain a constant circulating concentration of the instant compound. In order to maintain such a constant concentration, a continuous intravenous delivery device may - 17 - WO 99/10523 PCT/US98/17697 be utilized. An example of such a device is the Deltec CADD-PLUSTM model 5400 intravenous pump. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension for intramuscular 5 and subcutaneous administration. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for 10 example as a solution in 1,3-butane diol. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. 15 Compounds of Formula A may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release 20 the drug. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol. For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula A are employed. 25 (For purposes of this application, topical application shall include mouth washes and gargles.) The compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles and delivery devices, or via transdermal routes, using those 30 forms of transdermal skin patches well known to those of ordinary skill in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. - 18 - WO 99/10523 PCT/US98/17697 As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specific amounts, as well as any product which results, directly or indirectly, from combination of the specific ingredients in the specified amounts. 5 The compounds identified by the instant method may also be co-administered with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated. For example, the instant compounds may be useful in combination with known anti-cancer and cytotoxic agents. 10 Similarly, the instant compounds may be useful in combination with agents that are effective in the treatment and prevention of neuro fibromatosis, restinosis, polycystic kidney disease, infections of hepatitis delta and related viruses and fungal infections. The instant compounds may also be useful in combination with other inhibitors 15 of parts of the signaling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation. The instant compounds may be utilized in combination with farnesyl pyrophosphate competitive inhibitors of the activity of farnesyl-protein transferase or in combination with a compound 20 which has Raf antagonist activity. The instant compounds may also be co-administered with compounds that are selective inhibitors of geranylgeranyl protein transferase or selective inhibitors of farnesyl protein transferase. The compounds of the instant invention may also be 25 co-administered with other well known cancer therapeutic agents that are selected for their particular usefulness against the condition that is being treated. Included in such combinations of therapeutic agents are combinations of the instant prenyl-protein transferase inhibitors and an antineoplastic agent. It is also understood that the instant 30 combination of antineoplastic agent and inhibitor of prenyl-protein transferase may be used in conjunction with other methods of treating cancer and/or tumors, including radiation therapy and surgery. - 19 - WO 99/10523 PCT/US98/17697 If formulated as a fixed dose, such combination products employ the combinations of this invention within the dosage range described below and the other pharmaceutically active agent(s) within its approved dosage range. Combinations of the instant invention 5 may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when a multiple combination formulation is inappropriate. Radiation therapy, including x-rays or gamma rays which are delivered from either an externally applied beam or by implantation 10 of tiny radioactive sources, may also be used in combination with an inhibitor of prenyl-protein transferase alone to treat cancer. Additionally, compounds of the instant invention may also be useful as radiation sensitizers, as described in WO 97/38697, published on October 23, 1997, and herein incorporated by reference. 15 The instant compounds may also be useful in combination with other inhibitors of parts of the signaling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation. Thus, the instant compounds may be utilized in combination with farnesyl pyrophosphate competitive inhibitors of 20 the activity of farnesyl-protein transferase or in combination with a compound which has Raf antagonist activity. The instant compounds may also be useful in combination with an integrin antagonist for the treatment of cancer, as described in U.S. Ser. No. 09/055,487, filed April 6, 1998, which is incorporated 25 herein by reference. As used herein the term an integrin antagonist refers to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to an integrin(s) that is involved in the regulation of angiogenisis, or in the growth and invasiveness of tumor 30 cells. In particular, the term refers to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the axv33 integrin, which selectively antagonize, inhibit or counteract binding of a physiological ligand to the avP5 integrin, which antagonize, inhibit or counteract binding of a physiological ligand to - 20 - WO 99/10523 PCT/US98/17697 both the avP3 integrin and the ev35 integrin, or which antagonize, inhibit or counteract the activity of the particular integrin(s) expressed on capillary endothelial cells. The term also refers to antagonists of the cvP6, xav38, alp13l, a2pl, a531, 6pl31 and x6P4 integrins. The term 5 also refers to antagonists of any combination of av3, cxv35, av36, av38, alp1, c2pl, O 5pl, a6pl3 and u6P4 integrins. The instant compounds may also be useful with other agents that inhibit angiogenisis and thereby inhibit the growth and invasiveness of tumor cells, including, but not limited to angiostatin and endostatin. 10 When a composition according to this invention is administered into a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms. 15 In one exemplary application, a suitable amount of a prenyl-protein transferase inhibitor are administered to a mammal undergoing treatment for cancer. Administration occurs in an amount of each type of inhibitor of between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, preferably of between 0.5 20 mg/kg of body weight to about 40 mg/kg of body weight per day. A particular therapeutic dosage that comprises the instant composition includes from about 0.01mg to about 1000mg of a prenyl-protein transferase inhibitor. Preferably, the dosage comprises from about 1mg to about 1000mg of a prenyl-protein transferase inhibitor. 25 Examples of an antineoplastic agent include, in general, microtubule-stabilising agents ( such as paclitaxel (also known as Taxol®), docetaxel (also known as Taxotere®), or their derivatives); alkylating agents, anti-metabolites; epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; 30 mitoxantrone; platinum coordination complexes; biological response modifiers and growth inhibitors; hormonal/anti-hormonal therapeutic agents and haematopoietic growth factors. Example classes of antineoplastic agents include, for example, the anthracycline family of drugs, the vinca drugs, the - 21 - WO 99/10523 PCT/US98/17697 mitomycins, the bleomycins, the cytotoxic nucleosides, the taxanes, the epothilones, discodermolide, the pteridine family of drugs, diynenes and the podophyllotoxins. Particularly useful members of those classes include, for example, doxorubicin, carminomycin, 5 daunorubicin, aminopterin, methotrexate, methopterin, dichloro methotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin or podo-phyllotoxin derivatives such as etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, 10 vincristine, leurosidine, vindesine, leurosine, paclitaxel and the like. Other useful antineoplastic agents include estramustine, cisplatin, carboplatin, cyclophosphamide, bleomycin, gemcitibine, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT-11, 15 topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons and interleukins. Compounds of the instant invention that are identified by the properties described hereinabove include: (a) a compound represented by formula I:
(R
8 )r N R 9 a R 2 V - Al(CRa 2 )nA 2 (CRa 2 ) R N N-Z 20
R
4
R
3 wherein: Rla is selected from: hydrogen or C1-C6 alkyl; 25 Rlb is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 10 0-, -N(R 10 )2 or C2-C6 alkenyl, - 22 - WO 99/10523 PCT/US98/17697 c) C 1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, R 10 0-, or -N(R 10 ) 2 ;
R
3 and R 4 selected from H and CH3; 5 R 2 is selected from H; unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, " NR 6
R
7 0 or Ci1-5 alkyl, unbranched or branched, unsubstituted or substituted with one or more of: 10 1) aryl, 2) heterocycle, 3) OR 6 , 4) SR 6 a, SO2R 6 a, or 5) NR 6
R
7 O 0 15 and R 2 and R 3 are optionally attached to the same carbon atom;
R
6 and R 7 are independently selected from: H; C1-4 alkyl, C3-6 cycloalkyl, aryl, heterocycle, unsubstituted or substituted with: 20 a) C1-4 alkoxy, b) halogen, c) perfluoro-C1-4 alkyl, or d) aryl or heterocycle; 25 R 6 a is selected from: C1-4 alkyl or C3-6 cycloalkyl, unsubstituted or substituted with: a) C1-4 alkoxy, b) halogen, or 30 c) aryl or heterocycle; - 23 - WO 99/10523 PCT/US98/17697
R
8 is independently selected from: a) hydrogen, b) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 10 0-, R10C(O)NR 10 -, CN, NO2, 5 (R 10 )2N-C(NR 1 0)-, RO10C(O)-, -N(R10)2, or
R
1 1
OC(O)NR
10 -, and c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R 10 0-,
R
1 0C(O)NRO10-, (R 10 )2N-C(NR 1 0)-, RO10C(O)-, -N(R10)2, or R 1 1 0C(O)NRO- 10 ; 10
R
9 a is hydrogen or methyl;
R
10 is independently selected from hydrogen, C 1-C6 alkyl, C 1-C6 perfluoroalkyl, 2,2,2-trifluoroethyl, benzyl and aryl; 15
R
1 1 is independently selected from C1 -C6 alkyl and aryl;
A
1 and A 2 are independently selected from: a bond, -CH=CH-, -CEC-, -C(O)-, -C(O)NRO 10 -, O, -N(RO10)-, or S(O)m; 20 V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, 25 quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, and 30 provided that V is not hydrogen if A 1 is S(O)m and V is not hydrogen if A 1 is a bond, n is 0 and A 2 is S(O)m; X is -CH2- or -C(=O)-; - 24 - WO 99/10523 PCT/US98/17697 Z is selected from: 1) a unsubstituted or substituted group selected from aryl, heteroaryl, arylmethyl, heteroarylmethyl, arylsulfonyl, 5 heteroarylsulfonyl, wherein the substituted group is substituted with one or more of the following: a) C1-4 alkyl, unsubstituted or substituted with: C1-4 alkoxy, NR 6
R
7 , C3-6 cycloalkyl, unsubstituted or substituted aryl, heterocycle, HO, -S(O)mR 6 a, or 10 -C(O)NR 6
R
7 , b) aryl or heterocycle, c) halogen, d) OR 6 , e) NR 6
R
7 , 15 f) CN, g) NO2, h) CF3; i) -S(O)mR 6 a, j) -C(O)NR 6
R
7 , or 20 k) C3-C6 cycloalkyl; or 2) unsubstituted Ci1-C6 alkyl, substituted C1-C6 alkyl, unsubstituted C3-C6 cycloalkyl or substituted C3-C6 cycloalkyl, wherein the substituted C1-C6 alkyl and substituted C3-C6 cycloalkyl is substituted with one or two of the 25 following: a) C1-4 alkoxy, b) NR 6
R
7 , c) C3-6 cycloalkyl, d) -NR 6
C(O)R
7 , 30 e) HO, f) -S(O)mR 6 a, g) halogen, or h) perfluoroalkyl; - 25 - WO 99/10523 PCT/US98/17697 m is 0, 1 or 2; nis 0, 1, 2, 3 or4; p is 0, 1, 2, 3 or 4; and r is 0 to 5, provided that r is 0 when V is hydrogen; 5 provided that the substituent (R 8 )r- V -A (CR 1 a2)nA 2 (CR1 a2)n is not H; b) the inhibitors of farnesyl-protein transferase are 10 illustrated by the formula II: (R )r R 9a
R
2 3 V - A'(CR 1 a 2 )nA 2 (CRl1a 2 ) q X N\ (CRib2) p xl-(CRlc2)-Z II
R
4 wherein: R1a is selected from: hydrogen or C1-C6 alkyl; 15 Rlb is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 10 0-, -N(R 10 )2 or C2-C6 alkenyl, 20 c) C1-C6 alkyl unsubstituted or substituted by unsubstituted or substituted aryl, heterocycle, cycloalkyl, alkenyl, R 10 0-, or -N(R10)2; R1c is selected from: 25 a) hydrogen, b) unsubstituted or substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R 10 0-, - 26 - WO 99/10523 PCT/US98/17697
R
1 1 S(O)m-, R10C(O)NR10-, (R 10 )2N-C(O)-, CN,
(R
10 )2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3,
-N(R
10 )2, and R 1 1
OC(O)-NR
10 -, and c) unsubstituted or substituted aryl; 5
R
3 and R 4 independently selected from H and CH3;
R
2 is selected from H; OR 10 ;
NR
6
R
7 0 10 or C1-5 alkyl, unbranched or branched, unsubstituted or substituted with one or more of: 1) aryl, 2) heterocycle, 3) OR 6 , 15 4) SR 6 a, SO2R 6 a, or 5) NR 6
R
7 O and R 2 , R 3 and R 4 are optionally attached to the same carbon atom; 20 R 6 and R 7 are independently selected from: H; C1-4 alkyl, C3-6 cycloalkyl, aryl, heterocycle, unsubstituted or substituted with: a) C1-4 alkoxy, b) halogen, or c) aryl or heterocycle; 25
R
6 a is selected from: C1-4 alkyl or C3-6 cycloalkyl, unsubstituted or substituted with: a) C1-4 alkoxy, 30 b) halogen, or c) aryl or heterocycle; - 27 - WO 99/10523 PCT/US98/17697
R
8 is independently selected from: a) hydrogen, b) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 5 perfluoroalkyl, F, Cl, R 10 0-, RO10C(O)NRO 10 -, CN, NO2, (R10)2N-C(NR 10 )-, RO10C(O)-, -N(R10)2, or
R
1 1
OC(O)NR
10 -, and c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R 10 0-, R10OC(O)NR 10 -, (R 10 )2N-C(NR 10 )-, R10C(O)-, 10 -N(R 10 )2, or R 1 1
OC(O)NR
10 -;
R
9 a is hydrogen or methyl;
R
10 is independently selected from hydrogen, C 1-C6 alkyl, C 1-C6 perfluoroalkyl, 2,2,2-trifluoroethyl, benzyl and aryl; 15 R 1 1 is independently selected from C1-C6 alkyl and aryl;
R
12 is selected from: H; unsubstituted or substituted C1-8 alkyl, unsubstituted or substituted aryl or unsubstituted or substituted heterocycle, wherein the substituted alkyl, substituted aryl or substituted 20 heterocycle is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) C1-4 alkyl, b) (CH2)pOR 6 , c) (CH2)pNR 6
R
7 , 25 d) halogen, e) CN, f) aryl or heteroaryl, g) perfluoro-C1-4 alkyl, h) SR 6 a, S(O)R 6 a, SO 2 R6a, 30 2) C3-6 cycloalkyl, 3) OR 6 , 4) SR 6 a, S(O)R 6 a, or SO 2 R6a, - 28 - WO 99/10523 PCT/US98/17697 5)
-NR
6
R
7 R6 6) -N-
R
7 O 7) R 6 -N
NR
7
R
7 a O 0 8) -0
NR
6
R
7 O 0 9) - O OR 6 O 0 10) . NR 6
R
7 O 0 11) -SO 2
-NR
6
R
7 R6 12)
-N-SO
2 - R 6 a 13) R 6 0 O 14) "rOR 6 O 0 15)
N
3 , 16) F, 17) perfluoro-C l
-
4 -alkyl, or 18) Cl.- 6 -alkyl; 5 Al and A 2 are independently selected from: a bond, -CH=CH-, -C-=C-, - 29 - WO 99/10523 PCT/US98/17697 -C(O)-, -C(O)NRO 10 -, -NRO10C(O)-, O, -N(RO10)-, or S(O)m; V is selected from: 5 a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, 10 d) C 1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, and provided that V is not hydrogen if A 1 is S(O)m and V is not hydrogen if A 1 is a bond, n is 0 and A 2 is S(O)m; 15 X is -CH2- or -C(=O)-; X1 is a bond, -C(=0)-, -NR 6 C(=0)-, -NR 6 -, -0- or -S(=O)m-; 20 Y is selected from: a) hydrogen, b) R 10 0-, R 1 1 S(0)m-, R 10
C(O)NR
10 -, (R 10 )2N-C(O)-, CN, NO2, (R 10 )2N-C(NR10)-, R 12 C(O)-, R10OC(O)-, N3, F, -N(R10)2, or R11 OC(O)NR10-, 25 c) unsubstituted or substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, R 10 0-, RO10C(0)NR10-,
(R
10 )2N-C(0)-, RO10C(O)- and R10OC(O)-; 30 Z is an unsubstituted or substituted aryl, wherein the substituted aryl is substituted with one or more of the following: 1) C 1-4 alkyl, unsubstituted or substituted with: a) C1-4 alkoxy, b) NR 6
R
7 , - 30 - WO 99/10523 PCT/US98/17697 c) C3-6 cycloalkyl, d) aryl, substituted aryl or heterocycle, e) HO, f) -S(O)mR 6 a, or 5 g) -C(O)NR 6
R
7 , 2) aryl or heterocycle, 3) halogen, 4) OR 6 , 5) NR 6
R
7 , 10 6) CN, 7) NO2, 8) CF3; 9) -S(O)mR 6 a, 10) -C(O)NR 6
R
7 , or 15 11) C3-C6 cycloalkyl; mis 0, 1 or 2; nis 0, 1, 2, 3 or4; p is 0, 1, 2, 3 or 4; and 20 r is 0 to 5, provided that r is 0 when V is hydrogen; and vis 0, 1 or 2; (c) a compound represented by formula III:
R
9 (R 8 )r (28)N N z (ca 42)qA 3(Ca 52)na E V -ARA'(CR'2)nA 2 (CR'2 (R 4 2 )qA 3 ()p
A
R
5 2 )nR 4 N
L
1 III R3 wherein: 25 R1 is independently selected from: hydrogen or C1-C6 alkyl;
R
2 is independently selected from: a) hydrogen, - 31 - WO 99/10523 PCT/US98/17697 b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C3-C10 cycloalkyl, R 10
O
0- or C2-C6 alkenyl, c) C1-C6 alkyl unsubstituted or substituted by aryl, 5 heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, R 10 0-, or -N(R10)2;
R
3 is selected from: a) hydrogen, 10 b) C 1-C6 alkyl unsubstituted or substituted by C2-C6 alkenyl, R1 0 0-, R 11 S(O)m-, R10C(O)NR 10 -, CN, N3, (R 10 )2N-C(NR 1 0)-, RO10C(O)-, -N(R 10 )2, or
R
1 1OC(O)NR10-, c) substituted or unsubstituted aryl, substituted or 15 unsubstituted heterocycle, C3-C 10 cycloalkyl, C2-C6 alkenyl, fluoro, chloro, R 12 0-,
R
1 1 S(O)m-, R10C(O)NR10-, CN, NO2,
(R
10 )2N-C(NR10)-, RO10C(O)-, N3, -N(R 10 )2, or R11 OC(O)NRO10-, and 20 d) C 1-C6 alkyl substituted with an unsubstituted or substituted group selected from substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic and C3-C10 cycloalkyl; 25 R 4 and R5 are independently selected from: a) hydrogen, b) C1-C6 alkyl unsubstituted or substituted by C2-C6 alkenyl, R 10 0-, R 1 1 S(O)m-, R 10
C(O)NR
10 -, CN, N3, (R 10 )2N-C(NR10)-, RO10C(O)-, -N(R10)2, or 30 R110C(O)NR10-, c) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C3-C 10 cycloalkyl, - 32 - WO 99/10523 PCT/US98/17697 C2-C6 alkenyl, fluoro, chloro, R 10 0-,
R
1 1 S(O)m-, R 10
C(O)NR
10 -, CN, NO2, (RO10)2N-C(NR 1 0)-, RO10C(O)-, N3, -N(R 10 )2, or R 1 1
OC(O)NR
10 -, and 5 d) C 1-C6 alkyl substituted with an unsubstituted or substituted group selected from substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic and C3-C10 cycloalkyl; 10 R 6 is independently selected from: a) hydrogen, b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 10 0-, 15 allyloxy, R10OC(O)NR 1 0-, CN, NO2, (R10)2N-C(NR 1 0)-,
R
1 0C(O)-, -N(R 10 )2, (R 12 )2NC(O)- or R11 OC(O)NR10-, and c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R 10 0-,
R
1 0OC(O)NR 10 - , (R 10 )2N-C(NR10)-, RO10C(O)-, 20 -N(R 10 )2, or R 1 1
OC(O)NR
10 -; R7 is independently selected from a) hydrogen, b) unsubstituted or substituted aryl, 25 c) unsubstituted or substituted heterocycle, d) unsubstituted or substituted cycloalkyl, and e) C1-C6 alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocycle and cycloalkyl; 30 wherein heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, indolyl, quinolinyl, isoquinolinyl, and thienyl; - 33 - WO 99/10523 PCT/US98/17697
R
8 is selected from: a) hydrogen, b) Cl1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 10 0-, RO10C(O)NR 10 -, CN, NO2, 5 (R10)2N-C(NR 10 )-, R10C(O)-, R10OC(O)-, -N(R 10 )2, or
R
1 1 0C(O)NRO 10 -, and c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R 10 0-, R10OC(O)NR 10 -, (R 10 )2N-C(NR 10 )-, R10C(O)-,
R
10 0C(O)-, -N(R 10 )2, or R 1 1
OC(O)NR
10 -; 10
R
9 is selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 10 0-, R 1 1 S(O)m-, R 10
C(O)NR
10 -, CN, NO2, 15 (R 10 )2N-C(NR 10 )-, RO10C(O)-, R10OC(O)-, -N(R 10 )2, or
R
1 1
OC(O)NRO
10 -, and c) C 1-C6 alkyl unsubstituted or substituted by C 1-C6 perfluoroalkyl, F, Cl, R 10 0-, R 1 1 S(O)m-, R 10 C(O)NR10-, CN, (R 10 )2N-C(NR 10 )-, RO10C(O)-, R10OC(O)-, 20 -N(R 10 )2, or R 1 1
OC(O)NR
10 -;
R
10 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 perfluoroalkyl, 2,2,2-trifluoroethyl, benzyl and aryl; 25 R 1 1 is independently selected from C1-C6 alkyl and aryl;
R
12 is independently selected from hydrogen, C1 -C6 alkyl, C1 -C6 alkyl substituted with CO2R 10 , C1-C6 alkyl substituted with aryl, Ci1-C6 alkyl substituted with substituted aryl, CI1-C6 alkyl 30 substituted with heterocycle, C 1-C6 alkyl substituted with substituted heterocycle, aryl and substituted aryl;
A
1 and A 2 are independently selected from: a bond, -CH=CH-, - 34 - WO 99/10523 PCT/US98/17697
-C-=C
-, -C(O)-, -C(O)NR7-, -NR7C(O)-, -S(0)2NR7-,
-NR
7 S(O)2-, O, -N(R 7 )-, or S(O)m;
A
3 is selected from: a bond, -C(0)NR 7 -, -NR 7 C(O)-, -S(O)2NR 7 -, 5 -NR 7 S(O)2- or-N(R7)-;
A
4 is selected from: a bond, O, -N(R 7 )- or S; V is selected from: 10 a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, 15 d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, and provided that V is not hydrogen if A 1 is S(O)m and V is not hydrogen if A 1 is a bond, n is 0 and A 2 is S(O)m; 20 Z is independently (R 1 )2 or O; m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; 25 pis 0, 1,2, 3 or4; q is 0 or 1; and r is 0 to 5, provided that r is 0 when V is hydrogen; d) a compound represented by formula A: R2a R2b RS 4 R3
R
? ~ "N/.il'/. 5' N- (CRlb2P 30 A O - 35 - WO 99/10523 PCT/US98/17697 wherein: Rla is selected from: hydrogen or C1-C6 alkyl; 5 Rlb is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 10 0-, -N(R 10 )2 or C2-C6 alkenyl, c) CI1-C6 alkyl unsubstituted or substituted by aryl, 10 heterocycle, cycloalkyl, alkenyl, R 10 0-, or -N(R10)2; R2a, R2b and R 3 are independently selected from: a) hydrogen, b) C 1-C6 alkyl unsubstituted or substituted by C2-C6 15 alkenyl, R100-, R 1 1 S(O)m
-
, RO10C(O)NR 10 - , CN, N3,
(R
10 )2N-C(NR 1 0)-, R10C(O)
-
, R10OC(O)-, -N(R10)2, or
R
1 10C(O)NR 10 - , c) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or 20 substituted cycloalkyl, alkenyl, R 10 0-,
R
1 1 S(O)m-, R10OC(O)NR10-, CN, NO2,
(R
10 )2N-C(NR10)-, R10C(O)-, R10OC(O)-, N3, -N(R10)2, halogen or R 1 1
OC(O)NR
10 -, and d) C1-C6 alkyl substituted with an unsubstituted or 25 substituted group selected from aryl, heterocyclic and C3-C10 cycloalkyl;
R
4 is
(R
8 )r R 9a V - A'(CR 1 a 2 )nA 2 (CR a 2 ) N 2 (CRlb2 ) 30 R 5 is hydrogen; - 36 - WO 99/10523 PCT/US98/17697 R8 is selected from: a) hydrogen, b) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 5 perfluoroalkyl, F, Cl, R 10 0-, R10C(O)NR1 0 -, CN, NO2,
(R
10 )2N-C(NR 10 )-, R 10 C(O)-, R10OC(O)-, -N(R10)2, or
R
1 1 OC(O)NR10-, and c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R 10 0-, R10OC(O)NR 10 -, (R10)2N-C(NR10)-, R10C(O)-, 10 R10OC(O)-, -N(R 10 )2, or R 1 1
OC(O)NR
10 -;
R
9 a is independently selected from C1 -C6 alkyl and aryl;
R
10 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 15 perfluoroalkyl, 2,2,2-trifluoroethyl, benzyl and aryl;
R
1 1 is independently selected from C1-C6 alkyl, benzyl and aryl;
A
1 and A 2 are independently selected from: a bond, -CH=CH-, 20 -CEC-, -C(O)-, -C(O)NR 8 -, -NR 8 C(O)-, O, -N(R 8 )-, -S(O)2N(R 8 )-, -N(R 8 )S(O)2-, or S(O)m; V is selected from: a) hydrogen, 25 b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) C 1-C20 alkyl wherein from 0 to 4 carbon atoms are 30 replaced with a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, provided that V is not hydrogen if A 1 is S(O)m and V is not hydrogen if A 1 is a bond, n is 0 and A 2 is S(O)m; - 37 - WO 99/10523 PCT/US98/17697 Z is H2 or O; m is 0, 1 or 2; nis 0, 1, 2, 3 or4; 5 p is independently 0, 1, 2, 3 or 4; and r is 0 to 5, provided that r is 0 when V is hydrogen; or the pharmaceutically acceptable salts thereof. In a further embodiment of the formula I compounds 10 of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula I-a: H -, NN N N-Z \ / (CR lb 2 )p
R
2
(R
8 )r I-a wherein: 15 Rlb is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 10 0-, -N(R 10 )2 or C2-C6 alkenyl, c) C 1-C6 alkyl unsubstituted or substituted by aryl, 20 heterocycle, cycloalkyl, alkenyl, R1 0 0-, or -N(R10)2;
R
2 is selected from H; unsubstituted or substituted aryl or C1-5 alkyl, unbranched or branched, unsubstituted or substituted with one or more of: 25 1) aryl, 2) heteroaryl, 3) OR 6 , or 4) SR 6 a; - 38 - WO 99/10523 PCT/US98/17697
R
6 and R 7 are independently selected from: C 1-4 alkyl, aryl, and heteroaryl, unsubstituted or substituted with: a) Ci1-4 alkoxy, 5 b) halogen, c) perfluoro-C 1-4 alkyl, or d) aryl or heteroaryl;
R
6 a is selected from: 10 C 1-4 alkyl, unsubstituted or substituted with: a) C1-4 alkoxy, or b) aryl or heteroaryl;
R
8 is independently selected from: 15 a) hydrogen, b) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 10 0-, RO10C(O)NR10-, CN, NO2, (R10)2N-C(NR10)-, RO10C(O)-, -N(R 10 )2, or RIIOC(O)NR10-, and 20 c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R 10 0-, R10C(O)NR10-, (R10)2N-C(NR10)-, R10C(O)-, -N(R10)2, or R 1 1
OC(O)NR
10 - ;
R
10 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 25 perfluoroalkyl, 2,2,2-trifluoroethyl, benzyl and aryl;
R
1 1 is independently selected from C1-C6 alkyl and aryl; X is -CH2- or -C(=O)-; 30 Z is an unsubstituted or substituted group selected from aryl, arylmethyl and arylsulfonyl, wherein the substituted group is substituted with one or more of the following: a) C1-4 alkyl, unsubstituted or substituted with: - 39 - WO 99/10523 PCT/US98/17697 C1-4 alkoxy, NR 6
R
7 , C3-6 cycloalkyl, unsubstituted or substituted aryl, heterocycle, HO, -S(O)mR 6 a, or
-C(O)NR
6
R
7 , b) aryl or heterocycle, 5 c) halogen, d) OR 6 , e) NR 6
R
7 , f) CN, g) NO2, 10 h) CF3; i) -S(O)mR 6 a, j) -C(O)NR 6
R
7 , or k) C3-C6 cycloalkyl; 15 m is 0, 1 or 2; and p is 0, 1, 2, 3 or 4; and r is 0 to 3; or the pharmaceutically acceptable salts thereof. 20 In another embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula II-a: H N N N (CRlb 2 )p
X
1-(CRic 2 )v-Z
(R
8 )r II-a wherein: 25 Rlb is independently selected from: a) hydrogen, - 40 - WO 99/10523 PCT/US98/17697 b) aryl, heterocycle, cycloalkyl, R 10 0-, -N(R 10 )2 or C2-C6 alkenyl, c) C 1-C6 alkyl unsubstituted or substituted by unsubstituted or substituted aryl, heterocycle, cycloalkyl, alkenyl, R 10 0-, or 5 -N(R10)2; Rlc is selected from: a) hydrogen, b) unsubstituted or substituted CI1-C6 alkyl wherein the 10 substituent on the substituted C 1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R 10 0-,
R
1 1 S(O)m-, R 10
C(O)NR
10 -, (R 10 )2N-C(O)-, CN,
(R
10 )2N-C(NRO10)-, R10OC(O)-, R10OC(O)-, N3, 15 -N(R 10 )2, and R 1 1 0C(O)-NR 10 -, and c) unsubstituted or substituted aryl;
R
6 , R 7 and R 7 a are independently selected from: H; C1-4 alkyl, C3-6 cycloalkyl, aryl, heterocycle, 20 unsubstituted or substituted with: a) C1-4 alkoxy, b) halogen, or c) aryl or heterocycle; 25 R 6 a is selected from: C1-4 alkyl or C3-6 cycloalkyl, unsubstituted or substituted with: a) C1-4 alkoxy, b) halogen, or 30 c) aryl or heterocycle;
R
8 is independently selected from: a) hydrogen, - 41 - WO 99/10523 PCT/US98/17697 b) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 10 0-, RO10C(O)NRO10-, CN, NO2,
(R
10 )2N-C(NR 10 )-, R10C(O)-, -N(R 10 )2, or R IOC(O)NR10-, and 5 c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R 10 0-,
R
1 0C(O)NR 1 0-, (R 10 )2N-C(NR 10 )-, R0C(O)-, -N(R10)2, or R11 OC(O)NR10-;
R
10 is independently selected from hydrogen, C1-C6 alkyl, C1 -C6 10 perfluoroalkyl, 2,2,2-trifluoroethyl, benzyl and aryl;
R
1 1 is independently selected from C 1-C6 alkyl and substituted or unsubstituted aryl; 15 R 12 is selected from: H; unsubstituted or substituted C1-8 alkyl, unsubstituted or substituted aryl or unsubstituted or substituted heterocycle, wherein the substituted alkyl, substituted aryl or substituted heterocycle is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: 20 a) C1-4 alkyl, b) halogen, c) CN, d) perfluoro-C1-4 alkyl, 2) C3-6 cycloalkyl, 25 3) OR 6 , 4) SR 6 a, S(O)R 6 a, or SO2R 6 a, - 42 - WO 99/10523 PCT/US98/17697 5) R 6 0 6) -- OR 6 O 0 7)
N
3 , 8) F, 9) perfluoro-C 1 l 4 -alkyl, or 10) Cl- 6 -alkyl; XI is a bond, -C(=O)- or -S(=O)m-; 5 Y is selected from: a) hydrogen, b) R 10 0-, R 1 1 S(O)m-, R10C(O)NR 10 -, (R 10 )2N-C(O)-, CN, NO2, (R 10 )2N-C(NRO10)-, R1 2 C(O)-, R10OC(O)-, N3, F, -N(R10)2, or R 1 1
OC(O)NR
10 -, 10 c) unsubstituted or substituted C1-C6 alkyl wherein the substituent on the substituted Ci1-C6 alkyl is selected from unsubstituted or substituted aryl, R 10 0-, R10C(O)NR 10 -, (R10)2N-C(O)-, RO10C(O)- and R10OC(O)-; 15 Z is an unsubstituted or substituted aryl, wherein the substituted aryl is substituted with one or more of the following: 1) C1-4 alkyl, unsubstituted or substituted with: a) C1-4 alkoxy, b) NR 6
R
7 , 20 c) C3-6 cycloalkyl, d) aryl, substituted aryl or heterocycle, e) HO, f) -S(O)mR 6 a, or - 43 - WO 99/10523 PCT/US98/17697 g) -C(O)NR 6
R
7 , 2) aryl or heterocycle, 3) halogen, 4) OR 6 , 5 5) NR 6
R
7 , 6) CN, 7) NO2, 8) CF3; 9) -S(O)mR 6 a, 10 10) -C(O)NR 6
R
7 , or 11) C3-C6 cycloalkyl; m is 0, 1 or 2; p is 1 or 2 ; 15 r is 0 to 3; and v is 0, 1 or 2; or a pharmaceutically acceptable salt thereof. In a further embodiment of this invention, the inhibitors of 20 farnesyl-protein transferase are illustrated by the formula III-a: H N Z (CR 4 2 )qA 3 (C R 5 2 )nR 6 / (CR 2 (R )r III-a R 3 wherein:
R
2 is independently selected from: 25 a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 10 0-, -N(R 10 )2 or C2-C6 alkenyl, - 44 - WO 99/10523 PCT/US98/17697 c) Ci1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, R 10 0-, or-N(R10)2; R3 is selected from: 5 a) hydrogen, b) C1-C6 alkyl unsubstituted or substituted by C2-C6 alkenyl, R 10 0-, R 1 1 S(O)m-, R 10
C(O)NR
10 -, CN, N3,
(R
10 )2N-C(NRO10)-, R 10 C(O)-, -N(R10)2, or
R
1 1 OC(O)NR10-, 10 c) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C3-C 10 cycloalkyl, C2-C6 alkenyl, fluoro, chloro, R 12 0-,
R
1 1 S(O)m-, R 10
C(O)NR
10 -, CN, NO2, (R10)2N-C(NR 1 0)-, R10C(O)-, N3, -N(R 10 )2, 15 or R 1 1
OC(O)NR
10 -, and d) C1-C6 alkyl substituted with an unsubstituted or substituted group selected from substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic and C3-C10 cycloalkyl; 20
R
4 and R5 are independently selected from: a) hydrogen, b) C1-C6 alkyl unsubstituted or substituted by R 10 0 or -N(R10)2, 25 c) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, fluoro, chloro, R 10 0-,
R
1 1 S(O)m-, R 10
C(O)NR
10 -, CN, NO2, (R10)2N-C(NR 10 )-, RO10C(O)-, N3, -N(R 10 )2, 30 or R 1 1
OC(O)NRO
10 -, and d) CI1-C6 alkyl substituted with an unsubstituted or substituted group selected from substituted or - 45 - WO 99/10523 PCT/US98/17697 unsubstituted aryl, substituted or unsubstituted heterocyclic and C3-C10 cycloalkyl;
R
6 is independently selected from: 5 a) hydrogen, b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, Ci1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 10 0-, allyloxy, R10C(O)NR10-, CN, NO2, (R 10 )2N-C(NR10)-, 10 RO10C(O)-, -N(R 10 )2, (R 12 )2NC(O)- or R 1 1
OC(O)NR
10 -, and c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R 10 0-,
R
1 0C(O)NR 10 - , (R 10 )2N-C(NR10)-, R10OC(O)-, -N(R10)2, or R 1 1
OC(O)NR
10 -; 15 R7 is independently selected from a) hydrogen, b) unsubstituted or substituted aryl, c) unsubstituted or substituted heterocycle, 20 d) unsubstituted or substituted cycloalkyl, and e) Ci1-C6 alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocycle and cycloalkyl; wherein heterocycle is selected from pyrrolidinyl, 25 imidazolyl, pyridinyl, thiazolyl, pyridonyl, indolyl, quinolinyl, isoquinolinyl, and thienyl;
R
8 is independently selected from: a) hydrogen, 30 b) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 10 0-, RO10C(O)NR 10 -, CN, NO2,
(R
10 )2N-C(NR 10)-, RO10C(O)-, -N(R 10)2, or R11OC(O)NR10-, and - 46 - WO 99/10523 PCT/US98/17697 c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R 10 0-,
R
1 0C(O)NR10-, (R 10 )2N-C(NR 1 0)-, RO10C(O)-, -N(R10)2, or R 1 1
OC(O)NR
10 -; 5 R 10 is independently selected from hydrogen, C 1-C6 alkyl, C 1-C6 perfluoroalkyl, 2,2,2-trifluoroethyl, benzyl and aryl;
R
1 1 is independently selected from C1 -C6 alkyl and aryl; 10 R 12 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with CO2R 10 , C1-C6 alkyl substituted with aryl, C1-C6 alkyl substituted with substituted aryl, C1-C6 alkyl substituted with heterocycle, C1-C6 alkyl substituted with substituted heterocycle, aryl and substituted aryl; 15
A
3 is selected from: a bond, -C(O)NR 7 -, -NR 7 C(O)-, -S(O)2NR 7 -,
-NR
7 S(O)2- or-N(R7)-; Z is independently H2 or O; 20 m is 0, 1 or 2; and nis 0, 1, 2, 3 or4; pis 0, 1, 2, 3 or4; q is 0 or 1; and r is 0 to 3; 25 or the pharmaceutically acceptable salts thereof. In a further embodiment of the formula A compounds of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula A-i: - 47 - WO 99/10523 PCT/US98/17697
R
2 a
R
2 b , N-(CRb2 p
R
5 lb A-i O wherein: Rlb is independently selected from: 5 a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 10 0-, -N(R 10 )2 or C2-C6 alkenyl, c) C 1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, R1 0 0-, or-N(R10)2; 10 R2a and R2b are independently selected from: a) hydrogen, b) C1-C6 alkyl unsubstituted or substituted by C2-C6 alkenyl, R 10 0-, R 1 1 S(O)m-, R 10
C(O)NR
10 -, 15 CN, N3, (R 10 )2N-C(NR10)-, RO10C(O)-, R10OC(O)-, -N(R10)2, or R 1 1
OC(O)NR
10 -, c) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or substituted cycloalkyl, alkenyl, R 10 0-, 20 R 1 1 S(O)m-, R 10
C(O)NR
10 -, CN, NO2,
(R
10 )2N-C(NR 1 0)-, R10OC(O)-, R10OC(O)-, N3,
-N(R
10 )2, halogen or R 1 1
OC(O)NR
10 -, and d) C1-C6 alkyl substituted with an unsubstituted or substituted group selected from aryl, heterocyclic and 25 C3-C10 cycloalkyl;
R
4 is - 48 - WO 99/10523 PCT/US98/17697 H N Z / (CR b 2 ) ~p
(R
8 )r
R
5 is hydrogen;
R
8 is independently selected from: 5 a) hydrogen, b) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 10 0-, RO10C(O)NRO10-, CN, NO2, (R10)2N-C(NR10)-, R 10 C(O)-, -N(R10)2, or
RIOC(O)NR
10 -, and 10 c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R 10 0-,
R
1 0C(O)NR 10 -, (R 10 )2N-C(NR 10 )-, R10C(O)-, -N(R10)2, or R 1 1O
C(O)NR
10 -;
R
10 is independently selected from hydrogen, C1 -C6 alkyl, substituted 15 or unsubstituted C1 -C6 aralkyl and substituted or unsubstituted aryl;
R
1 1 is independently selected from CI1-C6 alkyl, benzyl and aryl; 20 Z is H2 or O; m is 0, 1 or 2; nis 0, 1, 2, 3 or4; p is independently 0, 1 or 2; and r is 0 to 5; 25 or the pharmaceutically acceptable salts thereof. Specific compounds which are inhibitors of prenyl-protein transferases and are therefore useful in the present invention include: - 49 - WO 99/10523 PCT/US98/17697 1-[2(R)-Amino-3-mercaptopropyl]-2(S)-[(3-pyridyl)methoxyethyl)]-4 (1-naphthoyl)piperazine 1-[2(R)-Amino-3-mercaptopropyl]-2(S)-(benzyloxymethyl)-4-(1 5 naphthoyl)piperazine 1-[2(R)-Amino-3-mercaptopropyl]-2(S)-(benzyloxymethyl)-4-[7-(2,3 dihydrobenzofuroyl)]piperazine 10 1-[2(R)-Amino-3-mercaptopropyl]-2(S)-(benzamido)-4-(1 naphthoyl)piperazine 1-[2(R)-Amino-3-mercaptopropyl]-2(S)-[4-(5-dimethylamino- 1 naphyhalenesulfonamido)- 1 -butyl]-4-( 1 -naphthoyl)piperazine 15 N- [2(S)- (1 -(4-Nitrophenylmethyl)- 1H-imidazol-5-ylacetyl)amino-3(S) methylpentyl]-N- 1-naphthylmethyl-glycyl-methionine N-[2(S)-( 1 -(4-Nitrophenylmethyl)- 1H-imidazol-5-ylacetyl)amino-3(S) 20 methylpentyl]-N-1-naphthylmethyl-glycyl-methionine methyl ester N-[2(S)-([1 -(4-cyanobenzyl)- 1H-imidazol-5-yl]acetylamino)-3(S) methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine 25 N-[2(S)-([1-(4-cyanobenzyl)- 1H-imidazol-5-yl]acetylamino)-3(S) methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine methyl ester 2(S)-n-Butyl-4-( 1 -naphthoyl)- 1-[1 -(2-naphthylmethyl)imidazol-5 ylmethyl]-piperazine 30 2(S)-n-Butyl- 1-[1-(4-cyanobenzyl)imidazol-5-ylmethyl]-4-(1 naphthoyl)piperazine 1- { [1 -(4-cyanobenzyl)- 1H-imidazol-5-yl]acetyl }-2(S)-n 35 butyl-4-(1-naphthoyl)piperazine - 50 - WO 99/10523 PCT/US98/17697 1-(3-chlorophenyl)-4- [1-(4-cyanobenzyl)imidazolylmethyl]-2 piperazinone 5 1-phenyl-4-[1-(4-cyanobenzyl)- 1H-imidazol-5-ylethyl]-piperazin-2-one 1-(3-trifluoromethylphenyl)-4-[1-(4-cyanobenzyl)- 1H-imidazol-5 ylmethyl]-piperazin-2-one 10 1-(3-bromophenyl)-4- [1-(4-cyanobenzyl)- 1H-imidazol-5-ylmethyl] piperazin-2-one 5 (S)-(2- [2,2,2-trifluoroethoxy] ethyl)- 1-(3-trifluoromethylphenyl)- 4-[1 (4-cyanobenzyl)-4-imidazolylmethyl]-piperazin-2-one 15 1-(5,6,7,8-tetrahydronaphthyl)-4-[1-(4-cyanobenzyl)-1H-imidazol-5 ylmethyl]-piperazin-2-one 1 -(2-methyl-3-chlorophenyl)-4-[ 1-(4-cyanobenzyl)-4 20 imidazolylmethyl)]-piperazin-2-one 2(RS)- { [1-(Naphth-2-ylmethyl)- 1H-imidazol-5-yl)] acetyl } amino-3-(t butoxycarbonyl)amino- N-(2-methylbenzyl) propionamide 25 N- { 1-(4-Cyanobenzyl)- 1H-imidazol-5-ylmethyl } -4(R)-benzyloxy-2(S) { N'-acetyl-N'-3-chlorobenzyl } aminomethylpyrrolidine N- { 1-(4-Cyanobenzyl)- 1H-imidazol-5-ylethyl } -4(R)-benzyloxy-2(S) { N'-acetyl-N'-3-chlorobenzyl } aminomethyl pyrrolidine 30 1-[1-(4-Cyanobenzyl)- 1H-imidazol-5-ylacetyl] pyrrolidin-2(S) ylmethyl]-(N-2-methylbenzyl)-glycine N'-(3-chlorophenylmethyl) amide 1-[1-(4-Cyanobenzyl)- 1H-imidazol-5-ylacetyl] pyrrolidin-2(S) 35 ylmethyl]-(N-2-methylbenzyl)-glycine N'-methyl-N'-(3 chlorophenylmethyl) amide - 51 - WO 99/10523 PCT/US98/17697 (S)-2-[(1-(4-Cyanobenzyl)-5-imidazolylmethyl)amino]-N (benzyloxycarbonyl)-N-(3-chlorobenzyl)-4 (methanesulfonyl)butanamine 5 1-(3,5-Dichlorobenzenesulfonyl)-3(S)-[N-( 1 -(4-cyanobenzyl)- 1H imidazol-5-ylethyl)carbamoyl] piperidine N- { [1-(4-Cyanobenzyl)- 1 H-imidazol-5-yl] methyl } -4-(3-methylphenyl) 10 4-hydroxy piperidine, N- { [1-(4-Cyanobenzyl)- 1H-imidazol-5-yl]methyl }-4-(3-chlorophenyl)-4 hydroxy piperidine, 15 4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-1-(2,3-dimethylphenyl) piperazine-2,3-dione 1-(2-(3-Trifluoromethoxyphenyl)-pyrid-5-ylmethyl)-5-(4 cyanobenzyl)imidazole 20 4- { 5- [ 1-(3-Chloro-phenyl)-2-oxo-1,2-dihydro-pyridin-4-ylmethyl] imidazol- 1 -ylmethyl } -2-methoxy-benzonitrile 25 3(R)-3-[1-(4-Cyanobenzyl)imidazol-5-yl-ethylamino]-5-phenyl- 1-(2,2,2 trifluoroethyl)-H-benzo[e] [1,4] diazepine 3(S)-3- [1-(4-Cyanobenzyl) imidazol-5-yl]-ethylamino]-5-phenyl- 1 (2,2,2-trifluoroethyl)-H-benzo[e][1,4] diazepine 30 N-[1-(4-Cyanobenzyl)- 1H-imidazol-5-ylacetyl)pyrrolidin-2(S) ylmethyl]- N-(1-naphthylmethyl)glycyl-methionine N-[1 -(4-Cyanobenzyl)- 1H-imidazol-5-ylacetyl)pyrrolidin-2(S) 35 ylmethyl]- N-(1-naphthylmethyl)glycyl-methionine methyl ester - 52 - WO 99/10523 PCT/US98/17697 N-[I1-(1H-Imidazol-4-ylpropionyl)pyrrolidin-2(S)-ylmethyl]- N-(2 methoxybenzyl)glycyl-methionine 5 N- [1-(1H-Imidazol-4-ylpropionyl)pyrrolidin-2(S)-ylmethyl]- N-(2 methoxybenzyl)glycyl-methionine methyl ester 2(S)-(4-Acetamido- 1 -butyl)- 1- [2(R)-amino-3-mercaptopropyl]-4-( 1 naphthoyl)piperazine 10 2(RS)- { [1-(Naphth-2-ylmethyl)- 1H-imidazol-5-yl)] acetyl } amino-3-(t butoxycarbonyl)amino- N-cyclohexyl-propionamide 1- { 2(R,S)- [1 -(4-cyanobenzyl)- 1H-imidazol-5-yl]propanoyl } -2(S)-n 15 butyl-4-(1-naphthoyl)piperazine 1-[1 -(4-cyanobenzyl)imidazol-5-ylmethyl]-4-(diphenylmethyl)piperazine 1-(Diphenylmethyl)-3(S)-[N-(1- (4-cyanobenzyl)-2-methyl- 1H-imidazol 20 5-ylethyl)-N-(acetyl)aminomethyl] piperidine N-[ 1-(1H-Imidazol-4-ylpropionyl)pyrrolidin-2(S)-ylmethyl]- N-(2 chlorobenzyl)glycyl-methionine 25 N- [I1-(1H-Imidazol-4-ylpropionyl)pyrrolidin-2(S)-ylmethyl]- N-(2 chlorobenzyl)glycyl-methionine methyl ester 3(R)-3- [1- (4-Cyanobenzyl)imidazol-5-yl-methylamino]-5-phenyl- 1 (2,2,2-trifluoroethyl)-H-benzo[e][1,4] diazepine 30 1-(3-trifluoromethoxyphenyl)-4- [1 -(4-cyanobenzyl)imidazolylmethyl] 2-piperazinone 1-(2,5-dimethylphenyl)-4- [1 -(4-cyanobenzyl)imidazolylmethyl] -2 35 piperazinone - 53 - WO 99/10523 PCT/US98/17697 1-(3-methylphenyl)-4-[1-(4-cyanobenzyl)imidazolylmethyl]-2 piperazinone 5 1-(3-iodophenyl)-4- [1-(4-cyanobenzyl)imidazolylmethyl]-2-piperazinone 1-(3-chlorophenyl)-4-[1-(4-cyano-3-methoxybenzyl)imidazolylmethyl] 2-piperazinone 10 1-(3-trifluoromethoxyphenyl)-4- [1-(4-cyano-3 methoxybenzyl)imidazolyl methyl]-2-piperazinone 4-[((1-(4-cyanobenzyl)-5-imidazolyl)methyl)amino]benzophenone 15 1-(1- { [3-(4-cyano-benzyl)-3H-imidazol-4-yl]-acetyl } -pyrrolidin-2(S) ylmethyl)-3(S)-ethyl-pyrrolidine-2(S)-carboxylic acid 3-chloro benzylamide or the pharmaceutically acceptable salt thereof. 20 Compounds within the scope of this invention previously described as inhibitors of farnesyl-protein transferase but which have been further identified by the instant assays as inhibitors of prenyl protein transferases and are therefore useful in the present invention, and methods of synthesis thereof, can be found in the following patents, 25 pending applications and publications, which are herein incorporated by reference: U.S. Pat. No. 5,736,539 (April 7, 1998); WO 95/00497 (January 5, 1995) 30 U.S. Pat. No. 5,652,257 (July 29, 1997); WO 96/10034 (April 4, 1996) WO 96/30343 (October 3, 1996); USSN 08/412,829 filed on March 29, 1995; and USSN 08/470,690 filed on June 6, 1995; and USSN 08/600,728 filed on February 28, 1996; U.S. Pat. No. 5,661,161 (August 26, 1997); - 54 - WO 99/10523 PCT/US98/17697 U.S. Pat. No. 5,756,528 (May 6, 1998); WO 96/39137 (December 12, 1996); WO 96/37204 (November 28, 1996); USSN 08/449,038 filed on May 24, 1995; USSN 08/648,330 filed on May 15, 1996; 5 WO 97/18813 (May 29, 1997); USSN 08/749,254 filed on November 15, 1996; WO 97/38665 (October 23, 1997); USSN 08/831,308 filed on April 1, 1997; WO 97/36889 (October 9, 1997); USSN 08/823,923 filed on March 25, 10 1997; WO 97/36901 (October 9, 1997); USSN 08/827,483 filed on March 27, 1997; WO 97/36879 (October 9, 1997); USSN 08/823,920 filed on March 25, 1997; 15 WO 97/36605 (October 9, 1997); USSN 08/823,934 filed on March 25, 1997; WO 98/28980, (July 9, 1998); USSN 08/997,171 filed on December 22, 1997; and USSN 60/014,791 filed on April 3, 1996; USSN 08/831,308, filed on 20 April 4, 1997. All patents, publications and pending patent applications identified are hereby incorporated by reference. With respect to the compounds of formulas I through IIIa 25 the following definitions apply: The term "alkyl" refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 15 carbon atoms unless otherwise defined. It may be straight, branched or cyclic. Preferred straight or branched alkyl groups include methyl, ethyl, 30 propyl, isopropyl, butyl and t-butyl. Preferred cycloalkyl groups include cyclopentyl and cyclohexyl. When substituted alkyl is present, this refers to a straight, branched or cyclic alkyl group as defined above, substituted with 1-3 groups as defined with respect to each variable. - 55 - WO 99/10523 PCT/US98/17697 Heteroalkyl refers to an alkyl group having from 2-15 carbon atoms, and interrupted by from 1-4 heteroatoms selected from O, S and N. The term "alkenyl" refers to a hydrocarbon radical 5 straight, branched or cyclic containing from 2 to 15 carbon atoms and at least one carbon to carbon double bond. Preferably one carbon to carbon double bond is present, and up to four non-aromatic (non resonating) carbon-carbon double bonds may be present. Examples of alkenyl groups include vinyl, allyl, iso-propenyl, pentenyl, hexenyl, 10 heptenyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, isoprenyl, farnesyl, geranyl, geranylgeranyl and the like. Preferred alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkenyl group may 15 contain double bonds and may be substituted when a substituted alkenyl group is provided. The term "alkynyl" refers to a hydrocarbon radical straight, branched or cyclic, containing from 2 to 15 carbon atoms and at least one carbon to carbon triple bond. Up to three carbon-carbon 20 triple bonds may be present. Preferred alkynyl groups include ethynyl, propynyl and butynyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkynyl group may contain triple bonds and may be substituted when a substituted alkynyl group is provided. 25 Aryl refers to aromatic rings e.g., phenyl, substituted phenyl and like groups as well as rings which are fused, e.g., naphthyl and the like. Aryl thus contains at least one ring having at least 6 atoms, with up to two such rings being present, containing up to 10 atoms therein, with alternating (resonating) double bonds between adjacent 30 carbon atoms. The preferred aryl groups are phenyl and naphthyl. Aryl groups may likewise be substituted as defined below. Preferred substituted aryls include phenyl and naphthyl substituted with one or two groups. With regard to the farnesyl transferase inhibitors, "aryl" - 56 - WO 99/10523 PCT/US98/17697 is intended to include any stable monocyclic, bicyclic or tricyclic carbon ring(s) of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of aryl groups include phenyl, naphthyl, anthracenyl, biphenyl, tetrahydronaphthyl, indanyl, phenanthrenyl and 5 the like. The term "heteroaryl" refers to a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing at least one heteroatom, O, S or N, in which a carbon or nitrogen atom is the point of 10 attachment, and in which one additional carbon atom is optionally replaced by a heteroatom selected from O or S, and in which from 1 to 3 additional carbon atoms are optionally replaced by nitrogen heteroatoms. The heteroaryl group is optionally substituted with up to three groups. 15 Heteroaryl thus includes aromatic and partially aromatic groups which contain one or more heteroatoms. Examples of this type are thiophene, purine, imidazopyridine, pyridine, oxazole, thiazole, oxazine, pyrazole, tetrazole, imidazole, pyridine, pyrimidine, pyrazine and triazine. Examples of partially aromatic groups are tetrahydro 20 imidazo[4,5-c]pyridine, phthalidyl and saccharinyl, as defined below. With regard to the farnesyl transferase inhibitors, the term heterocycle or heterocyclic, as used herein, represents a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic or stable 11-15 membered tricyclic heterocycle ring which is either saturated or 25 unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined hetero cyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation 30 of a stable structure. Examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydro-benzothienyl, dihydrobenzothiopyranyl, - 57 - WO 99/10523 PCT/US98/17697 dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, 2-oxopiperazinyl, 5 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, pyridonyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinolinyl N-oxide, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydro-quinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, 10 thiazolyl, thiazolinyl, thienofuryl, thienothienyl, and thienyl. Preferably, heterocycle is selected from imidazolyl, 2-oxopyrrolidinyl, piperidyl, pyridyl and pyrrolidinyl. With regard to the farnesyl transferase inhibitors, the terms "substituted aryl", "substituted heterocycle" and "substituted cycloalkyl" 15 are intended to include the cyclic group which is substituted with 1 or 2 substituents selected from the group which includes but is not limited to F, Cl, Br, CF3, NH2, N(C1-C6 alkyl)2, NO2, CN, (C1-C6 alkyl)O-, -OH, (C1-C6 alkyl)S(O)m-, (C1-C6 alkyl)C(O)NH-, H2N-C(NH)-, (C1-C6 alkyl)C(O)-, (C1-C6 alkyl)OC(O)-, N3,(C1-C6 alkyl)OC(O) 20 NH- and C1-C20 alkyl. In the present method, amino acids which are disclosed are identified both by conventional 3 letter and single letter abbreviations as indicated below: 25 Alanine Ala A Arginine Arg R Asparagine Asn N Aspartic acid Asp D Asparagine or 30 Aspartic acid Asx B Cysteine Cys C Glutamine Gln Q Glutamic acid Glu E Glutamine or 35 Glutamic acid Glx Z - 58 - WO 99/10523 PCT/US98/17697 Glycine Gly G Histidine His H Isoleucine Ile I Leucine Leu L 5 Lysine Lys K Methionine Met M Phenylalanine Phe F Proline Pro P Serine Ser S 10 Threonine Thr T Tryptophan Trp W Tyrosine Tyr Y Valine Val V 15 With respect to the term "CAAX" the letter "A" represents an aliphatic amino acid and is not limited to alanine. The compounds used in the present method may have asymmetric centers and occur as racemates, racemic mixtures, and as 20 individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention. Unless otherwise specified, named amino acids are understood to have the natural "L" stereoconfiguration When R 2 and R 3 are combined to form - (CH2)u -, cyclic 25 moieties are formed. Examples of such cyclic moieties include, but are not limited to: In addition, such cyclic moieties may optionally include a heteroatom(s). Examples of such heteroatom-containing cyclic moieties 30 include, but are not limited to: - 59 - WO 99/10523 PCT/US98/17697 0 S 0 S S J\JS 00 H 0 N
COR'
o When R 6 and R 7 , R 7 and R 7 a, or are combined to form - (CH2)u -, cyclic moieties are formed. Examples of such cyclic moieties include, but are not limited to: 5 The pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed, e.g., from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those 10 derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like: and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenyl-acetic, glutamic, benzoic, salicylic, sulfanilic, 15 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like. It is intended that the definition of any substituent or variable (e.g., R10, Z, n, etc.) at a particular location in a molecule be independent of its definitions elsewhere in that molecule. Thus, 20 -N(R10)2 represents -NHH, -NHCH3, -NHC2H5, etc. It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily - 60 - WO 99/10523 PCT/US98/17697 synthesized by techniques known in the art as well as those methods set forth below. The pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention which contain a basic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base with stoichiometric amounts or with an excess of the desired salt forming inorganic or organic acid in a suitable solvent or various combinations of solvents. Peptidyl compounds useful in the instant methods can be synthesized from their constituent amino acids by conventional peptide synthesis techniques, and the additional methods described below. Standard methods of peptide synthesis are disclosed, for example, in the following works: Schroeder et al., "The Peptides", Vol. I, Academic Press 1965, or Bodanszky et al., "Peptide Synthesis", Interscience Publishers, 1966, or McOmie (ed.) "Protective Groups in Organic Chemistry", Plenum Press, 1973, or Barany et al., "The Peptides: Analysis, Synthesis, Biology" 2, Chapter 1, Academic Press, 1980, or Stewart et al., "Solid Phase Peptide Synthesis", Second Edition, Pierce Chemical Company, 1984. Also useful in exemplifying syntheses of specific unnatural amino acid residues are European Pat. Appl. No. 0 350 163 A2 (particularly page 51-52) and J. E. Baldwin et al. Tetrahedron, 50:5049-5066 (1994). With regards to the synthesis of such peptidyl compounds containing a (3-acetylamino)alanine residue at the C-terminus, use of the commercially available Na(-Z-L-2,3 diaminopropionic acid (Fluka) as a starting material is preferred. Abbreviations used in the description of the chemistry and in the Examples that follow are: Ac20 Acetic anhydride; Boc t-Butoxycarbonyl; DBU 1,8-diazabicyclo[5.4.0]undec-7-ene; DMAP 4-Dimethylaminopyridine; DME 1,2-Dimethoxyethane; - 61 - WO 99/10523 PCT/US98/17697 DMF Dimethylformamide; EDC 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride; HOBT 1-Hydroxybenzotriazole hydrate; Et3N Triethylamine; EtOAc Ethyl acetate; FAB Fast atom bombardment; HOOBT 3-Hydroxy- 1,2,2-benzotriazin-4(3H)-one; HPLC High-performance liquid chromatography; MCPBA m-Chloroperoxybenzoic acid; MsCl Methanesulfonyl chloride; NaHMDS Sodium bis(trimethylsilyl)amide; Py Pyridine; TFA Trifluoroacetic acid; THF Tetrahydrofuran. The compounds are useful in various pharmaceutically acceptable salt forms. The term "pharmaceutically acceptable salt" refers to those salt forms which would be apparent to the pharma ceutical chemist. i.e., those which are substantially non-toxic and which provide the desired pharmacokinetic properties, palatability, absorption, distribution, metabolism or excretion. Other factors, more practical in nature, which are also important in the selection, are cost of the raw materials, ease of crystallization, yield, stability, hygroscopicity and flowability of the resulting bulk drug. Conveniently, pharmaceutical compositions may be prepared from the active ingredients in combination with pharmaceutically acceptable carriers. Pharmaceutically acceptable salts include conventional non-toxic salts or quarternary ammonium salts formed, e.g., from non-toxic inorganic or organic acids. Non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, - 62 - WO 99/10523 PCT/US98/17697 methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like. The pharmaceutically acceptable salts of the present invention can be synthesized by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt forming inorganic or organic acid or base, in a suitable solvent or solvent combination. The prenyl transferase inhibitors of formula (I) can be synthesized in accordance with Schemes 1-11, in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures. Substituents R, Ra and Rb, as shown in the Schemes, represent the substituents R 2 , R 3 , R 4 , and R 5 ; however their point of attachment to the ring is illustrative only and is not meant to be limiting. These reactions may be employed in a linear sequence to provide the compounds of the invention or they may be used to synthesize fragments which are subsequently joined by the alkylation reactions described in the Schemes. Synopsis of Schemes 1-11: The requisite intermediates are in some cases commercially available, or can be prepared according to literature procedures, for the most part. Piperazin-5-ones can be prepared as shown in Scheme 1. Thus, the protected suitably substituted amino acid IV can be converted to the corresponding aldehyde V by first forming the amide and then reducing it with LAH. Reductive amination of Boc-protected amino aldehydes V gives rise to compound VI. The intermediate VI can be converted to a piperazinone by acylation with chloroacetyl chloride to give VII, followed by base-induced cyclization to VIII. Deprotection, followed by reductive alkylation with a protected imidazole carboxalde - 63 - WO 99/10523 PCT/US98/17697 hyde leads to IX, which can be alkylated with an arylmethylhalide to give the imidazolium salt X. Final removal of protecting groups by either solvolysis with a lower alkyl alcohol, such as methanol, or treatment with triethylsilane in methylene chloride in the presence of trifluoroacetic acid gives the final product XI. The intermediate VIII can be reductively alkylated with a variety of aldehydes, such as XII. The aldehydes can be prepared by standard procedures, such as that described by O. P. Goel, U. Krolls, M. Stier and S. Kesten in Organic Syntheses, 1988, 67, 69-75, from the appropriate amino acid (Scheme 2). The reductive alkylation can be accomplished at pH 5-7 with a variety of reducing agents, such as sodium triacetoxyborohydride or sodium cyanoborohydride in a solvent such as dichloroethane, methanol or dimethylformamide. The product XIII can be deprotected to give the final compounds XIV with trifluoro acetic acid in methylene chloride. The final product XIV is isolated in the salt form, for example, as a trifluoroacetate, hydrochloride or acetate salt, among others. The product diamine XIV can further be selectively protected to obtain XV, which can subsequently be reductively alkylated with a second aldehyde to obtain XVI. Removal of the protecting group, and conversion to cyclized products such as the dihydroimidazole XVII can be accomplished by literature procedures. Alternatively, the imidazole acetic acid XVIII can be converted to the acetate XIX by standard procedures, and XIX can be first reacted with an alkyl halide, then treated with refluxing methanol to provide the regiospecifically alkylated imidazole acetic acid ester XX (Scheme 3). Hydrolysis and reaction with piperazinone VIII in the presence of condensing reagents such as 1-(3-dimethylaminopropyl) 3-ethylcarbodiimide (EDC) leads to acylated products such as XXI. If the piperazinone VIII is reductively alkylated with an aldehyde which also has a protected hydroxyl group, such as XXII in Scheme 4, the protecting groups can be subsequently removed to unmask the hydroxyl group (Schemes 4, 5). The alcohol can be oxidized under standard conditions to e.g. an aldehyde, which can then be reacted with a variety of organometallic reagents such as Grignard - 64 - WO 99/10523 PCT/US98/17697 reagents, to obtain secondary alcohols such as XXIV. In addition, the fully deprotected amino alcohol XXV can be reductively alkylated (under conditions described previously) with a variety of aldehydes to obtain secondary amines, such as XXVI (Scheme 5), or tertiary amines. The Boc protected amino alcohol XXIII can also be utilized to synthesize 2-aziridinylmethylpiperazinones such as XXVII (Scheme 6). Treating XXIII with 1,1'-sulfonyldiimidazole and sodium hydride in a solvent such as dimethylformamide led to the formation of aziridine XXVII. The aziridine reacted in the presence of a nucleophile, such as a thiol, in the presence of base to yield the ring-opened product XXVIII. In addition, the piperazinone VIII can be reacted with aldehydes derived from amino acids such as O-alkylated tyrosines, according to standard procedures, to obtain compounds such as XXX (Scheme 7). When R' is an aryl group, XXX can first be hydrogenated to unmask the phenol, and the amine group deprotected with acid to produce XXXI. Alternatively, the amine protecting group in XXX can be removed, and O-alkylated phenolic amines such as XXXII produced. Scheme 8 illustrates the use of an optionally substituted homoserine lactone XXXIII to prepare a Boc-protected piperazinone XXXVII. Intermediate XXXVII may be deprotected and reductively alkylated or acylated as illustrated in the previous Schemes. Alternatively, the hydroxyl moiety of intermediate XXXVII may be mesylated and displaced by a suitable nucleophile, such as the sodium salt of ethane thiol, to provide an intermediate XXXVIII. Intermediate XXXVII may also be oxidized to provide the carboxylic acid on intermediate IXL, which can be utilized form an ester or amide moiety. N-Aralkyl-piperazin-5-ones can be prepared as shown in Scheme 9. Reductive amination of Boc-protected amino aldehydes V (prepared from III as described previously) gives rise to compound XL. This is then reacted with bromoacetyl bromide under Schotten-Baumann conditions; ring closure is effected with a base such as sodium hydride in a polar aprotic solvent such as dimethylformamide to give XLI. The carbamate protecting group is removed under acidic conditions such as trifluoroacetic acid in methylene chloride, or hydrogen chloride gas in - 65 - WO 99/10523 PCT/US98/17697 methanol or ethyl acetate, and the resulting piperazine can then be carried on to final products as described in Schemes 1-7. The isomeric piperazin-3-ones can be prepared as described in Scheme 10. The imine formed from arylcarboxamides XLII and 2-aminoglycinal diethyl acetal (XLIII) can be reduced under a variety of conditions, including sodium triacetoxyborohydride in dichloroethane, to give the amine XLIV. Amino acids I can be coupled to amines XLIV under standard conditions, and the resulting amide XLV when treated with aqueous acid in tetrahydrofuran can cyclize to the unsaturated XLVI. Catalytic hydrogenation under standard conditions gives the requisite intermediate XLVII, which is elaborated to final products as described in Schemes 1-7. Amino acids of the general formula IL which have a sidechain not found in natural amino acids may be prepared by the reactions illustrated in Scheme 11 starting with the readily prepared imine XLVIII. SCHEME 1 O Ra O Ra OH ii.N(CH 3
)OCH
3 O N CH 3
NHOCH
3 - HCI O N H O EDC. HCI, HOBT H O TV DMF, Et 3 N, pH 7 R R H LAH, Et 2 0 _.._ArNH 2 _N r , BocNH CHO ArNH 2 BocNH Ar NaBH(OAc) 3 V CICH 2
CH
2 CI VI - 66 - WO 99/10523 PCT/US98/17697 SCHEME 1 (continued) R R 0 C Cl BocNH N-Ar NH BocN N-Ar HCI EtOAc / H 2 0 CI O DMF O EtOAc NaHCO 3 VII Vll CHO R N R N\ I -N N-Ar HCI-HN N-Ar C(Ph) 3 N -Ar O NaBH(OAc) 3 N CICH2CH2C I VIII CICH 2
H
2 CI (Ph) 3 C IX pH 5-6 R ArCH 2 X Ar-\ N N-Ar CHaCN N ( (Ph) 3 C X R MeOH or Ar-\ N N-Ar N TFA, CH 2 Cl
(C
2
H
5
)
3 SiH N XI - 67 - WO 99/10523 PCT/US98/17697 SCHEME 2 Boc NH xIIl R Boc NH CHO HCl-HN N-Ar NaBH(OAc)3 O Et 3 N , CICH 2
CH
2 CI VIII R >i-\ CF3CO2H Boc NH N N-Ar C0H 2 C1 2 O 0 NHBoc XIII R - Boc 2 0
NH
2 N N-Ar
CH
2
CI
2
NH
2 O xiv R C HO BocNH N N-Ar NaBH(OAc)3
NH
2 Et 3 N , CICH 2
CH
2 CI NH 2 0 XV xv- 68 - 68 - WO 99/10523 PCT/US98/17697 SCHEME 2 (continued) R BocNH N N-Ar CF 3 C0 2 H, 0H 2 01 2 ; NNaHCO 3 NH O /\/ xvi R
NH
2 N N-Ar NC - NH O AgCN A R N N-Ar N N 0 XVII - 69 - WO 99/10523 PCT/US98/17697 SCHEME 3
-'CH
2 C O 2 H N CH 2 CO2CH 3
CH
3 OH N HCI N HCI H H HCI XIX N CH 2 CO2CH 3 1) ArCH 2 X CH 3 CN
(C
6
H
5
)
3 CBr (- reflux
(C
2
H
5
)
3 N N 2) CH 3 OH, reflux DMF Tr XIX Ar- N
CH
2
CO
2
CH
3 2.5N HClaqI N aq 55oC Ar0 CH 2
CO
2 H N xx XX- 70 - 70 - WO 99/10523 PCT/US98/17697 SCHEME 3 (continued) R Ar-\N CH 2
CO
2 H N HCI - HN N-Ar +O 0 xx VIII EDC HCI HOBt DMF R Ar O R N N N-Ar N O XXI xx- 71 - 71 - WO 99/10523 PCT/US98/17697 SCHEME 4 R NaBH(OAc) 3 HCI HN N-Ar Et 3 N, CICH 2
CH
2 CI BnO VIII Vil BocNH CHO XXII R BnO N -N-Ar 20% Pd(OH) 2 2 CH 3 0H NHBoc O CH 3
CO
2 H R CICOCOCI HO N >N-Ar DMSO CH 2
C
2 NHBoc O (0 2
H
5
)
3 N XXIII R R R 1. R'MgX >--\1.R'gX HO N X\N-Ar 0 N N-Ar (C 2
H
5
)
2 0 HO N N-Ar H NHBoc O 2. TFA, R' NH 2 O
CH
2 Cl 2 XXiv - 72 - WO 99/10523 PCT/US98/17697 SCHEME 5 R
RCF
3
CO
2 H HO. N N-Ar CH2Cl2 NHBoc O XXIIl R RR'CHO HO N N N-Ar NaBH(OAc) 3 NaBH(OAc)3
NH
2 O CICH 2
CH
2 CI XXV R HO N N-Ar NH O /
R'CH
2 XXVI - 73 - WO 99/10523 PCT/US98/17697 SCHEME 6 H H R N /=-N NN HO N N-Ar 02 02 NHBoc O NaH, DMF 0oC XXIII R R N N-Ar R'S -N N-Ar R'SH N O (0 2
H
5
)
3 N A NH 2 O H CH30H XXVIIIl XXVII SCHEME 7 HO HO 1) Boc20, K 2
CO
3
THF-H
2 0
H
2 N CO 2 H 2) CH 2
N
2 , EtOAc BocNH 2
H
3 H2N 02H ocNH CO2CH 3 HO LiAIH 4
R'CH
2 X THF C0S 2 C00 3 0-200C BocNH CH 2 OH DMF
R'CH
2 0 R'CH 2 0 R H pyridine - SO 3 DMSO (0 2
H
5
)
3 N BocNH CH 2 OH 200 BocNH CHO 20C- 74 - 74- WO 99/10523 PCT/US98/17697 SCHEME 7 (continued)
R'CH
2 0 R + HCI - HN N-Ar BocNH CHO 0 XXIX VIII NaBH(OAc) 3
CICH
2
CH
2 CI R N N-Ar
R'CH
2 0 Ar O NHBoc XXX HCI ETOAc 1) 20% Pd(OH) 2
CH
3 OH, CH 3
CO
2 H 2) HCI, EtOAc
R'CH
2 0 N N-Ar
N
2 H0 XXXII R Hoz N N-Ar
NH
2 O XXXI - 75 - WO 99/10523 PCT/US98/17697 SCHEME 8 sub sub 1. BOC20, i-Pr 2 EtN O 0
H
2 N \ 2. DIBAL BocHN \ O OH HCI 0 OH XXXIII OH Ssub ArNH 2 BocNH , HAr BocNH Ar NaBH(OAc) 3
CICH
2
CH
2 CI XXXIV HO sub 0 CI C Cl_ _Cl BocNH N-Ar EtOAc / H 2 0 NaHCO 3 CI O XXXV HO sub CS2CO3 0s 2 00 3
/'-
S BocN N-Ar DMF 0 O XXXVI - 76 - WO 99/10523 PCT/US98/17697 SCHEME 8 (continued) HO sub BocN N-Ar 0 1. (COCI)2, Et 3 N DMSO 1. MsCI, iPr 2 NEt XXXVI 2. NaCIO 2 , t-BuOH 2. NaSEt, DMF 2-Me-2-butene NaH 2
PO
4 EtS sub HO sub BocN N-Ar BocN N-Ar 0 0 XXXVill IXL - 77 - WO 99/10523 PCT/US98/17697 SCHEME 9 0 Ra ArCH 2
NH
2 O9 N H NaBH(OAc) 3 H O
CICH
2
CH
2 CI V pH 6 O Ra NHCH 1) BrCH 2 COBr O N NHCH 2 Ar EtOAc, H 2 0, NaHCO 3 H 2) NaH, THF, DMF XL
R
a 0 1) TFA, CH 2
CI
2 N 0 Ar 0 XLI
R
a HN N--\ H Ar -780 - 78 - WO 99/10523 PCT/US98/17697 SCHEME 10 ArCHO + NH 2
CH
2
CH(OC
2
H
5
)
2 NaBH(OAc) 3 XLII XLIII Ra O R a Ar CH 2
NHCH
2
CH(OC
2
H
5
)
2 O N O H I H O XLIV" XLIV EDC. HCI, HOBT DMF, Et 3 N, pH 7 O R a
I
' A r O Ra Ar 6N HCI O N NOCH(OC 2
H
5
)
2 THF H O XLV Ra O Ro O
H
2 10%Pd/C N N-- CH 3 OH O Ar XLVI
R
a 0 - N N r XLVII - 79 - WO 99/10523 PCT/US98/17697 SCHEME 11 1. KOtBu, THF R 2 - CO 2 Et R 2 X ) CO 2 Et /N H 2 N Ph 2. 5% aqueous HCI HCI XLVIII 1. Boc20, NaHCO 3
R
2 )-CO2H BocHN 2. LiAIH 4 , Et 2 0 I IL Reactions used to generate the compounds of the formula (II) are prepared by employing reactions as shown in the Schemes 16 37, in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures. Substituents Ra and Rb, as shown in the Schemes, represent the substituents R 2 , R 3 , R 4 , and R 5 ; substituent "sub" represents a suitable substituent on the substituent Z. The point of attachment of such substituents to a ring is illustrative only and is not meant to be limiting. These reactions may be employed in a linear sequence to provide the compounds of the invention or they may be used to synthesize fragments which are subsequently joined by the alkylation reactions described in the Schemes. Synopsis of Schemes 16-37: The requisite intermediates utilized as starting material in the Schemes hereinbelow are in some cases commercially available, or can be prepared according to literature procedures. In Scheme 16, for example, a suitably substituted Boc protected isonipecotate LI may be deprotonated and then treated with a suitably substituted alkylating - 80 - WO 99/10523 PCT/US98/17697 group, such as a suitably substituted benzyl bromide, to provide the gem disubstituted intermediate LIII. Deprotection and reduction provides the hydroxymethyl piperidine LIV which can be utilized is synthesis of compounds of the invention or which may be nitrogen-protected and methylated to give the intermediate LV. As shown in Scheme 17, the protected piperidine intermediate LIII can be deprotected and reductively alkylated with aldehydes such as 1-trityl-4-imidazolyl-carboxaldehyde or 1-trityl 4-imidazolylacetaldehyde, to give products such as LVI. The trityl protecting group can be removed from LVI to give LVII, or alternatively, LVI can first be treated with an alkyl halide then subsequently deprotected to give the alkylated imidazole LVIII. The deprotected intermediate LIII can also be reductively alkylated with a variety of other aldehydes and acids as shown above in Schemes 4-7. An alternative synthesis of the hydroxymethyl intermediate LIV and utilization of that intermediate in the synthesis of the instant compounds which incorporate the preferred imidazolyl moiety is illustrated in Scheme 18. Scheme 19 illustrates the reductive alkylation of intermediate LIV to provide a 4-cyanobenzylimidazolyl substituted piperidine. The cyano moiety may be selectively hydrolyzed with sodium borate to provide the corresponding amido compound of the instant invention. Scheme 20 alternative preparation of the methyl ether intermediate LV and the alkylation of LV with a suitably substituted imidazolylmethyl chloride to provide the instant compound. Prepara tion of the homologous 1-(imidazolylethyl)piperidine is illustrated in Scheme 21. Specific substitution on the piperidine of the compounds of the instant invention may be accomplished as illustrated in Scheme 22. Thus, metal-halogen exchange coupling of a butynyl moiety to an isonicotinate, followed by hydrogenation, provides the 2-butylpiperidine intermediate that can then undergo the reactions previously described to provide the compound of the instant invention. - 81 - WO 99/10523 PCT/US98/17697 Incorporation of a 4-amido moiety for LV is illustrated in Scheme 23. Scheme 24 illustrates the synthesis of the instant compounds wherein the moiety Z is attached directly to the piperidine ring. Thus the piperidone LIX is treated with a suitably substituted phenyl Grignard reagent to provide the gem disubstituted piperidine LX. Deprotection provides the key intermediate LXI. Intermediate LXI may be acetylated as described above to provide the instant compound LXII (Scheme 25). As illustrated in Scheme 26, the protected piperidine LX may be dehydrated and then hydroborated to provide the 3 hydroxypiperidine LXIII. This compound may be deprotected and further derivatized to provide compounds of the instant invention (as shown in Scheme 27) or the hydroxyl group may be alkylated, as shown in Scheme 26, prior to deprotection and further manipulation. The dehydration product may also be catalytically reduced to provide the des-hydroxy intermediate LXV, as shown in Scheme 28, which can be processed via the reactions illustrated in the previous Schemes. Schemes 29 and 30 illustrate further chemical manipula tions of the 4-carboxylic acid functionality to provide instant compounds wherein the substituent Y is an acetylamine or sulfonamide moiety. Scheme 31 illustrates incorporation of a nitrile moiety in the 4-position of the piperidine of the compounds of formula II. Thus, the hydroxyl moiety of a suitably substituted 4-hydroxypiperidine is substituted with nitrile to provide intermediate LXVI, which can undergo reactions previously described in Schemes 17-21. Scheme 32 illustrates the preparation of several pyridyl intermediates that may be utilized with the piperidine intermediates such as compound LI in Scheme 16 to provide the instant compounds. Scheme 33 shows a generalized reaction sequence which utilizes such pyridyl intermediates. Compounds of the instant invention wherein X 1 is a carbonyl moiety may be prepared as shown in Scheme 34. Inter - 82 - WO 99/10523 PCT/US98/17697 mediate LXVII may undergo subsequent reactions as illustrated in Schemes 17-21 to provide the instant compounds. Preparation of the instant compounds wherein X 1 is sulfur in its various oxidation states is shown in Scheme 35. Intermediates LXVIII-LXXI may undergo the previously described reactions to provide the instant compounds. Scheme 36 illustrated preparation of compounds of the formula A wherein Y is hydrogen. Thus, suitably substituted isonipecotic acid may be treated with N,O-dimethylhydroxylamine and the intermediate LXXII reacted with a suitably substituted phenyl Grignard reagent to provide intermediate LXXIII. That intermediate may undergo the reactions previously described in Schemes 17-21 and may be further modified by reduction of the phenyl ketone to provide the alcohol LXXIV. Compounds of the instant invention wherein X 1 is an amine moiety may be prepared as shown in Scheme 37. Thus the N-protected 4-piperidinone may be reacted with a suitably substituted aniline in the presence of trimethylsilylcyanide to provide the 4-cyano 4-aminopiperidine LXXV. Intermediate LXXV may then be converted in sequence to the corresponding amide LXXVI, ester LXXVII and alcohol LXXVIII. Intermediates LXXVI-LXXVIII can be deprotected and can then undergo the reactions previously described in Schemes 17-21 to provide the compounds of the instant invention. - 83 - WO 99/10523 PCT/US98/17697 SCHEME 16 a O , 1. LDA, -780C N CO 2 0H 3 +0 V LI Rb Br sub L LIl Ra OC ' CO2C H3 ,-N 1) HCI, CH 2
CI
2 / L2) LiAIH 4 Rb LIII Rb sub Ra H OH 1) (Boc) 2 0, Et 3 N HN Uri_ 02 ,____ 01 /-I 2) NaH, CH 3 1 LIV Rb sub Ra O
NOCH
3 LV Rb sub - 84 - WO 99/10523 PCT/US98/17697 SCHEME 17 S1. HCI O F CO2CH 3 2. NaBH(OAc) 3 N Et 3 N , CICH 2
CH
2 CI LIII Rb / su(CH 2 )nCHO sub N I Ra Tr r- COCH 3 N
(CH
2 )n+ L Rb N ; sub N LVI Tr 1) Ar CH 2 X, CH 3 CN
CF
3
CO
2 H, 0H 2 1 2 2) CF 3
CO
2 H, CH 2
CI
2
(C
2
H
5
)
3 SiH (C2H 5
)
3 SiH
R
a A C02CH 3
H
2)n+ 1 R| N I / \ \ Rb N sub H LVII Ra r 'C'OI2CH 3 A r- (C H2)n l N\ bsu N LVIII - 85 - WO 99/10523 PCT/US98/17697 SCHEME 18
R
a O N CNaHMDS -N -CO 2 Et O Br Sub
R
a O / CO 2 Et LiAIH 4 O Sub Ra O OH
-
- N = -HCI, CH 2 C1 2 O Sub R8 OH
/CO
2 H p OH N in HCIHN I )/ N LIV Sub EDC, HOAt
R
a
R
8 0 OH N nx, N N Sub - 86 - WO 99/10523 PCT/US98/17697 SCHEME 19 Ra NC CHO /-- OH N HCI*HN R9 \ LIV Sub NaCNBH 3 Ra NC NN OH Na 2
B
4 07
R
9 \ N Sub Ra OH
H
2 NOC N N Sub - 87 - WO 99/10523 PCT/US98/17697 SCHEME 20 a O (Ra OH KH, (CH 3
)
2
SO
4 N o Sub a O -OCH 3 >-N - HCI, EtOAc O LV Sub R8 RI "'X CI -I OCH 3 N HCI*HN R N Sub iPr 2 NEt Ra
NOCH
3 N Ri N Sub - 88 - WO 99/10523 PCT/US98/17697 SCHEME 21
R
a O>
CO
2 R HCI, EtOAc 0 -N R = OH 3 , CH 3
CH
2 Sub R8 Ra NOH A
CO
2 R HCI-HN Sub (0F 3
SO
2
)
2 0
R
a R A CO 2 R N N \ / N Sub - 89 - WO 99/10523 PCT/US98/17697 SCHEME 22 NCO2H3 Cu(I)l N 0C20H 3 C0 2 0H 3 C0H Cl Br 1. H 2 , Pt 2 0 O CO2CH 3 sub 2. (Boc) 2 0 NaHMDS 0 2
H
3 1. HCI, EtOAc 2. iPr 2 NEt Osub R CI N
-
,CpO 2
CH
3 N R N sub N - 90 - WO 99/10523 PCT/US98/17697 SCHEME 23
R
a - 1. (Boc) 2 0 HN CO 2 H 2. BnOH, EDC na 0 0 BE\ O-N o 0 Sub NaHMDS Rao P/ O 0 1. H 2 ,Pd/C N 2. NH 4 CI, EDC Sub Ra O 0
NH
2 0 N -z Sub - 91 - WO 99/10523 PCT/US98/17697 SCHEME 24 S O sub MgBr o 000 LIX O OH HCI OH _--N , HN O /sub LX sub LXI SCHEME 25 OH H-N LXI sub ArN CH 2
CO
2 H EDC HI /" N EDC" HCI HOBt DMF ArN O O OH N N (N Ssub LXII - 92 - WO 99/10523 PCT/US98/17697 SCHEME 26 1. POCI3, pyridine O / OH O 2. BH 3 , H 2 0 2 NaOH sub LX OH OH sub 1. NaH, CH 3 1 / 2. HCI +0 LXIII
OCH
3 HN O - sub LXIV - 93 - WO 99/10523 PCT/US98/17697 SCHEME 27 OH 0 N .sub HCI LXIII OH NaBH(OAc) 3 Ssub Et 3 N, CICH 2
CH
2 CI H-N j.. \
(CH
2 )nCHO N I Tr OH CH- sub (C H 2 )n N ... N I Tr - 94 - WO 99/10523 PCT/US98/17697 SCHEME 28 1. POCl 3 , pyridine N OH___ _ O0 2. H 2 , Pd/C LX sub O sub HCI ON 0 LXV Ar\ CH 2
CO
2 H H-N sub EDC HCI HOBt DMF Ar 0 - sub - 95 -95- WO 99/10523 PCT/US98/17697 SCHEME 29 0 (Boc) 2 0 R0 O Aq NaOH O OH -0 N HN \ Rb Rb O 1. Na HMDS Benzyl alcohol Ra 2. benzyl bromide EDC, DMAP 0 . ______brmid 0 y N b 0 R O 0O
H
2 5% Pd on C
R
a H . O N sub - 96 HO 0 Rb - 96 - WO 99/10523 PCT/US98/17697 SCHEME 29 (continued) a HO O DPPA NEt 3 Ra NH 2 O sub O N sub H3C NH AC20 Ra/ Py R HCI O . N \sub 0 R 0
(CH
2)n CHO
H
3 C-J NH N Ra ITr HN sub NaBH(OAc) 3 Rb Et 3 N, CICH 2
CH
2 CI O 0 RaH3 C NH N CH 2 )n+1 \I/ Rb sub N I Tr - 97 - WO 99/10523 PCT/US98/17697 SCHEME 30 O 0 H3C / Ra NH 2 MS I S Py Ra NH O sub O N sub
H
3 0. /0 HCI S ______Ra NH HCI * HN ssub Rb - 98 - WO 99/10523 PCT/US98/17697 SCHEME 31 a Ra OH (Boc)20 O R OH 1. MsCI H H 0N H 2. KCN Ra O CN NaHMDS N O HBrB LXVI Sub 0 ON -N HOI, EtOAc OI Sub a ON HCI.HNa Sub - 99 - WO 99/10523 PCT/US98/17697 SCHEME 32 O N_ m-CPBA N
+
_ 1. (0F 3 C00 2
)
2 H3C 3C" 2. Na 2
CO
3 , H 2 0
OH
3
OH
3 HO N- SOC 2 CI N
CH
3
CH
3 HO - SOCI 2 Cl N N
CH
3
OH
3 Cl CI LiAIH 4 HO HO 2 O \ /N \ /N
CH
3 CH 3 Cl / N
OH
3 - 100 - WO 99/10523 PCT/US98/17697 SCHEME 32 (continued) N LiAIH 4 HO N
H
3 00 2 C . CI CI
SOCI
2 CI N CI +Na H3 Nm-CPBA H3 N
H
3 C- QN/
~H
3 C \+/ CI "O CI HO H 3 C 1. Ac20 0 0 2. NaO H CI
SOCI
2 N
-
101 - 101 - WO 99/10523 PCT/US98/17697 SCHEME 33 Cl Ra O N CO 2 Et Sub NaHMDS Ra O lCO 2 Et " 0 N LiAIH 4 0 C- Et Sub pa Sub l A OH HCHHNI, CH 2 2 Sub OH102 HCI*HNC) Sub - 102 - WO 99/10523 PCT/US98/17697 SCHEME 34 Ra N CO 2 R Sub NaHMDS R = CH 3 , CH3CH 2 Ra 0 C0 2 R 0 0 LXVII Sub Ha R 8 N C0 2 R N N0 N Sub - 103 - WO 99/10523 PCT/US98/17697 SCHEME 35 O NaHMDS N CO2R Ra S R = CH 3 , CH 3
CH
2 sub 2 Ra O /| CO2R Nr NV LiAIH 4 O S sub Ra 0 O OH KH, CH 3 1 NX_ LXVIII sub
R
a O OCH 3 NalO 4 -N O S LXIX sub
R
a O /-I OCH 3 . O N ' Oxone LXX O sub
R
a O -I OCH 3 N LXXI sub - 104 - WO 99/10523 PCT/US98/17697 SCHEME 36 Ra ga /| 1. (Boc) 2 0 0 o HN CO 2 H , N, 2. HNCH 3
(OCH
3 ), O N-O EDC LXXII H 3 C
CH
3 a BrMg 0 - H Sub \ N HCI, EtOAc 0 0 Sub a R R H Cl HCI*HN N 0 N1 LXXIII Sub iPr 2 NEt Ra R 8 R'N H NaBH 4 R O N Sub R aH NN R 8 ) HO N Sub LXXIV Sub - 105 - WO 99/10523 PCT/US98/17697 SCHEME 37 Ra
H
2 N RO N9 N I, , sOub N N / TMSCN,HOAc H LXXV sub Ra -l CONH 2
H
2 S0 4 N 1. NaOH - N H 2. EtOH, H + sub LXXVI Ra - CO 2 Et N -LiAIH 4 LXXVII sub a A OH N
H
2 N \Pd/C LXXVIII sub IR HN R LXXIX sub - 106 - WO 99/10523 PCT/US98/17697 Compounds of this invention of formula (III) are prepared by employing the reactions shown in the following Reaction Schemes 38-51, in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures. Some key bond-forming and peptide modifying reactions are: Reaction A Amide bond formation and protecting group cleavage using standard solution or solid phase methodologies. Reaction B Preparation of a reduced peptide subunit by reductive alkylation of an amine by an aldehyde using sodium cyanoborohydride or other reducing agents. Reaction C Alkylation of a reduced peptide subunit with an alkyl or aralkyl halide or, alternatively, reductive alkylation of a reduced peptide subunit with an aldehyde using sodium cyanoborohydride or other reducing agents. Reaction D Peptide bond formation and protecting group cleavage using standard solution or solid phase methodologies. Reaction E Preparation of a reduced subunit by borane reduction of the amide moiety. These reactions may be employed in a linear sequence to provide the compounds of the invention or they may be used to synthesize fragments which are subsequently joined by the alkylation reactions described in the Reaction Schemes and in Reaction Schemes 43-51 hereinbelow. - 107 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 38 Reaction A. Coupling of residues to form an amide bond O RA RB O N OH +
H
2 N OR H 0 0 O R A O EDC, HOBT 0 RA H 0 or HOOBT O N N OR H B Et 3 N, DMF O R HCI or RA O TFA N . H 2 N OR O RB REACTION SCHEME 39 Reaction B. Preparation of reduced peptide subunits by reductive alkylation O RA RB H O NaCNBH 3 O RA H 0 _ _K N-,'_ N -AOR H RB - 108 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 40 Reaction C. Alkylation/reductive alkylation of reduced peptide subunits O RA H 0 R 7 XL, base O N OR or H RB O II RYCH, NaCNBH 3 O RA R7 O ~K N O N N OR H RB REACTION SCHEME 41 Reaction D. Coupling of residues to form an amide bond EDC, HOBT O RA or HOOBT > 0- N OH + HNRCRD O NH Et 3 N, DMF O H 0 O RA O N NRCRD HCI or TFA H 0 O RA H2N NRcRD O - 109 - 109 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 42 Reaction E. Preparation of reduced dipeptides from peptides O RA O N
BH
3 THF H B O RB O RA O 'I H N 0 N OR H RB where RA and RB are R2, R3 or R5 as previously defined; RC and RD are R 7 or R 12 ; XL is a leaving group, e.g., Br-, I- or MsO-; and RY is defined such that R 7 is generated by the reductive alkylation process. In addition to the reactions described in Reaction Schemes 26-30, other reactions used to generate the compounds of formula (III) of this invention are shown in the Reaction Schemes 43-51. All of the substituents shown in the Reaction Schemes, represent the same substi tuents as defined hereinabove. The substituent "Ar" in the Reaction Schemes represents a carbocyclic or heterocyclic, substituted or unsubstituted aromatic ring. These reactions may be employed in a linear sequence to provide the compounds of the invention or they may be used to synthesize fragments which are subsequently joined by the alkylation reactions described in the Reaction Schemes. The sequential order whereby substituents are incorporated into the compounds is often not critical and thus the order of reactions described in the Reaction Schemes are illustrative only and are not limiting. Synopsis of Reaction Schemes 43-51: The requisite intermediates are in some cases commercially available, or can be readily prepared according to known literature - 110 - WO 99/10523 PCT/US98/17697 procedures, including those described in Reaction Schemes 38-42 hereinabove. Reaction Scheme 43 illustrates incorporation of the cyclic amine moiety, such as a reduced prolyl moiety, into the compounds of the formula III of the instant invention. Reduction of the azide LXXXI provides the amine LXXXII, which may be mono- or di-substituted using techniques described above. As an example, incorporation of a naphthylmethyl group and an acetyl group is illustrated. As shown in Reaction Scheme 44, direct attachment of a aromatic ring to a substituted amine such as LXXXIII is accomplished by coupling with a triarylbismuth reagent, such as tris(3-chlorophenyl) bismuth. Reaction Scheme 45 illustrates the use of protecting groups to prepare compounds of the instant invention wherein the cyclic amine contains an alkoxy moiety. The hydroxy moiety of key intermediate LXXXIVa may be further converted to a fluoro or phenoxy moiety, as shown in Reaction Scheme 46. Intermediates LXXXV and LXXXVI may then be further elaborated to provide the instant compounds. Reaction Scheme 474 illustrates syntheses of instant compounds wherein the variable -(CR 4 2)qA 3
(CR
5 2)nR 6 is a suitably substituted cx-hydroxybenzyl moiety. Thus the protected intermediate aldehyde is treated with a suitably substituted phenyl Grignard reagent to provide the enantiomeric mixture LXXXVII. Treatment of the mixture with 2-picolinyl chloride allows chromatographic resolution of compounds LXXXVIII and IXC. Removal of the picolinoyl group followed by deprotection provides the optically pure intermediate XC which can be further processed as described hereinabove to yield the instant compounds. Syntheses of imidazole-containing intermediates useful in synthesis of instant compounds wherein the variable p is 0 or 1 and Z is H2 are shown in Reaction Scheme 48 and 49. Thus the mesylate XCI can be utilized to alkylate a suitably substituted amine or cyclic amine, while aldehyde XCII can be used to similarly reductively alkylate such an amine. - 111 - WO 99/10523 PCT/US98/17697 Reaction Scheme 50 illustrates the syntheses of imidazole-containing intermediates wherein the attachment point of the
-(CR
2 2)p-C(Z)- moiety to W (imidazolyl) is through an imidazole ring nitrogen. Reaction Scheme 51 illustrates the synthesis of an intermediate wherein an R 2 substituent is a methyl. REACTION SCHEME 43 /OH -OH S (CF 3 00) 2 0 MeSO 2 CI HN
F
3 C NEt 3
OSO
2 Me N 3 7~~N i. LiN3 F3
.NH
3 HN MeOH Ar' N CH 2 C0 2 H EDCHCI ,N EDC'H.C HOOBT DMF LXXX - 112 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 43 (continued) A N N3
H
2 , Pd/C Nj CHO LXXXI C NH (.N.. 0 : Arq/N NL LXXXII NNH o . CH3C(O)CI ArN N N CH Ar -N N O - 113 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 44 O N AcCI, NEt 3 0
NH
2 O N Cu(OAc) 2 ON K ' H a NEt 3 , Bi(aryl) 3 N OH 3 H 0 O
--------
N CH3 R NI N N CH 3 NC R - 114 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 45 ,,OH ,,OH HN HCI, MeOH CI H 2 N TBSCI, NEt3 O OH 0 OMe 0 ,,OTBS ,OTBS S N LiAIH 4 OfN MsCI, NEt 3 0 ?- 0 O OMe OH S,,OTBS ,OTBS N Bu 4
NN
3
NH
2 ,Pd O 0 OMs
N
3 ,,OTBS 0 ,OTBS O -N NaBH 3 CN OO AcCI, NEt 3 O R'CHO
NH
2 NH R' - 115 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 45 (continued) 0 ,OTBS N O N ON O OO TBAF, THF N.. o NA. '' R, XXXIV R ,OR O i.HCI NaH, RX -------------- O ii.EDC Coupling or 0O reductive amination N or alkylation R' N ,,OR ,,,OR N 00 o N0 etc "'' o o. or N N o /R ' 'R' NC NC - 116 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 46 OH F N DAST O N O O N ON LXXXIV\ 0 N"" N 0k LXXXIII LXXXV R R OH OPh NO PPh 3 , DEAD, Phenol N N N ~LXXXV LXXXIII LXXXV\ R R - 117 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 47 OTBS OTBS R 03-s/ MgBr
SO
3 .Py N NN N- O O HO O O LXXXVI OTBS 2-Picolinoyl Chloride N NEt 3 O HO R LXXXVII OTBS OTBS N + N O0 0 0 N N LXXXVII / IXC - 118 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 47 (continued) OTBS LiOH N N OTBS OH N 1.Bu 4 NF O 2.HCI N HO R xc XC OH Coupling/alkylation N ------- / etc //- N HO R Ny CN - 119 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 48 Ar- N
CH
2 C0 2
CH
3 NaBH 4 N MeOH ArCH 2
CH
2 OH MeSO 2 CI NEt 3 N Ar-- OSO2CH 3 N xcl - 120 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 49 N- CH 2 OH (C 6
H
5
)
3 CBr N CH 2 OH N
(C
2
H
5
)
3 N N H DMF Tr N CH 2 OAc 1) ArCH 2 X CH 3 CN Ac20N reflux pyridine N 2) CH 3 OH, reflux Tr Ar* CH 2 OAc LiOH
H
2 0, THF N Ar\ N
CH
2 OH SO3'PY NEt 3 N Ar- N CHO N XCII - 121 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 50 N Ni(PPh3)2CI 2 + BrZnCH 2 Ar N I Tr N- Ar TfOCH 2 CO2CH 3 N Tr H3C02 N Ar LiOH HO2C A _ _ _ N "Ar N INaBH 4 XCVII HO N Ar N (MeSO 2
)
2 0 Et 3 N MsO N N-- Ar N XCVIII - 122 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 51 N CH 2
CO
2
CH
3 N CH(Me)CO2C i. LiHMDS, -780C N ii. Mel N Tr Tr Me Ar-- -OH N --- ------------ (O N XCVI The prenyl transferase inhibitors of formula (A) can be synthesized in accordance with Reaction Scheme below, in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures. Some key reactions utilized to form the aminodiphenyl moiety of the instant compounds are shown. The reactions may be employed in a linear sequence to provide the compounds of the invention or they may be used to synthesize fragments which are subsequently joined by the alkylation reactions described in the Reaction Scheme. A method of forming the benzophenone intermediates, illustrated in Reaction Scheme 52, is a Stille reaction with an aryl stannane. Such amine intermediates may then be reacted as illustrated hereinabove with a variety of aldehydes and esters/acids. - 123 - WO 99/10523 PCT/US98/17697 REACTION SCHEME 52 O 0 2 N Br or I
R
2 b +
R
2 a
R
3 Pd(PPh 3
)
4 (n-Bu) 3 Sn-Sn(n-Bu) 3 O 0 2 N 0
/R
2 b R2a
R
3 Fe, HOAc O R0 R 2 b H2
R
2 a
R
3
(CH
2 )nCHO N- NaBH(OAc) 3 N Et 3 N, CICH 2
CH
2 CI I Tr O
CH
2 )n+ 1 HN R 2 b N NR2a R 3 Tr - 124 - WO 99/10523 PCT/US98/17697 EXAMPLES Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be further illustrative of the invention and not limitative of the reasonable scope thereof. The standard workup referred to in the examples refers to solvent extraction and washing the organic solution with 10% citric acid, 10% sodium bicarbonate and brine as appropriate. Solutions were dried over sodium sulfate and evaporated in vacuo on a rotary evaporator. EXAMPLE 1 1-(3-Chlorophenyl)-4-[1-(4-cyanobenzyl)imidazolylmethyl]-2 piperazinone dihydrochloride (Compound 1) Step A: Preparation of 1-triphenylmethyl-4-(hydroxymethyl) imidazole To a solution of 4-(hydroxymethyl)imidazole hydrochloride (35.0 g, 260 mmol) in 250 mL of dry DMF at room temperature was added triethylamine (90.6 mL, 650 mmol). A white solid precipitated from the solution. Chlorotriphenylmethane (76.1 g, 273 mmol) in 500 mL of DMF was added dropwise. The reaction mixture was stirred for 20 hours, poured over ice, filtered, and washed with ice water. The resulting product was slurried with cold dioxane, filtered, and dried in vacuo to provide the titled product as a white solid which was sufficiently pure for use in the next step. Step B: Preparation of 1-triphenylmethyl-4-(acetoxymethyl) imidazole Alcohol from Step A (260 mmol, prepared above) was suspended in 500 mL of pyridine. Acetic anhydride (74 mL, 780 mmol) was added dropwise, and the reaction was stirred for - 125 - WO 99/10523 PCT/US98/17697 48 hours during which it became homogeneous. The solution was poured into 2 L of EtOAc, washed with water (3 x 1 L), 5% aq. HC1 soln. (2 x 1 L), sat. aq. NaHCO3, and brine, then dried (Na2SO4), filtered, and concentrated in vacuo to provide the crude product. The acetate was isolated as a white powder which was sufficiently pure for use in the next reaction. Step C: Preparation of 1-(4-cyanobenzyl)-5-(acetoxymethyl) imidazole hydrobromide A solution of the product from Step B (85.8 g, 225 mmol) and c-bromo-p-tolunitrile (50.1 g, 232 mmol) in 500 mL of EtOAc was stirred at 60oC for 20 hours, during which a pale yellow precipitate formed. The reaction was cooled to room temperature and filtered to provide the solid imidazolium bromide salt. The filtrate was concentrated in vacuo to a volume 200 mL, reheated at 60oC for two hours, cooled to room temperature, and filtered again. The filtrate was concentrated in vacuo to a volume 100 mL, reheated at 60'C for another two hours, cooled to room temperature, and concentrated in vacuo to provide a pale yellow solid. All of the solid material was combined, dissolved in 500 mL of methanol, and warmed to 60oC. After two hours, the solution was reconcentrated in vacuo to provide a white solid which was triturated with hexane to remove soluble materials. Removal of residual solvents in vacuo provided the titled product hydrobromide as a white solid which was used in the next step without further purification. Step D: Preparation of 1-(4-cyanobenzyl)-5-(hydroxymethyl) imidazole To a solution of the acetate from Step C (50.4 g, 150 mmol) in 1.5 L of 3:1 THF/water at O'C was added lithium hydroxide monohydrate (18.9 g, 450 mmol). After one hour, the reaction was concentrated in vacuo, diluted with EtOAc (3 L), and washed with water, sat. aq. NaHCO3 and brine. The solution was then dried (Na2SO4), filtered, and concentrated in vacuo to provide - 126 - WO 99/10523 PCT/US98/17697 the crude product as a pale yellow fluffy solid which was sufficiently pure for use in the next step without further purification. Step E: Preparation of 1-(4-cyanobenzyl)-5 imidazolecarboxaldehyde To a solution of the alcohol from Step D (21.5 g, 101 mmol) in 500 mL of DMSO at room temperature was added triethylamine (56 mL, 402 mmol), then SO3-pyridine complex (40.5 g, 254 mmol). After 45 minutes, the reaction was poured into 2.5 L of EtOAc, washed with water (4 x 1 L) and brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the aldehyde as a white powder which was sufficiently pure for use in the next step without further purification. Step F: Preparation of N-(3-chlorophenyl)ethylenediamine hydrochloride To a solution of 3-chloroaniline (30.0 mL, 284 mmol) in 500 mL of dichloromethane at 0OC was added dropwise a solution of 4 N HCl in 1,4-dioxane (80 mL, 320 mmol HC1). The solution was warmed to room temperature, then concentrated to dryness in vacuo to provide a white powder. A mixture of this powder with 2-oxazolidinone (24.6 g, 282 mmol) was heated under nitrogen atmosphere at 160oC for 10 hours, during which the solids melted, and gas evolution was observed. The reaction was allowed to cool, forming the crude diamine hydrochloride salt as a pale brown solid. Step G: Preparation of N-(tert-butoxycarbonyl)-N'-(3 chlorophenyl)ethylenediamine The amine hydrochloride from Step F (ca. 282 mmol, crude material prepared above) was taken up in 500 mL of THF and 500 mL of sat. aq. NaHCO3 soln., cooled to O'C, and di-tert butylpyrocarbonate (61.6 g, 282 mmol) was added. After 30 h, the reaction was poured into EtOAc, washed with water and brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the titled - 127 - WO 99/10523 PCT/US98/17697 carbamate as a brown oil which was used in the next step without further purification. Step H: Preparation of N-[2-(tert-butoxycarbamoyl)ethyl]-N-(3 chlorophenyl)-2-chloroacetamide A solution of the product from Step G (77 g, ca. 282 mmol) and triethylamine (67 mL, 480 mmol) in 500 mL of CH2C12 was cooled to 0OC. Chloroacetyl chloride (25.5 mL, 320 mmol) was added dropwise, and the reaction was maintained at 0OC with stirring. After 3 h, another portion of chloroacetyl chloride (3.0 mL) was added dropwise. After 30 min, the reaction was poured into EtOAc (2 L) and washed with water, sat. aq. NH4C1 soln, sat. aq. NaHCO3 soln., and brine. The solution was dried (Na2SO4), filtered, and concentrated in vacuo to provide the chloroacetamide as a brown oil which was used in the next step without further purification. StepI: Preparation of 4-(tert-butoxycarbonyl)-1-(3 chlorophenyl)-2-piperazinone To a solution of the chloroacetamide from Step H (ca. 282 mmol) in 700 mL of dry DMF was added K2CO3 (88 g, 0.64 mol). The solution was heated in an oil bath at 70-75 0 C for 20 hrs., cooled to room temperature, and concentrated in vacuo to remove ca. 500 mL of DMF. The remaining material was poured into 33% EtOAc/hexane, washed with water and brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the product as a brown oil. This material was purified by silica gel chromatography (25 50% EtOAc/hexane) to yield pure product, along with a sample of product (ca. 65% pure by HPLC) containing a less polar impurity. Step J: Preparation of 1-(3-chlorophenyl)-2-piperazinone Through a solution of Boc-protected piperazinone from Step I (17.19 g, 55.4 mmol) in 500 mL of EtOAc at -78 0 C was bubbled anhydrous HCI gas. The saturated solution was warmed to - 128 - WO 99/10523 PCT/US98/17697 0OC, and stirred for 12 hours. Nitrogen gas was bubbled through the reaction to remove excess HC1, and the mixture was warmed to room temperature. The solution was concentrated in vacuo to provide the hydrochloride as a white powder. This material was taken up in 300 mL of CH2Cl2 and treated with dilute aqueous NaHCO3 solution. The aqueous phase was extracted with CH2C12 (8 x 300 mL) until tlc analysis indicated complete extraction. The combined organic mixture was dried (Na2SO4), filtered, and concentrated in vacuo to provide the titled free amine as a pale brown oil. Step K: Preparation of 1-(3-chlorophenyl)-4-[1-(4 cyanobenzyl)imidazolylmethyl]-2-piperazinone dihydrochloride To a solution of the amine from Step J (55.4 mmol, prepared above) in 200 mL of 1,2-dichloroethane at 0OC was added 4A powdered molecular sieves (10 g), followed by sodium triacetoxyborohydride (17.7 g, 83.3 mmol). The imidazole carboxaldehyde from Step E of Example 1 (11.9 g, 56.4 mmol) was added, and the reaction was stirred at 0OC. After 26 hours, the reaction was poured into EtOAc, washed with dilute aq. NaHCO3, and the aqueous layer was back-extracted with EtOAc. The combined organics were washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo. The resulting product was taken up in 500 mL of 5:1 benzene:CH2Cl2, and propylamine (20 mL) was added. The mixture was stirred for 12 hours, then concentrated in vacuo to afford a pale yellow foam. This material was purified by silica gel chromatography (2-7% MeOH/CH2C12), and the resultant white foam was taken up in CH2Cl2 and treated with 2.1 equivalents of 1 M HCl/ether solution. After concentrated in vacuo, the product dihydrochloride was isolated as a white powder. Examples 2-5 (Table 1) were prepared using the above protocol, which describes the synthesis of the structurally related compound - 129 - WO 99/10523 PCT/US98/17697 1 -(3-chlorophenyl)-4- [1- (4-cyanobenzyl)-imidazolylmethyl]-2 piperazinone dihydrochloride. In Step F, the appropriately substituted aniline was used in place of 3-chloroaniline. Table 1: 1-Aryl-4-[1-(4-cyanobenzyl)imidazolylmethyl]-2 piperazinones NC N N FAB mass spectrum CHN Example X (M+ 1) Analysis 2 3-OCF3 456 C23H20 F3N502*2.0HCl*0.60H20 calcd; C, 51.24; H, 4.34; N, 12.99. found; C, 51.31; H, 4.33; N, 12.94. 3 2,5-(CH3) 2 400 C24H25N50*2.00HCl*0.65H20 called; C, 59.54; H, 5.89; N, 14.47 found; C, 59.54; H, 5.95; N, 14.12. 4 3-CH3 386 C23H23N50*2.0HCl*0.80H20 calcd; C, 58.43; H, 5.67; N, 14.81. found; C, 58.67; H, 6.00; N, 14.23. 5 3-I 498 C22H20N501*2.25HC*0.90H20 called; C, 44.36; H, 4.07; N, 11.76. found; C, 44.37; H, 4.06; N, 11.42. - 130 - WO 99/10523 PCT/US98/17697 EXAMPLE 6 1-(3-chlorophenyl)-4-[1-(4-cyano-3-methoxybenzyl)imidazolylmethyl] 2-piperazinone dihydrochloride Step A: Preparation of Methyl 4-Amino-3-hydroxybenzoate Through a solution of 4-amino-3-hydroxybenzoic acid (75 g, 0.49 mol) in 2.0 L of dry methanol at room temperature was bubbled anhydrous HCI gas until the solution was saturated. The solution was stirred for 48 hours, then concentrated in vacuo. The product was partitioned between EtOAc and saturated aq. NaHCO 3 solution, and the organic layer was washed with brine, dried (Na 2 SO4), and concentrated in vacuo to provide the titled compound (79 g, 96% yield). Step B: Preparation of Methyl 3-Hydroxy-4-iodobenzoate A cloudy, dark solution of the product from Step A (79 g, 0.47 mol), 3N HCI (750 mL), and THF (250 mL) was cooled to 0 0 C. A solution of NaNO 2 (35.9 g, 0.52 mol) in 115 mL of water was added over ca. 5 minutes, and the solution was stirred for another 25 minutes. A solution of potassium iodide (312 g, 1.88 mol) in 235 mL of water was added all at once, and the reaction was stirred for an additional 15 minutes. The mixture was poured into EtOAc, shaken, and the layers were separated. The organic phase was washed with water and brine, dried (Na 2
SO
4 ), and concentrated in vacuo to provide the crude product (148 g). Purification by column chromatography through silica gel (0%-50% EtOAc/hexane) provided the titled product (96 g, 73% yield). Step C: Preparation of Methyl 4-Cyano-3-hydroxybenzoate A mixture of the iodide product from Step B (101 g, 0.36 mol) and zinc(II)cyanide (30 g, 0.25 mol) in 400 mL of dry DMF was degassed by bubbling argon through the solution for 20 minutes. Tetrakis(triphenylphosphine)palladium (8.5 g, 7.2 mmol) was added, and the solution was heated to 80 0 C for 4 hours. The - 131 - WO 99/10523 PCT/US98/17697 solution was cooled to room temperature, then stirred for an additional 36 hours. The reaction was poured into EtOAc/water, and the organic layer was washed with brine (4x), dried (Na 2
SO
4 ), and concentrated in vacuo to provide the crude product. Purification by column chromatography through silica gel (30%-50% EtOAc/hexane) provided the titled product (48.8 g, 76% yield). Step D: Preparation of Methyl 4-Cyano-3-methoxybenzoate Sodium hydride (9 g, 0.24 mol as 60% wt. disp. mineral oil) was aded to a solution of the phenol from Step C (36.1 g, 204 mmol) in 400 mL of dry DMF at room temperature. Iodomethane was added (14 mL. 0.22 mol) was added, and the reaction was stirred for 2 hours. The mixture was poured into EtOAc/water, and the organic layer was washed with water and brine (4x), dried (Na 2
SO
4 ), and concentrated in vacuo to provide the titled product (37.6 g, 96% yield). Step E: Preparation of 4-Cyano-3-methoxybenzvl Alcohol To a solution of the ester from Step D (48.8 g, 255 mmol) in 400 mL of dry THF under argon at room temperature was added lithium borohydride (255 mL, 510 mmol, 2M THF) over 5 minutes. After 1.5 hours, the reaction was warmed to reflux for 0.5 hours, then cooled to room temperature. The solution was poured into EtOAc/1N HCI soln. [CAUTION], and the layers were separated. The organic layer was washed with water, sat Na 2
CO
3 soln. and brine (4x), dried (Na 2
SO
4 ), and concentrated in vacuo to provide the titled product (36.3 g, 87% yield). Ste F: Preparation of 4-Cvano-3-methoxybenzyl Bromide A solution of the alcohol from Step E (35.5 g, 218 mmol) in 500 mL of dry THF was cooled to 0OC. Triphenylphosphine was added (85.7 g, 327 mmol), followed by carbontetrabromide (108.5 g, 327 mmol). The reaction was stirred at 0oC for 30 minutes, then at room temperature for 21 hours. Silica - 132 - WO 99/10523 PCT/US98/17697 gel was added (ca. 300 g), and the suspension was concentrated in vacuo. The resulting solid was loaded onto a silica gel chroma tography column. Purification by flash chromatography (30%-50% EtOAc/hexane) provided the titled product (42 g, 85% yield). Step G: Preparation of 1-(4-cyano-3-methoxybenzyl)-5 (acetoxymethyl)-imidazole hydrobromide The titled product was prepared by reacting the bromide from Step F (21.7 g, 96 mmol) with the imidazole product from Step B of Example 1 (34.9 g, 91 mmol) using the procedure outlined in Step C of Example 1. The crude product was triturated with hexane to provide the titled product hydrobromide (19.43 g, 88% yield). Step H: Preparation of 1-(4-cyano-3-methoxybenzyl)-5 (hydroxymethyl)-imidazole The titled product was prepared by hydrolysis of the acetate from Step G (19.43 g, 68.1 mmol) using the procedure outlined in Step D of Example 1. The crude titled product was isolated in modest yield (11 g, 66% yield). Concentration of the aqueous extracts provided solid material (ca. 100 g) which contained a significant quantity of the titled product, as judged by 1 H NMR spectroscopy. Step : Preparation of 1-(4-cyano-3-methoxybenzyl)-5 imidazolecarboxaldehyde The titled product was prepared by oxidizing the alcohol from Step H (11 g, 45 mmol) using the procedure outlined in Step E of Example 1. The titled aldehyde was isolated as a white powder (7.4 g, 68% yield) which was sufficiently pure for use in the next step without further purification. - 133 - WO 99/10523 PCT/US98/17697 Ste J: Preparation of 1-(3-chlorophenyl)-4-[1-(4-cyano-3 methoxybenzyl)imidazolylmethyl]-2-piperazinone dihydrochloride The titled product was prepared by reductive alkylation of the aldehyde from Step I (859 mg, 3.56 mmol) and the amine (hydrochloride) from Step K of Example 1 (800 mg, 3.24 mmol) using the procedure outlined in Step H of Example 1. Purification by flash column chromatography through silica gel (50%-75% acetone CH 2 C1 2 ) and conversion of the resulting white foam to its dihydrochloride salt provided the titled product as a white powder (743 mg, 45% yield). FAB ms (m+1) 437. Anal. Calc. for C23H23C1N502*2.0HCl*0.35CH2C12: C, 51.97; H, 4.80; N, 12.98. Found: C, 52.11; H, 4.80; N, 12.21. EXAMPLE 7 1-(3-trifluoromethoxyphenyl)-4-[1 -(4-cyano-3 methoxybenzyl)imidazolyl methyl]-2-piperazinone dihydrochloride 1-(3-trifluoromethoxy-phenyl)-2-piperazinone hydrochloride was prepared from 3-trifluoromethoxyaniline using Steps F-J of Example 1. This amine (1.75 g, 5.93 mmol) was coupled to the aldehyde from Step I of Example 6 (1.57 g, 6.52 mmol) using the procedure outlined in Step H of Example 1. Purification by flash column chromatography through silica gel (60%-100% acetone CH 2 C1 2 ) and conversion of the resulting white foam to its dihydrochloride salt provided the titled product as a white powder (1.947 g, 59% yield). FAB ms (m+1) 486. Anal. Calc. for C24H23F3N503*2.0HCl*0.60H20: C, 50.64; H, 4.46; N, 12.30. Found: C, 50.69; H, 4.52; N, 12.13. - 134 - WO 99/10523 PCT/US98/17697 EXAMPLE 8 4-[((1-(4-cyanobenzyl)-5-imidazolyl)methyl)amino]benzophenone hydrochloride The titled product was prepared by reductive alkylation of the aldehyde from Step E of Example 1 (124 mg, 0.588 mmol) and 4-aminobenzophenone (116 mg, 0.588 mmol) using the procedure outlined in Step K of Example 1. Purification by flash column chroma tography through silica gel (2-6% MeOH/CH 2 C1 2 ) and conversion to the hydrochloride salt provided the titled product as a white solid (126 mg, 50% yield). FAB ms (m+1) 393.11. Anal. Calc. for C25H20N50*1.40HCl*0.40H20: C, 66.62; H, 4.96; N, 12.43. Found: C, 66.73; H, 4.94; N, 12.46. - 135 - WO 99/10523 PCT/US98/17697 EXAMPLE 9 N- { 1-(4-Cyanobenzyl)- 1H-imidazol-5-ylethyl } -4(R)-benzyloxy-2(S) { N'-acetyl-N'-3-chlorobenzyl } aminomethylpyrolidine Step A: 4(R)-Hydroxyproline methyl ester A suspension of 4(R)-hydroxyproline (35.12g, 267.8 mmol) in methanol (500ml) was saturated with gaseous hydrochloric acid. The resulting solution was allowed to stand for 16hrs and the solvent evaporated in vacuo to afford the title compound as a white solid. 1 H NMR CD3OD 8 4.60 (2H, m), 3.86(3H, s), 3.48(1H, dd, J=3.6 and 12.0Hz), 3.23(1H, d, J=12.0Hz), 2.43(1H, m) and 2.21(1H, m) ppm. Step B: N-t-Butoxycarbonyl-4(R)-hydroxyproline methyl ester To a solution of 4(R)-hydroxyproline methyl ester (53.5g, 268mmol), and triethylamine (75ml, 540mmol), in CH2Cl2 (500ml), at 0OC, was added a solution of di-t-butyl dicarbonate (58.48, 268mmol), in CH2Cl2 (75ml). The resulting mixture was stirred for 48hrs at room temperature. The solution was washed with 10% aqueous citric acid solution, saturated NaHCO3 solution, dried (Na2SO4) and the solvent evaporated in vacuo. The title compound was obtained as a yellow oil and used in the next step without furthur purification. 1 H NMR CD3OD 8 4.40-4.30 (2H, m), 3.75(3H, m), 3.60-3.40(2H, m), 2.30(1H, m), 2.05(1H, m) and 1.55-1.40(9H, m) ppm. Step C: N-t-Butoxycarbonyl-4(R)-t-butyldimethylsilyloxy proline methyl ester To a solution of N-t-butoxycarbonyl-4(R)-hydroxy proline methyl ester (65.87g, 268mmol), and triethylamine (41ml, 294mmol), in CH2Cl2 (536ml), at 0 0 C, was added a solution of - 136 - WO 99/10523 PCT/US98/17697 t-butyldimethyl silylchloide (42.49g, 282mmol), in CH2C12 (86ml). The resulting mixture was stirred for 16hrs at room temperature. The solution was washed with 10% aqueous citric acid solution, saturated NaHCO3 solution, dried (Na2SO4) and the solvent evaporated in vacuo. The title compound was obtained as a yellow oil and used in the next step without furthur purification. 1 H NMR CD3OD 5 4.60-4.40 (2H, m), 3.75(3H, m), 3.60-3.20(2H, m), 2.30-1.90(2H, m), 1.45-1.40(9H, m), 0.90-0.85(9H, m), 0.10 0.00(6H, m) ppm. Step D: N-t-Butoxycarbonyl-4(R)-t-butyldimethylsilyloxy-2(S) hydroxymethylpyrrolidine A solution of N-t-butoxycarbonyl-4-(R)-t-butyldimethyl silyloxy proline methyl ester (86.65g, 241mmol), in THF (150ml), was added over 90 minutes to a solution of lithium aluminum hydride (247ml of a IM solution in THF, 247mmol), under argon, so that the temperature did not exceed 12 0 C. Stirring was continued for 50 mins and then EtOAc (500ml) was added cautiously, followed by sodium sulphate decahydrate (34g), and the resulting mixture stirred for 16 hrs at room temperature. Anhydrous Na 2
SO
4 (34g) was added and the mixture stirred an additional 30 min and then filtered. The solids were washed with EtOAc (800ml), the filtrates combined and the solvent evaporated in vacuo. The title compound was obtained as a colourless oil and used in the next step without further purification. Step E: N-t-Butoxycarbonyl-4(R)-t-butyldimethylsilyloxy-2(S) methanesulfonyloxymethylpyrrolidine To a solution of N-t-butoxycarbonyl-4(R)-t butyldimethylsilyloxy-2(S)-hydroxymethylpyrrolidine (50.0g, 150.8 mmol) and triethylamine (42.0 ml, 300 mmol) in CH 2 Cl 2 (1 1) was added methane sulfonyl chloride (12.4ml, 160 mmol) over a period of 5 minutes and stirring was continued for 1 hour. The solvent was evaporated in vacuo diluted with EtOAc (800 mL) - 137 - WO 99/10523 PCT/US98/17697 and washed sequentially with aqueous citric acid and NaHCO 3 . The organic extracts were dried (Na 2
SO
4 ), evaporated in vacuo and the residue purified by chromatography (SiO 2 , 15% EtOAc in hexanes). The title compound was obtained as a pale yellow solid FAB Mass spectrum, m/z = 410(M+1). 1 H NMR CDC13 8 4.60-4.00 (4H, m), 3.60-3.30(2H, m), 2.98(3H, s), 2.05-2.00(2H, m), 1.48-1.42(9H, m),0.90-0.80(9H, m), 0.10 0.00(6H, m) ppm. Step F: Preparation of N-t-Butoxycarbonyl-4(R)-t butyldimethylsilyloxy-2(S)-azidomethylpyrrolidine In a flask protected by a safety screen, a solution of N-t-butoxycarbonyl-4(S)-t-butyldimethylsilyloxy-2(S)-methane sulfonyloxy methyl pyrrolidine(10.40g, 25.39mmol) and tetrabutyl ammonium azide (8.18g, 28.7mmol) in toluene (250ml) was stirred at 80oC for 5 hr. The reaction was cooled to room temperature and diluted with EtOAc (250ml), washed with water and brine and dried (Na2SO4). The solvent was evaporated in vacuo to afford the title compound as a yellow oil which was used in the next step without furthur purification. 1 H NMR CDCl3 8 4.60-3.20 (6H, m), 2.05-1.90(2H, m), 1.47(9H, s), 0.87(9H, s) and 0.10-0.00(6H, m) ppm. Step G: Preparation of N-t-Butoxycarbonyl-4(R)-t butyldimethylsilyloxy-2(S)-aminomethylpyrrolidine A solution of N-t-butoxycarbonyl-4(R)-t butyldimethylsilyloxy-2(S)-azidomethylpyrrolidine (9.06g, 25.39mmol) in EtOAc (120ml) was purged with argon and 10% palladium on carbon (1.05g) added. The flask was evacuated and stirred under an atmosphere of hydrogen (49 psi) for 16hrs. The hydrogen was replaced by argon, the catalyst removed by filtration and the solvent evaporated in vacuo. The residue was chromato graphed (SiO2, 2.5 to 5% saturated NH4OH in acetonitrile, gradient elution), to afford the title compound as an oil. - 138 - WO 99/10523 PCT/US98/17697 1H NMR(CDCl3, 400 MHz) 8 4.40-2.60 (6H, s), 2.05-1.80(2H, m), 1.46(9H, s), 1.36(2H, s), 0.87(9H, s), 0.10-0.00(6H, m)ppm. Step H: Preparation of N-t-Butoxycarbonyl-4(R)-t butyldimethylsilyloxy-2(S)- { N'-3 chlorobenzvl } aminomethylpyrrolidine To a slurry of 3-chlorobenzaldehyde (1.2 ml, 10.6 mmol), crushed 3A molecular sieves (9.5g) and the amine from step G (3.50g, 10.6mmol) in methanol (150 ml) was added sodium cyanoborohydride (11.0ml of a 1M solution in THF, 11.0mmol) at room temperature. The pH was adjusted to 7 by the addition of glacial acetic acid (0.68ml, 12mmol) and the reaction was stirred for 16 hrs. The reaction was filtered and the filtrate evaporated in vacuo. The residue was partitioned between EtOAc and saturated NaHCO3 solution and the organic extract washed with brine, dried (Na2SO4), and the solvent evaporated in vacuo. The residue was purified by chromatography (SiO2, 2.5% MeOH in CH2C12) to provide the title compound as an oil. 1 HNMR(CDC13, 400 MHz) 8 7.40-7.10(4H, m), 4.36(1H, s), 4.15 3.90(2H, m), 3.90-3.30(2H, m), 2.85-2.60(2H, m), 2.05-1.90(2H, m), 1.44(9H, s), 0.87(9H, s) and 0.06(6H, m) ppm. Step I: Preparation of N-t-Butoxycarbonyl-4(R)-t butyldimethylsilyloxy-2(S)- { N'-3-chlorobenzyl-N' acetyl }- aminomethylpyrrolidine To a solution of N-t-butoxycarbonyl-4(R)-t-butyl dimethylsilyloxy-2(S)- { N'-3-chlorobenzyl } -aminomethyl pyrrolidine (3.80g, 8.35 mmol) in CH2Cl2 (85ml) and triethylamine (2.40ml, 17.0 mmol) at 0OC was added acetyl chloride (0.60ml, 8.44 mmol). The reaction was stirred at room temperature for lhr, diluted with water and extracted with CH2Cl2. The extracts were washed with brine, dried (Na2SO4) and the solvent evaporated in vacuo. The residue was purified by chromatography (SiO2, 10 to 25% EtOAc in CH2Cl2, gradient elution). - 139 - WO 99/10523 PCT/US98/17697 1 HNMR (CDCl3, 400 MHz) 8 7.40-7.00(4H, m), 5.10-3,00(8H, m), 2.20-1.70(5H, m), 1.50-1.30(9H, m), 0.87(9H, s) and 0.06(6H, m) ppm. Step J: Preparation of N-t-Butoxycarbonyl-4(R)-hydroxy-2(S1 { N' -3-chlorobenzyl-N'-acetyl } -aminomethylpyrrolidine To a solution of N-t-butoxycarbonyl-4(R)-t-butyl dimethylsilyloxy -2(S)- { N'-3-chlorobenzyl-N'-acetyl } -aminomethyl pyrrolidine (4.02g, 8.09 mmol) in THF (80ml) at 0OC was added tetrabutylammonium fluoride (9.00ml of a IM solution in THF, 9.00mmol). The reaction was stirred at 0OC for lhr and then at room temperature for 30min. The reaction was quenched by the addition of a saturated NH4C1 solution (50ml), dilution with EtOAc. The organic extracts were washed with brine, dried (Na2SO4) and the solvent evaporated in vacuo. The residue purified by chromatography (SiO2, 3 to 5% MeOH in CH2Cl2, gradient elution) to afford the title compound as a foam. 1 HNMR (CDCl3, 400 MHz) 8 7.40-7.00(4H, m), 5.00-4,00(4H, m), 4.00-3.10(4H, m), 2.30-1.60(5H, m) and 1.50-1.30(9H, m) ppm. Step K: N-t-Butoxycarbonyl-4(R)-benzyloxyoxy-2(S)- { N' acetyl-N'-3-chlorobenzyl } aminomethylpyrrolidine To a solution of N-t-Butoxycarbonyl-4(S)-hydroxy 2(S)- { N'-acetyl-N' 3-chlorobenzyl } aminomethylpyrrolidine (701mg, 1.83 mmol) in DMF (9ml) at 0 0 C was added sodium hydride (110mg of a 60% dispersion in mineral oil, 2.75mmol). After 15 min benzyl bromide (0.435ml, 3.66mmol), was added and the reaction stirred at room temperature for 16 hrs. The reaction was quenched with saturated NaHCO3 solution (2ml) and extracted with ethyl acetate. The organic extract was washed with brine and dried (Na2SO4), and the solvent evaporated in vacuo. The residue was purified by chromatography (SiO2, 25 to 50% EtOAc in CH2Cl2, gradient elution) to afford the title compound as a foam. - 140 - WO 99/10523 PCT/US98/17697 Step L: 4(S)-Benzyloxy-2(S)- { N'-acetyl-N'-3-chlorobenzyl} aminomethylpyrrolidine hydrochloride A solution of the product from step K (0.834g, 1.76 mmol) in EtOAc (25 ml) at 0OC was saturated with gaseous hydrogen chloride. The resulting solution was allowed to stand at room temperature for 30min. The solvent was evaporated in vacuo to afford the title compound as a white solid. Step M: Preparation of 1H-Imidazole-4- acetic acid methyl ester hydrochloride. A solution of 1H-imidazole-4-acetic acid hydrochloride (4.00g, 24.6 mmol) in methanol (100 ml) was saturated with gaseous hydrogen chloride. The resulting solution was allowed to stand at room temperature (RT) for 18hr. The solvent was evaporated in vacuo to afford the title compound as a white solid. 1 H NMR(CDCl3, 400 MHz) 8 8.85(1H, s),7.45(1H, s), 3.89(2H, s) and 3.75(3H, s) ppm. Step N: Preparation of 1-(Triphenylmethyl)-lH-imidazol-4 ylacetic acid methyl ester. To a solution of the product from Step M (24.85g, 0.141mol) in dimethyl formamide (DMF) (115ml) was added triethylamine (57.2 ml, 0.412mol) and triphenylmethyl bromide (55.3g, 0.171mol) and the suspension was stirred for 24hr. After this time, the reaction mixture was diluted with ethyl acetate (EtOAc) (11) and water (350 ml). The organic phase was washed with sat. aq. NaHCO3 (350 ml), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography (SiO2, 0-100% ethyl acetate in hexanes; gradient elution) to provide the title compound as a white solid. 1 H NMR (CDCl3, 400 MHz) 8 7.35(1H, s), 7.31(9H, m), 7.22(6H, m), 6.76(1H, s), 3.68(3H, s) and 3.60(2H, s) ppm. - 141 - WO 99/10523 PCT/US98/17697 Step O: Preparation of [1-(4-cyanobenzyl)-l1H-imidazol-5 yl]acetic acid methyl ester. To a solution of the product from Step N (8.00g, 20.9mmol) in acetonitrile (70 ml) was added bromo-p-tolunitrile (4.10Og, 20.92 mmol) and heated at 55oC for 3 hr. After this time, the reaction was cooled to room temperature and the resulting imidazolium salt (white precipitate) was collected by filtration. The filtrate was heated at 55 0 C for 18hr. The reaction mixture was cooled to room temperature and evaporated in vacuo. To the residue was added EtOAc (70 ml) and the resulting white precipitate collected by filtration. The precipitated imidazolium salts were combined, suspended in methanol (100 ml) and heated to reflux for 30min. After this time, the solvent was removed in vacuo, the resulting residue was suspended in EtOAc (75ml) and the solid isolated by filtration and washed (EtOAc). The solid was treated with sat aq NaHCO3 (300ml) and CH2Cl2 (300ml) and stirred at room temperature for 2 hr. The organic layer was separated, dried (MgSO4) and evaporated in vacuo to afford the title compound as a white solid: 1HNMR(CDC13, 400 MHz) 8 7.65(1H, d, J=8Hz), 7.53(1H, s), 7.15(1H, d, J=8Hz), 7.04(1H, s), 5.24(2H, s), 3.62(3H, s) and 3.45(2H, s) ppm. Step P: Preparation of (1-(4-Cyanobenzyl)- 1H-imidazol-5-yl) ethanol To a stirred solution of the ester from step O, (1.50g, 5.88 mmol), in methanol (20ml) at 0OC, was added sodium borohydride (1.0g, 26.3mmol) portionwise over 5 minutes. The reaction was stirred at 0OC for 1 hr and then at room temperature for an additional 1 hr. The reaction was quenched by the addition of sat.NH4C1 solution and the methanol was evaporated in vacuo.. The residue was partitioned between EtOAc and sat NaHCO3 solution and the organic extracts dried (MgSO4), and evaporated in vacuo.. The residue was purified by chromatography (SiO2, 4 to 10% methanol - 142 - WO 99/10523 PCT/US98/17697 in methylene chloride, gradient elution) to afford the title compound as a solid. 1 H NMR CDCl3 5 7.64(2H, d, J=8.2Hz), 7.57(1H, s), 7.11(2H, d, J=8.2Hz), 6.97(1H, s), 5.23(2H, s), 3.79(2H, t, J=6.2Hz) and 2.66(2H, t, J=6.2Hz) ppm. Step Q: 1-(4-Cyanobenzyl)-imidazol-5-yl-ethylmethanesulfonate A solution of (1-(4-Cyanobenzyl)- 1H-imidazol-5-yl) ethanol (0.500 g, 2.20 mmol) in methylene chloride (6.0 ml) at O'C was treated with Hunig's base (0.460ml, 2.64mmol) and methane sulfonyl chloride (0.204ml, 2.64mmol). After 2 hrs, the reaction was quenched by addition of saturated NaHCO3 solution (50ml) and the mixture was extracted with methylene chloride (50ml), dried (MgSO4) and the solvent evaporated in vacuo. The title compound was used without furthur purification. 1 H NMR CDCl3 8 7.69 (1H, s) 7.66(2H, d, J=8.2Hz), 7.15 (2H, d, J=8.2Hz), 7.04(1H, s), 5.24(2H, s), 4.31(2H, t, J=6.7Hz), 2.96(3H, s), and 2.88(2H, t, J=6.6Hz)ppm. Step R: N { 1-(4-Cyanobenzyl)- 1H--imidazol-5-ylethyl }-4(R) benzyloxyoxy-2(S)- { N'-acetyl-N'-3 chlorobenzvl } aminomethylpyrrolidine A mixture of 4(R)-benzyloxy-2(S)- { N'-acetyl-N'-3 chlorobenzyl-aminomethyl } pyrrolidine (199mg, 0.486mmol), the mesylate from step Q (140mg, 0.458mmol), potassium carbonate (165mg, 1.19mmol), and sodium iodide (289mg, 1.93mmol) in DMF (1.5ml), were heated at 55 0 C for 16 hrs. The cooled mixture was diluted with EtOAc, washed with NaHCO3 solution and brine, dried (Na2SO4) and the solvent evaporated in vacuo. The residue was purified by preparative HPLC (C-18, 95:5 to 5:95 water in acetonitrile containing 0.1% TFA, gradient elution). The title compound was obtained as a white solid after lyophillisation. - 143 - WO 99/10523 PCT/US98/17697 Anal. calc'd for C34H36N502C1 3.00 TFA, 0.85 H20: C, 51.14; H, 4.37, N, 7.45. Found: C, 51.15; H, 4.42; N, 6.86. FAB HRMS exact mass calc'd for C34H37N502C1 582.263579(MH+), Found: 582.263900. EXAMPLE 10 In vitro inhibition Transferase Assays. Prenyl-protein transferase activity assays are carried out at 30 oC unless noted otherwise. A typical reaction contains (in a final volume of 50 jtL): [ 3 H]farnesyl diphosphate or [ 3 H]geranylgeranyl diphosphate, Ras protein, 50 mM HEPES, pH 7.5, 5 mM MgCl 2 , 5 mM dithiothreitol, 10 gM ZnCl 2 , 0.1% polyethyleneglycol (PEG) (15,000-20,000 mw) and isoprenyl-protein transferase. The FPTase employed in the assay is prepared by recombinant expression as described in Omer, C.A., Kral, A.M., Diehl, R.E., Prendergast, G.C., Powers, S., Allen, C.M., Gibbs, J.B. and Kohl, N.E. (1993) Biochemistry 32:5167-5176. The geranylgeranyl-protein transferase-type I employed in the assay is prepared as described in U.S. Pat. No. 5,470,832, incorporated by reference. After thermally pre equilibrating the assay mixture in the absence of enzyme, reactions are initiated by the addition of isoprenyl-protein transferase and stopped at timed intervals (typically 15 min) by the addition of 1 M HC1 in ethanol (1 mL). The quenched reactions are allowed to stand for 15 m (to complete the precipitation process). After adding 2 mL of 100% ethanol, the reactions are vacuum-filtered through Whatman GF/C filters. Filters are washed four times with 2 mL aliquots of 100% ethanol, mixed with scintillation fluid (10 mL) and then counted in a Beckman LS3801 scintillation counter. For inhibition studies, assays are run as described above, except inhibitors are prepared as concentrated solutions in 100% dimethyl sulfoxide and then diluted 20-fold into the enzyme assay mixture. Substrate conditions for inhibitor IC50 determinations are as - 144 - WO 99/10523 PCT/US98/17697 follows: FTase, 650 nM Ras-CVLS (SEQ.ID.NO.: 11), 100 nM farnesyl diphosphate; GGPTase-I, 500 nM Ras-CAIL (SEQ.ID.NO.: 12), 100 nM geranylgeranyl diphosphate. Alternatively, enzymologic K i values for inhibition of either FPTase or GGPTase-I can be determined using the methodology described by I. H. Segel ("Enzyme Kinetics", pages 342-345; Wiley and Sons, New York, N.Y. (1975) and references cited therein). EXAMPLE 11 Modified In vitro GGTase inhibition assay The modified geranylgeranyl-protein transferase inhibition assay is carried out at room temperature. A typical reaction contains (in a final volume of 50 gL): [ 3 H]geranylgeranyl diphosphate, biotinylated Ras peptide, 50 mM HEPES, pH 7.5, a modulating anion (for example 10 mM glycerophosphate or 5mM ATP), 7 mM MgC1 2 , 10 gM ZnCl 2 , 0.1% PEG (15,000-20,000 mw), 2 mM dithiothreitol, and geranylgeranyl-protein transferase type I (GGTase-I). The GGTase type I enzyme employed in the assay is prepared as described in U.S. Pat. No. 5,470,832, incorporated by reference. The Ras peptide is derived from the K4B-Ras protein and has the following sequence: biotinyl-GKKKKKKSKTKCVIM (single amino acid code) (SEQ.ID.NO.: 13). Reactions are initiated by the addition of GGTase and stopped at timed intervals (typically 15 min) by the addition of 200 gL of a 3 mg/mL suspension of streptavidin SPA beads (Scintillation Proximity Assay beads, Amersham) in 0.2 M sodium phosphate, pH 4, containing 50 mM EDTA, and 0.5% BSA. The quenched reactions are allowed to stand for 2 hours before analysis on a Packard TopCount scintillation counter. For inhibition studies, assays are run as described above, except inhibitors are prepared as concentrated solutions in 100% dimethyl sulfoxide and then diluted 25-fold into the enzyme assay mixture. For inhibition studies with slow-binding inhibitors, GGTase and inhibitors are preincubated for one hour and reactions are initiated by the addition of peptide substrate, following methodology described - 145 - WO 99/10523 PCT/US98/17697 by J.F. Morrison, C.T. Walsh, Adv. Enzymol. & Related Areas Mol. Biol., 61 201-301 (1988). IC 5 0 values are determined with Ras peptide near KM concentrations. Enzyme and substrate concentrations for inhibitor IC 5 0 determinations are as follows: 75 pM GGTase-I, 1.6 RtM Ras peptide, 100 nM geranylgeranyl diphosphate. Alternatively, enzymologic K i values for inhibition of GGPTase-I can be determined using the methodology described by I. H. Segel ("Enzyme Kinetics", pages 342-345; Wiley and Sons, New York, N.Y. (1975) and references cited therein). EXAMPLE 12 Cell-based in vitro ras prenylation assay The cell lines used in this assay consist of either Rat1 or NIH3T3 cells transformed by either viral H-ras; an N-ras chimeric gene in which the C-terminal hypervariable region of viral-H-ras was substituted with the corresponding region from the N-ras gene; or ras-CVLL (SEQ.ID.NO.: 2), a viral-H-ras mutant in which the C terminal exon encodes leucine instead of serine, making the encoded protein a substrate for geranylgeranylation by GGTase-I. The assay can also be performed using cell lines transformed with human H-ras, N-ras or K4B-ras. The assay is performed essentially as described in DeClue, J.E. et al., Cancer Research 51:712-717, (1991). Cells in 10 cm dishes at 50-75% confluency are treated with the test compound(s) (final concentration of solvent, methanol or dimethyl sulfoxide, is 0.1%). After 4 hours at 37oC, the cells are labeled in 3 ml methionine-free DMEM supplemented with 10% regular DMEM, 2% fetal bovine serum, 400 gtCi[ 35 S]methionine (1000 Ci/mmol) and test compound(s). Cells treated with lovastatin, a compound that blocks Ras processing in cells by inhibiting the rate-limiting step in the isoprenoid biosynthetic pathway (Hancock, J.F. et al. Cell, 57:1167 (1989); DeClue, J.E. et al. Cancer Res., 51:712 (1991); Sinensky, M. et al. J. Biol. Chem., 265:19937 (1990)), serve as a positive control in this assay. After an additional 20 hours, the cells are lysed in 1 ml lysis buffer (1% NP40/20 mM HEPES, pH 7.5/5 mM MgC12/lmM DTT/10 mg/ml aprotinen/2 - 146 - WO 99/10523 PCT/US98/17697 mg/ml leupeptin/2 mg/ml antipain/0.5 mM PMSF) and the lysates cleared by centrifugation at 100,000 x g for 45 min. Alternatively, four hours after the addition of the labeling media, the media is removed, the cells washed, and 3 ml of media containing the same or a different test compound added. Following an additional 16 hour incubation, the lysis is carried out as above. Aliquots of lysates containing equal numbers of acid-precipitable counts are bought to 1 ml with IP buffer (lysis buffer lacking DTT) and immunoprecipitated with the ras-specific monoclonal antibody Y13-259 (Furth, M.E. et al., J. Virol. 43:294-304, (1982)). Following a 2 hour antibody incubation at 4oC, 200 pl of a 25% suspension of protein A-Sepharose coated with rabbit anti rat IgG is added for 45 min. The immunoprecipitates are washed four times with IP buffer (20 nM HEPES, pH 7.5/1 mM EDTA/1% Triton X-100.0.5% deoxycholate/0.1%/SDS/0.1 M NaC1) boiled in SDS-PAGE sample buffer and loaded on 13% acrylamide gels. When the dye front reached the bottom, the gel is fixed, soaked in Enlightening, dried and auto radiographed. The intensities of the bands corresponding to prenylated and nonprenylated Ras proteins are compared to determine the percent inhibition of prenyl transfer to protein. EXAMPLE 13 Cell-based in vitro anchorage independent growth assay (SALSA) SALSA (Soft Agar-Like Surrogate Assay) measures the inhibition of anchorage-independent growth by prenyl transferase inhibitors. Only transformed cells are able to grow anchorage-independently in the SALSA format. Additionally, cells growing in the SALSA format grow in clumps, resembling the colonies formed in soft agar. SALSA may been used to measure the growth inhibition by prenyl-transferase inhibitors in a variety of transformed cell lines, including Rat1 fibroblasts transformed with viral-H-ras (H-ras/ratl), as well as a panel of human tumor cell lines (HTL's). - 147 - WO 99/10523 PCT/US98/17697 SALSA is performed in 96-well plates that are coated with a thin film of the polymer, PolyHEMA (Poly(2-hydroxyethyl methacrylate)), which prevents cells from attaching to the plate. Rat1 fibroblast cells transformed with v-Ha-ras (this cell line has been deposited in the ATCC on August 19, 1997 under the terms of the Budapest convention and has been given a designation of ATCC CRL-12387) are seeded at 5000 cells/well, grown for 4 hr, then vehicle or half-log dilutions of test compound (in either an 8 or 12 point titration) are added. The cells are then grown for 6 days at 37 degrees, without changing the growth media or adding fresh compound. At day 6, cell growth is assessed via a colorimetric assay that measures the cleavage of the tetrazolium dye, MTT, to an insoluble purple formazan, a reaction dependent upon mitochondrial dehydrogenases. At day 6, the cells are incubated for 4 hr with 0.5 mg/ml MTT, and then SDS is added to 9% w/v to lyse the cells and solubilize the insoluble MTT-formazan. The amount of MTT metabolism is quantitated via spectrophotometric detection at 570 nM. Dose-inhibition curves and ICs 50 's are determined. EXAMPLE 15 In vivo tumor growth inhibition assay (nude mouse) In vivo efficacy as an inhibitor of the growth of cancer cells may be confirmed by several protocols well known in the art. Examples of such in vivo efficacy studies are described by N. E. Kohl et al. (Nature Medicine, 1:792-797 (1995)) and N. E. Kohl et al. (Proc. Nat. Acad. Sci. U.S.A., 91:9141-9145 (1994)). Rodent fibroblasts transformed with oncogenically mutated human Ha-ras or Ki-ras (106 cells/animal in 1 ml of DMEM salts) are injected subcutaneously into the left flank of 8-12 week old female nude mice (Harlan) on day 0. The mice in each oncogene group are randomly assigned to a vehicle, compound or combination treatment group. Animals are dosed subcutaneously starting on day 1 and daily - 148 - WO 99/10523 PCT/US98/17697 for the duration of the experiment. Alternatively, the farnesyl-protein transferase inhibitor may be administered by a continuous infusion pump. Compound, compound combination or vehicle is delivered in a total volume of 0.1 ml. Tumors are excised and weighed when all of the vehicle-treated animals exhibited lesions of 0.5 - 1.0 cm in diameter, typically 11-15 days after the cells were injected. The average weight of the tumors in each treatment group for each cell line is calculated. - 149 -
Claims (80)
1. A method of inhibiting prenyl-protein transferases which comprises administering to a mammal in need thereof a pharma 5 ceutically effective amount of a compound that is a dual inhibitor of farnesyl-protein transferase and geranylgeranyl-protein transferase type I, the compound which is characterized by: a) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 5 gM against transfer of a geranylgeran I residue to 10 a protein or peptide substrate comprising a CAAX motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion; and b) an IC 5 0 (a measurement of in vitro inhibitory activity) of less than about 1 gM against transfer of a farnes l residue to a protein or 15 peptide substrate, comprising a CAAX motif, by farnesyl-protein transferase.
2. The method according to Claim 1 wherein the compound is further characterized by: 20 c) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 100 nM against the anchorage independent growth of H-ras transformed mammalian fibroblasts.
3. The method according to Claim 1 wherein the 25 compound is characterized by: a) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 1 gM against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAX motif by geranylgeranyl-protein transferase type I in the presence of a 30 modulating anion.
4. The method according to Claim 1 wherein the compound is further characterized by: - 150- WO 99/10523 PCT/US98/17697 c) an IC 5 0 (a measurement of in vitro inhibitory activity) of less than about 20 nM against the anchorage independent growth of H-ras transformed mammalian fibroblasts.
5 5. The method according to Claim 1 wherein the compound has an IC50 of less than about 500 nM against transfer of a farnesyl residue to a protein or peptide substrate comprising a CAAXF motif by farnesyl-protein transferase. 10
6. The method according to Claim 1 wherein the modulating anion is a phosphate or sulfate containing anion.
7. The method according to Claim 1 wherein the modulating anion is selected from: adenosine 5'-triphosphate, 15 2'-deoxyadenosine 5'-triphosphate, 2'-deoxycytosine 5'-triphosphate, P3-glycerol phosphate, pyrophosphate, guanosine 5'-triphosphate, 2'-deoxyguanosine 5'-triphosphate, uridine 5'-triphosphate, dithiophosphate, thymidine 5'-triphosphate, tripolyphosphate, D-myo-inositol 1,4,5-triphosphate and sulfate. 20
8. The method according to Claim 7 wherein the modulating anion is selected from: adenosine 5'-triphosphate (ATP), 3-glycerol phosphate, pyrophosphate, dithiophosphate and sulfate. 25
9. The method according to Claim 7 wherein the concentration of the modulating anion in the assay is selected from a range of from about 0.1 mM to about 100 mM.
10. The method according to Claim 7 wherein the 30 concentration of the modulating anion in the assay is selected from a range of from about 1 mM to about 10 mM.
11. The method according to Claim 1 wherein the G CAAX motif is selected from: CVIM (SEQ.ID.: 1), CVLL (SEQ.ID.: - 151 - WO 99/10523 PCT/US98/17697 2), CVVM (SEQ.ID.: 3), CIIM (SEQ.ID.: 4), CLLL (SEQ.ID.: 5), CQLL (SEQ.ID.: 6), CSIM (SEQ.ID.: 7), CAIM (SEQ.ID.: 8), CKVL (SEQ.ID.: 9), CLIM (SEQ.ID.: 10) and CVIL (SEQ.ID.: 14). 5
12. The method according to Claim 11 wherein the CAAX motif is CVIM (SEQ.ID.: 1).
13. A method of inhibiting farnesyl-protein transferase and geranylgeranyl-protein transferase type I which comprises 10 administering to a mammal in need thereof a pharmaceutically effective amount of a compound that is a dual inhibitor of farnesyl-protein transferase and geranylgeranyl-protein transferase type I, the compound which is characterized by: a) an IC 50 (a measurement of in vitro inhibitory activity) of less than 15 about 5 gM against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAXG motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion; and b) an IC 50 (a measurement of in vitro inhibitory activity) of less than 20 about 1 gM against transfer of a farnes Vl residue to a protein or peptide substrate, comprising a CAAX motif, by farnesyl-protein transferase.
14. The method according to Claim 13 wherein the 25 compound is characterized by: a) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 1 gM against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAXG motif by geranylgeranyl-protein transferase type I in the presence of a 30 modulating anion.
15. The method according to Claim 13 wherein the compound is further characterized by: - 152 - WO 99/10523 PCT/US98/17697 c) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 100 nM against the anchorage independent growth of H-ras transformed mammalian fibroblasts. 5
16. The method according to Claim 13 wherein the compound is further characterized by: c) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 20 nM against the anchorage independent growth of H-ras transformed mammalian fibroblasts. 10
17. The method according to Claim 13 wherein the compound has an IC50 of less than about 500 nM against transfer of a farnesyl residue to a protein or peptide substrate comprising a CAAXF motif by farnesyl-protein transferase. 15
18. The method according to Claim 13 wherein the modulating anion is a phosphate or sulfate containing anion.
19. The method according to Claim 13 wherein the 20 modulating anion is selected from: adenosine 5'-triphosphate, 2'-deoxyadenosine 5'-triphosphate, 2'-deoxycytosine 5'-triphosphate, 1-glycerol phosphate, pyrophosphate, guanosine 5'-triphosphate, 2'-deoxyguanosine 5'-triphosphate, uridine 5'-triphosphate, dithiophosphate, thymidine 5'-triphosphate, tripolyphosphate, 25 D-myo-inositol 1,4,5-triphosphate and sulfate.
20. The method according to Claim 19 wherein the modulating anion is selected from: adenosine 5'-triphosphate (ATP), 1-glycerol phosphate, pyrophosphate, dithiophosphate and sulfate. 30
21. The method according to Claim 19 wherein the concentration of the modulating anion in the assay is selected from a range of from about 0.1 mM to about 100 mM. - 153 - WO 99/10523 PCT/US98/17697
22. The method according to Claim 19 wherein the concentration of the modulating anion in the assay is selected from a range of from about 1 mM to about 10 mM. 5
23. The method according to Claim 13 wherein the G CAAX motif is selected from: CVIM (SEQ.ID.: 1), CVLL (SEQ.ID.: 2), CVVM (SEQ.ID.: 3), CIIM (SEQ.ID.: 4), CLLL (SEQ.ID.: 5), CQLL (SEQ.ID.: 6), CSIM (SEQ.ID.: 7), CAIM (SEQ.ID.: 8), CKVL (SEQ.ID.: 9), CLIM (SEQ.ID.: 10) and CVIL (SEQ.ID.: 14). 10
24. The method according to Claim 23 wherein the CAAX motif is CVIM (SEQ.ID.: 1).
25. A method of inhibiting the growth of cancer 15 cells which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound, which is characterized by: a) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 5 gM against transfer of a geranylgeranyl residue to a 20 protein or peptide substrate comprising a CAAX motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion; b) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 1 gM against transfer of a farnesyl residue to a protein or 25 peptide substrate, comprising a CAAX motif, by farnesyl-protein transferase.
26. The method according to Claim 25 wherein the compound is characterized by: 30 a) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 1 RM against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAX motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion. - 154 - WO 99/10523 PCT/US98/17697
27. The method according to Claim 25 wherein the compound is further characterized by: c) an IC 50 (a measurement of in vitro inhibitory activity) of less than 5 about 100 nM against the anchorage independent growth of H-ras transformed mammalian fibroblasts.
28. The method according to Claim 25 wherein the compound is further characterized by: 10 c) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 20 nM against the anchorage independent growth of H-ras transformed mammalian fibroblasts.
29. The method according to Claim 25 wherein the 15 compound has an IC50 of less than about 500 nM against transfer of a farnesyl residue to a protein or peptide substrate comprising a CAAXF motif by farnesyl-protein transferase.
30. The method according to Claim 25 wherein the 20 modulating anion is a phosphate or sulfate containing anion.
31. The method according to Claim 25 wherein the modulating anion is selected from: adenosine 5'-triphosphate, 2'-deoxyadenosine 5'-triphosphate, 2'-deoxycytosine 5'-triphosphate, 25 P-glycerol phosphate, pyrophosphate, guanosine 5'-triphosphate, 2'-deoxyguanosine 5'-triphosphate, uridine 5'-triphosphate, dithiophosphate, thymidine 5'-triphosphate, tripolyphosphate, D-myo-inositol 1,4,5-triphosphate and sulfate. 30
32. The method according to Claim 31 wherein the modulating anion is selected from: adenosine 5'-triphosphate (ATP), 3-glycerol phosphate, pyrophosphate, dithiophosphate and sulfate. - 155 - WO 99/10523 PCT/US98/17697
33. The method according to Claim 31 wherein the concentration of the modulating anion in the assay is selected from a range of from about 0.1 mM to about 100 mM. 5
34. The method according to Claim 31 wherein the concentration of the modulating anion in the assay is selected from a range of from about 1 mM to about 10 mM.
35. The method according to Claim 25 wherein the 10 CAAX motif is selected from: CVIM (SEQ.ID.: 1), CVLL (SEQ.ID.: 2), CVVM (SEQ.ID.: 3), CIIM (SEQ.ID.: 4), CLLL (SEQ.ID.: 5), CQLL (SEQ.ID.: 6), CSIM (SEQ.ID.: 7), CAIM (SEQ.ID.: 8), CKVL (SEQ.ID.: 9), CLIM (SEQ.ID.: 10) and CVIL (SEQ.ID.: 14). 15
36. The method according to Claim 35 wherein the CAAX motif is CVIM (SEQ.ID.: 1).
37. A method of inhibiting prenyl-protein transferases which comprises administering to a mammal in need thereof a 20 pharmaceutically effective amount of a compound, which is characterized by: a) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 5 gM against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAX motif by 25 geranylgeranyl-protein transferase type I in the presence of a modulating anion.
38. The method according to Claim 37 wherein the compound is characterized by: 30 a) an IC 5 0 (a measurement of in vitro inhibitory activity) of less than about 1 gM against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAXG motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion. - 156- WO 99/10523 PCT/US98/17697
39. The method according to Claim 37 wherein the compound is further characterized by: b) an IC 50 (a measurement of in vitro inhibitory activity) of less than 5 about 100 nM against the anchorage independent growth of H-ras transformed mammalian fibroblasts.
40. The method according to Claim 37 wherein the compound is further characterized by: 10 b) an IC 5 0 (a measurement of in vitro inhibitory activity) of less than about 20 nM against the anchorage independent growth of H-ras transformed mammalian fibroblasts.
41. The method according to Claim 37 wherein the 15 modulating anion is a phosphate or sulfate containing anion.
42. The method according to Claim 37 wherein the modulating anion is selected from: adenosine 5'-triphosphate, 2'-deoxyadenosine 5'-triphosphate, 2'-deoxycytosine 5'-triphosphate, 20 P3-glycerol phosphate, pyrophosphate, guanosine 5'-triphosphate, 2'-deoxyguanosine 5'-triphosphate, uridine 5'-triphosphate, dithiophosphate, thymidine 5'-triphosphate, tripolyphosphate, D-myo-inositol 1,4,5-triphosphate and sulfate. 25
43. The method according to Claim 42 wherein the modulating anion is selected from: adenosine 5'-triphosphate (ATP), 3-glycerol phosphate, pyrophosphate, dithiophosphate and sulfate.
44. The method according to Claim 42 wherein the 30 concentration of the modulating anion in the assay is selected from a range of from about 0.1 mM to about 100 mM. - 157 - WO 99/10523 PCT/US98/17697
45. The method according to Claim 42 wherein the concentration of the modulating anion in the assay is selected from a range of from about 1 mM to about 10 mM. 5
46. The method according to Claim 37 wherein the G CAAX motif is selected from: CVIM (SEQ.ID.: 1), CVLL (SEQ.ID.: 2), CVVM (SEQ.ID.: 3), CIIM (SEQ.ID.: 4), CLLL (SEQ.ID.: 5), CQLL (SEQ.ID.: 6), CSIM (SEQ.ID.: 7), CAIM (SEQ.ID.: 8), CKVL (SEQ.ID.: 9), CLIM (SEQ.ID.: 10) and CVIL (SEQ.ID.: 14). 10
47. The method according to Claim 37 wherein the CAAX motif is CVIM (SEQ.ID.: 1).
48. A method of inhibiting prenyl-protein transferases 15 which comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, which is characterized by: a) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 5 gM against transfer of a geranylgeranyl residue to a 20 protein or peptide substrate comprising a CAAX motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion; and b) the IC 50 (a measurement of in vitro inhibitory activity) of the compound against transfer of a geranylgeranyl residue to a protein 25 or peptide substrate comprising a CAAXG motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion is greater than 5 fold lower than the IC 50 (a measurement of in vitro inhibitory activity) against said transfer of a geranylgeranyl residue in the absence of a modulating anion. 30
49. A method of inhibiting prenyl-protein transferases which comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound that is a dual inhibitor - 158- WO 99/10523 PCT/US98/17697 of farnesyl-protein transferase and geranylgeranyl-protein transferase type I, the compound which is characterized by: a) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 5 gM against transfer of a geranylgeranyl residue to a 5 protein or peptide substrate comprising a CAAX motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion; b) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 1 tM against transfer of a farnes Vl residue to a protein or 10 peptide substrate, comprising a CAAX motif, by farnesyl-protein transferase; and c) the IC 50 (a measurement of in vitro inhibitory activity) of the compound against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAX G motif by 15 geranylgeranyl-protein transferase type I in the presence of a modulating anion is greater than 5 fold lower than the IC 50 (a measurement of in vitro inhibitory activity) against said transfer of a geranylgeranyl residue in the absence of a modulating anion. 20
50. A method of inhibiting farnesyl-protein transferase and geranylgeranyl-protein transferase type I which comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound that is a dual inhibitor of farnesyl-protein transferase and geranylgeranyl-protein transferase type I, the compound 25 which is characterized by: a) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 5 gM against transfer of a geranylgeranyl residue to a G protein or peptide substrate comprising a CAAX motif by geranylgeranyl-protein transferase type I in the presence of a 30 modulating anion; b) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 1 RM against transfer of a farnes l residue to a protein or peptide substrate, comprising a CAAX motif, by farnesyl-protein transferase; and - 159 - WO 99/10523 PCT/US98/17697 c) the IC 50 (a measurement of in vitro inhibitory activity) of the compound against transfer of a geranylgeranyl residue to a protein G or peptide substrate comprising a CAAX motif by geranylgeranyl-protein transferase type I in the presence of a 5 modulating anion is greater than 5 fold lower than the IC 5 0 (a measurement of in vitro inhibitory activity) against said transfer of a geranylgeranyl residue in the absence of a modulating anion.
51. A method of inhibiting the growth of cancer 10 cells which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound, which is characterized by: a) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 5 gM against transfer of a geranylgeranyl residue to a 15 protein or peptide substrate comprising a CAAX motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion; b) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 1 gM against transfer of a farnes l residue to a protein or 20 peptide substrate, comprising a CAAX motif, by farnesyl-protein transferase; and c) the IC 50 (a measurement of in vitro inhibitory activity) of the compound against transfer of a geranylgeranyl residue to a protein G or peptide substrate comprising a CAAX motif by 25 geranylgeranyl-protein transferase type I in the presence of a modulating anion is greater than 5 fold lower than the IC 5 0 (a measurement of in vitro inhibitory activity) against said transfer of a geranylgeranyl residue in the absence of a modulating anion. 30
52. A method of inhibiting prenyl-protein transferases which comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound that is a dual inhibitor of farnesyl-protein transferase and geranylgeranyl-protein transferase type I, the compound which is characterized by: - 160 - WO 99/10523 PCT/US98/17697 a) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 500 nM, but greater than about 5 nM against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAXG motif by geranylgeranyl-protein transferase type I in the 5 presence of a modulating anion; and b) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 10 nM against transfer of a farnesFyl residue to a protein or peptide substrate, comprising a CAAX motif, by farnesyl-protein transferase. 10
53. A method of inhibiting farnesyl-protein transferase and geranylgeranyl-protein transferase type I which comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound that is a dual inhibitor of farnesyl-protein 15 transferase and geranylgeranyl-protein transferase type I, the compound which is characterized by: a) an IC 5 0 (a measurement of in vitro inhibitory activity) of less than about 500 nM, but greater than about 5 nM against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising 20 a CAAXG motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion; and b) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 10 nM against transfer of a farnesl residue to a protein or peptide substrate, comprising a CAAX motif, by farnesyl-protein 25 transferase.
54. A method of inhibiting the growth of cancer cells which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound, which is characterized 30 by: a) an IC 5 0 (a measurement of in vitro inhibitory activity) of less than about 500 nM, but greater than about 5 nM against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising - 161 - WO 99/10523 PCT/US98/17697 a CAAX G motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion; b) an IC 50 (a measurement of in vitro inhibitory activity) of less than about 10 nM against transfer of a farnesyl residue to a protein or 5 peptide substrate, comprising a CAAX motif, by farnesyl-protein transferase.
55. An assay for identifying a compound that inhibits geranylgeranyl-protein transferase type I activity, comprising: G 10 a) reacting a protein or peptide substrate comprising a CAAX motif with geranylgeranyl pyrophosphate and geranylgeranyl-protein transferase type I in the presence of a test compound and further in the presence of a modulating anion; b) detecting whether the geranylgeranyl residue is incorporated into 15 the protein or peptide substrate, in which the ability of the test compound to inhibit geranylgeranyl-protein transferase type I activity is indicated by a decrease in the incorporation of the geranylgeranyl residue into the protein or peptide substrate as compared to the amount of the geranylgeranyl residue incorporated 20 into the protein or peptide substrate in the absence of the test substance.
56. The assay according to Claim 55 for identifying a compound that inhibits in vivo geranylgeranyl-protein transferase type I 25 activity.
57. The assay according to Claim 55 wherein the modulating anion is a phosphate or sulfate containing anion. 30
58. The assay according to Claim 55 wherein the modulating anion is selected from: adenosine 5'-triphosphate, 2'-deoxyadenosine 5'-triphosphate, 2'-deoxycytosine 5'-triphosphate, f3-glycerol phosphate, pyrophosphate, guanosine 5'-triphosphate, - 162 - WO 99/10523 PCT/US98/17697 2'-deoxyguanosine 5'-triphosphate, uridine 5'-triphosphate, dithiophosphate, thymidine 5'-triphosphate, tripolyphosphate, D-myo-inositol 1,4,5-triphosphate and sulfate. 5
59. The assay according to Claim 58 wherein the modulating anion is selected from: adenosine 5'-triphosphate (ATP), 3-glycerol phosphate, pyrophosphate, dithiophosphate and sulfate.
60. The assay according to Claim 58 wherein the 10 concentration of the modulating anion in the assay is selected from a range of from about 0.1 mM to about 100 mM.
61. The assay according to Claim 58 wherein the concentration of the modulating anion in the assay is selected from a 15 range of from about 1 mM to about 10 mM.
62. The assay according to Claim 55 wherein the CAAX motif is selected from: CVIM (SEQ.ID.: 1), CVLL (SEQ.ID.: 2), CVVM (SEQ.ID.: 3), CIIM (SEQ.ID.: 4), CLLL (SEQ.ID.: 5), 20 CQLL (SEQ.ID.: 6), CSIM (SEQ.ID.: 7), CAIM (SEQ.ID.: 8), CKVL (SEQ.ID.: 9), CLIM (SEQ.ID.: 10) and CVIL (SEQ.ID.: 14).
63. The assay according to Claim 62 wherein the CAAX motif is CVIM (SEQ.ID.: 1). 25
64. A method for identifying a prenyl-protein transferase inhibitor which is efficacious in vivo as an inhibitor of geranylgeranyl protein transferase type I which comprises the steps of: a) assessing a test compound for its in vitro inhibitory activity against 30 transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAXG motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion; b) assessing the test compound for its in vitro inhibitory activity against said transfer of a geranylgeranyl residue in the absence - 163 - WO 99/10523 PCT/US98/17697 of a modulating anion; and c) comparing the inhibitory activity of the test compound in the assessment of step a) with the inhibitory activity of the test compound in the assessment of step b). 5
65. The method according to Claim 64 wherein the prenyl-protein transferase inhibitor is a dual inhibitor of farnesyl protein transferase and geranylgeranyl-protein transferase type I. 10
66. A method for identifying a compound which is a prenyl-protein transferase inhibitor, and which is efficacious in vivo as an inhibitor of the growth of cancer cells characterized by a mutated K-RasB protein, which comprises the steps of: a) assessing a test compound for its in vitro inhibitory activity against 15 transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAX motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion; and b) assessing the test compound for its ability to inhibit the anchorage independent growth of H-ras-transformed mammalian fibroblasts. 20
67. The method according to Claim 66 wherein the prenyl-protein transferase inhibitor is a dual inhibitor of farnesyl protein transferase and geranylgeranyl-protein transferase type I. 25
68. The method according to Claim 66 wherein the modulating anion is a phosphate or sulfate containing anion.
69. The method according to Claim 66 wherein the modulating anion is selected from: adenosine 5'-triphosphate, 30 2'-deoxyadenosine 5'-triphosphate, 2'-deoxycytosine 5'-triphosphate, f3-glycerol phosphate, pyrophosphate, guanosine 5'-triphosphate, 2'-deoxyguanosine 5'-triphosphate, uridine 5'-triphosphate, dithiophosphate, 3'-deoxythymidine 5'-triphosphate, tripolyphosphate, D-myo-inositol 1,4,5-triphosphate and sulfate. - 164 - WO 99/10523 PCT/US98/17697
70. The method according to Claim 69 wherein the modulating anion is selected from: adenosine 5'-triphosphate (ATP), P-glycerol phosphate, pyrophosphate, dithiophosphate and sulfate. 5
71. The method according to Claim 69 wherein the concentration of the modulating anion in the assay is selected from a range of from about 0.1 mM to about 100 mM. 10
72. The method according to Claim 69 wherein the concentration of the modulating anion in the assay is selected from a range of from about 1 mM to about 10 mM.
73. The method according to Claim 66 wherein the 15 CAAX motif is selected from: CVIM (SEQ.ID.: 1), CVLL (SEQ.ID.: 2), CVVM (SEQ.ID.: 3), CIIM (SEQ.ID.: 4), CLLL (SEQ.ID.: 5), CQLL (SEQ.ID.: 6), CSIM (SEQ.ID.: 7), CAIM (SEQ.ID.: 8), CKVL (SEQ.ID.: 9), CLIM (SEQ.ID.: 10) and CVIL (SEQ.ID.: 14). 20
74. The method according to Claim 73 wherein the CAAX motif is CVIM (SEQ.ID.: 1).
75. A method of inhibiting prenyl-protein transferases which comprises administering to a mammal in need thereof a 25 pharmaceutically effective amount of a compound that is a dual inhibitor of farnesyl-protein transferase and geranylgeranyl-protein transferase type I, the compound which is characterized by: a) a ratio of the apparent enzymologic Ki value of the compound against transfer of a geranylgeranyl residue to a protein or peptide G 30 substrate comprising a CAAX motif by geranylgeranyl-protein G transferase type I in the presence of a modulating anion (Kia ) to the apparent enzymologic K i value of the compound against transfer of a farnesyl residue to a protein or peptide substrate comprising a - 165 - WO 99/10523 PCT/US98/17697 CAAX F motif by farnesyl-protein transferase (Kia ) that is greater than 0.002 and less than 5,000.
76. A method of inhibiting farnesyl-protein transferase 5 and geranylgeranyl-protein transferase type I which comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound that is a dual inhibitor of farnesyl-protein transferase and geranylgeranyl-protein transferase type I, the compound which is characterized by: 10 a) a ratio of the apparent enzymologic K i value of the compound against transfer of a geranylgeranyl residue to a protein or peptide G substrate comprising a CAAX motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion (Kia G) to the apparent enzymologic Ki value of the compound against transfer 15 of a farnesyl residue to a protein or peptide substrate comprising a CAAX F motif by farnesyl-protein transferase (Kia F) that is greater than 0.002 and less than 5,000.
77. A method of inhibiting the growth of cancer 20 cells which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound, which is characterized by: a) a ratio of the apparent enzymologic Ki value of the compound against transfer of a geranylgeranyl residue to a protein or peptide G 25 substrate comprising a CAAX motif by geranylgeranyl-protein G transferase type I in the presence of a modulating anion (Kia ) to the apparent enzymologic Ki value of the compound against transfer of a farnesyl residue to a protein or peptide substrate comprising a CAAX F motif by farnesyl-protein transferase (Kia F ) that is greater 30 than 0.002 and less than 5,000.
78. The method according to Claim 77 wherein the ratio G F of Kia G to Kia F is greater than 0.02 and less than 500. - 166 - WO 99/10523 PCT/US98/17697
79. The method according to Claim 77 wherein the ratio G F of Kia G to Kia F is greater than 0.2 and less than 50. 5
80. The method according to Claim 25 wherein the compound is selected from: 1-[2(R)-Amino-3-mercaptopropyl]-2(S)-[(3-pyridyl)methoxyethyl)]-4 (1-naphthoyl)piperazine 10 1-[2(R)-Amino-3-mercaptopropyl]-2(S)-(benzyloxymethyl)-4-(1 naphthoyl)piperazine 1-[2(R)-Amino-3-mercaptopropyl]-2(S)-(benzyloxymethyl)-4-[7-(2,3 dihydrobenzofuroyl)] piperazine 15 1-[2(R)-Amino-3-mercaptopropyl]-2(S)-(benzamido)-4-(1 naphthoyl)piperazine 1-[2(R)-Amino-3-mercaptopropyl]-2(S)-[4-(5-dimethylamino- 1 20 naphyhalenesulfonamido)- 1 -butyl]-4- (1 -naphthoyl)piperazine N-[2(S)-(1-(4-Nitrophenylmethyl)- 1H-imidazol-5-ylacetyl)amino-3(S) methylpentyl]-N-1-naphthylmethyl-glycyl-methionine 25 N-[2(S)-( 1 -(4-Nitrophenylmethyl)- 1H-imidazol-5-ylacetyl)amino-3(S) methylpentyl]-N-1-naphthylmethyl-glycyl-methionine methyl ester N-[2(S)-([1 -(4-cyanobenzyl)- 1H-imidazol-5-yl]acetylamino)-3(S) methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine 30 N-[2(S)-([1-(4-cyanobenzyl)-1H-imidazol-5-yl]acetylamino)-3(S) methylpentyl]-N-(1-naphthylmethyl)glycyl-methionine methyl ester 2(S)-n-Butyl-4-(1-naphthoyl)-1-[1-(2-naphthylmethyl)imidazol-5 35 ylmethyl]-piperazine - 167 - WO 99/10523 PCT/US98/17697 2(S)-n-Butyl- 1-[1-(4-cyanobenzyl)imidazol-5-ylmethyl]-4-(1 naphthoyl)piperazine 5 1- { [1-(4-cyanobenzyl)- 1H-imidazol-5-yl]acetyl }-2(S)-n butyl-4-(1-naphthoyl)piperazine 1 -(3-chlorophenyl)-4- [1- (4-cyanobenzyl)imidazolylmethyl]-2 piperazinone 10 1 -phenyl-4- [1-(4-cyanobenzyl)- 1H-imidazol-5-ylethyl]-piperazin-2-one 1-(3-trifluoromethylphenyl)-4- [1-(4-cyanobenzyl)- 1H-imidazol-5 ylmethyl]-piperazin-2-one 15 1-(3-bromophenyl)-4- [1-(4-cyanobenzyl)- 1H-imidazol-5-ylmethyl] piperazin-2-one 5(S)-(2- [2,2,2-trifluoroethoxy] ethyl)- 1-(3-trifluoromethylphenyl)- 4-[1 20 (4-cyanobenzyl)-4-imidazolylmethyl]-piperazin-2-one 1-(5,6,7,8-tetrahydronaphthyl)-4- [1-(4-cyanobenzyl)- 1H-imidazol-5 ylmethyl]-piperazin-2-one 25 1-(2-methyl-3-chlorophenyl)-4- [1-(4-cyanobenzyl)-4 imidazolylmethyl)]-piperazin-2-one 2(RS)- { [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl } amino-3-(t butoxycarbonyl)amino- N-(2-methylbenzyl) propionamide 30 N- { 1-(4-Cyanobenzyl)- 1H-imidazol-5-ylmethyl } -4(R)-benzyloxy-2(S) { N'-acetyl-N'-3-chlorobenzyl } aminomethylpyrrolidine N- { 1-(4-Cyanobenzyl)- 1H-imidazol-5-ylethyl }-4(R)-benzyloxy-2(S) 35 { N'-acetyl-N'-3-chlorobenzyl } aminomethyl pyrrolidine - 168 - WO 99/10523 PCT/US98/17697 1-[1-(4-Cyanobenzyl)- 1H-imidazol-5-ylacetyl] pyrrolidin-2(S) ylmethyl]-(N-2-methylbenzyl)-glycine N'-(3-chlorophenylmethyl) amide 1-[1-(4-Cyanobenzyl)- 1H-imidazol-5-ylacetyl] pyrrolidin-2(S) 5 ylmethyl]-(N-2-methylbenzyl)-glycine N'-methyl-N'-(3 chlorophenylmethyl) amide (S)-2-[(1-(4-Cyanobenzyl)-5-imidazolylmethyl)amino]-N (benzyloxycarbonyl)-N-(3-chlorobenzyl)-4 10 (methanesulfonyl)butanamine 1-(3,5-Dichlorobenzenesulfonyl)-3(S)-[N-(1-(4-cyanobenzyl)-l1H imidazol-5-ylethyl)carbamoyl] piperidine 15 N- { [1 -(4-Cyanobenzyl)- 1H-imidazol-5-yl] methyl } -4-(3-methylphenyl) 4-hydroxy piperidine, N- { [1- (4-Cyanobenzyl)- 1H-imidazol-5-yl]methyl } -4-(3-chlorophenyl)-4 hydroxy piperidine, 20 4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-1-(2,3-dimethylphenyl) piperazine-2,3-dione 1-(2-(3-Trifluoromethoxyphenyl)-pyrid-5-ylmethyl)-5-(4 25 cyanobenzyl)imidazole 4- { 5- [1-(3-Chloro-phenyl)-2-oxo-1,2-dihydro-pyridin-4-ylmethyl] imidazol- 1 -ylmethyl } -2-methoxy-benzonitrile 30 3(R)-3-[1-(4-Cyanobenzyl)imidazol-5-yl-ethylamino]-5-phenyl- 1-(2,2,2 trifluoroethyl)-H-benzo[e][1,4] diazepine 3(S)-3- [1-(4-Cyanobenzyl) imidazol-5-yl]-ethylamino]-5-phenyl- 1 35 (2,2,2-trifluoroethyl)-H-benzo [e] [1,4] diazepine - 169 - WO 99/10523 PCT/US98/17697 N-[1- (4-Cyanobenzyl)- 1H-imidazol-5-ylacetyl)pyrrolidin-2(S) ylmethyl]- N-(1-naphthylmethyl)glycyl-methionine N-[l1-(4-Cyanobenzyl)- 1H-imidazol-5-ylacetyl)pyrrolidin-2(S) 5 ylmethyl]- N-(1-naphthylmethyl)glycyl-methionine methyl ester N-[i1-(1H-Imidazol-4-ylpropionyl)pyrrolidin-2(S)-ylmethyl]- N-(2 methoxybenzyl)glycyl-methionine 10 N-[1-(1H-Imidazol-4-ylpropionyl)pyrrolidin-2(S)-ylmethyl]- N-(2 methoxybenzyl)glycyl-methionine methyl ester 2(S)-(4-Acetamido-l1-butyl)- 1-[2(R)-amino-3-mercaptopropyl]-4-(1 naphthoyl)piperazine 15 2(RS)- { [1-(Naphth-2-ylmethyl)- 1H-imidazol-5-yl)] acetyl } amino-3-(t butoxycarbonyl)amino- N-cyclohexyl-propionamide 1- { 2(R,S)- [1 -(4-cyanobenzyl)- 1H-imidazol-5-yl]propanoyl } -2(S)-n 20 butyl-4-(1-naphthoyl)piperazine 1-[1-(4-cyanobenzyl)imidazol-5-ylmethyl]-4-(diphenylmethyl)piperazine 1-(Diphenylmethyl)-3(S)-[N-(1-(4-cyanobenzyl)-2-methyl-1H-imidazol 25 5-ylethyl)-N-(acetyl)aminomethyl] piperidine N-[l1-(1H-Imidazol-4-ylpropionyl)pyrrolidin-2(S)-ylmethyl]- N-(2 chlorobenzyl)glycyl-methionine 30 N-[1-(1H-Imidazol-4-ylpropionyl)pyrrolidin-2(S)-ylmethyl]- N-(2 chlorobenzyl)glycyl-methionine methyl ester 3(R)-3-[1-(4-Cyanobenzyl)imidazol-5-yl-methylamino]-5-phenyl-1 (2,2,2-trifluoroethyl)-H-benzo[e][1,4] diazepine 35 - 170 - WO 99/10523 PCT/US98/17697 1-(3-trifluoromethoxyphenyl)-4- [1-(4-cyanobenzyl)imidazolylmethyl] 2-piperazinone 1-(2,5-dimethylphenyl)-4- [1 -(4-cyanobenzyl)imidazolylmethyl]-2 5 piperazinone 1-(3-methylphenyl)-4-[1-(4-cyanobenzyl)imidazolylmethyl]-2 piperazinone 10 1-(3-iodophenyl)-4- [1-(4-cyanobenzyl)imidazolylmethyl]-2-piperazinone 1 -(3-chlorophenyl)-4- [1- (4-cyano-3-methoxybenzyl)imidazolylmethyl] 2-piperazinone 15 1-(3-trifluoromethoxyphenyl)-4- [1 -(4-cyano-3 methoxybenzyl)imidazolyl methyl]-2-piperazinone 4-[((1-(4-cyanobenzyl)-5-imidazolyl)methyl)amino]benzophenone 20 1-(1- { [3-(4-cyano-benzyl)-3H-imidazol-4-yl]-acetyl } -pyrrolidin-2(S) ylmethyl)-3(S)-ethyl-pyrrolidine-2(S)-carboxylic acid 3-chloro benzylamide or the pharmaceutically acceptable salt thereof. - 171 -
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5734097P | 1997-08-27 | 1997-08-27 | |
US60057340 | 1997-08-27 | ||
GB9724331 | 1997-11-18 | ||
GBGB9724331.5A GB9724331D0 (en) | 1997-11-18 | 1997-11-18 | A method of treating cancer |
PCT/US1998/017697 WO1999010523A1 (en) | 1997-08-27 | 1998-08-26 | A method of treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
AU9205898A true AU9205898A (en) | 1999-03-16 |
Family
ID=26312617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU92058/98A Abandoned AU9205898A (en) | 1997-08-27 | 1998-08-26 | A method of treating cancer |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1009854A1 (en) |
JP (1) | JP2001518281A (en) |
AU (1) | AU9205898A (en) |
CA (1) | CA2301877A1 (en) |
WO (1) | WO1999010523A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9809889D0 (en) | 1998-05-11 | 1998-07-08 | Univ Strathclyde | Prevention of restenosis |
US6849599B2 (en) | 2000-03-08 | 2005-02-01 | Rhode Island Hospital | Combination drug therapy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185248A (en) * | 1990-05-08 | 1993-02-09 | E. R. Squibb & Sons, Inc. | Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation |
-
1998
- 1998-08-26 AU AU92058/98A patent/AU9205898A/en not_active Abandoned
- 1998-08-26 CA CA002301877A patent/CA2301877A1/en not_active Abandoned
- 1998-08-26 JP JP2000507831A patent/JP2001518281A/en active Pending
- 1998-08-26 WO PCT/US1998/017697 patent/WO1999010523A1/en not_active Application Discontinuation
- 1998-08-26 EP EP98944537A patent/EP1009854A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1009854A1 (en) | 2000-06-21 |
WO1999010523A1 (en) | 1999-03-04 |
JP2001518281A (en) | 2001-10-16 |
CA2301877A1 (en) | 1999-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6989383B1 (en) | Method of treating cancer | |
AU716338B2 (en) | Inhibitors of farnesyl-protein transferase | |
AU727939B2 (en) | A method of treating cancer | |
US6387903B1 (en) | Inhibitors of prenyl-protein transferase | |
US6358956B1 (en) | Inhibitors of prenyl-protein transferase | |
CA2251955A1 (en) | A method of treating cancer | |
AU3248600A (en) | Inhibitors of prenyl-protein transferases | |
AU741725B2 (en) | Inhibitors of prenyl-protein transferase | |
CA2250353A1 (en) | Inhibitors of farnesyl-protein transferase | |
AU4726799A (en) | Inhibitors of prenyl-protein transferase | |
US6103487A (en) | Method of treating cancer | |
AU706495B2 (en) | Inhibitors of farnesyl-protein transferase | |
US6376496B1 (en) | Inhibitors of prenyl-protein transferase | |
AU9205898A (en) | A method of treating cancer | |
US6335343B1 (en) | Inhibitors of prenyl-protein transferase | |
AU703988B2 (en) | Inhibitors of farnesyl-protein transferase | |
AU707347B2 (en) | Inhibitors of farnesyl-protein transferase | |
AU9205998A (en) | A method of treating cancer | |
US6355643B1 (en) | Inhibitors of prenyl-protein transferase | |
AU8921398A (en) | A method of treating cancer | |
WO1999010329A1 (en) | Inhibitors of prenyl-protein transferase | |
WO2000016626A1 (en) | A method of treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |